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Chapter 1
General introduction and 
outline of the thesis
Published in part in: 
Int J Vasc Med 2012;2012:271030 




Atherosclerosis is the primary cause of death in the world [1]. Classical risk factors such 
as smoking, hypertension, hyperlipidemia, insulin resistance, increased body fat mass 
and unfavourable body fat distribution are strongly interrelated and can often be found 
in one and the same subject. Subjects with fasting hypertriglyceridemia usually have 
elevated postprandial triglycerides (TG) due to the close correlation of fasting and 
postprandial TG [2]. Postprandial lipemia is interesting because of recent reports show-
ing that non-fasting TG independently predict the risk for atherosclerosis [3,4] and are 
possibly, even stronger predictors of cardiovascular disease (CVD) than fasting TG [3,5]. 
The postprandial state is characterized by accumulation of TG-rich lipoproteins inducing 
leukocyte activation [6,7], which is of special interest since atherosclerosis is considered 
a low-grade chronic inflammatory disease [8]. One of the early signs of atherosclerosis 
is the development of endothelial dysfunction and postprandial leukocyte activation 
has been related to temporary impaired endothelial function [9,10]. Besides leukocytes, 
there is also evidence of an interaction between lipoproteins and erythrocytes, which 
make up the majority of circulating blood cells [11]. A mouse model has shown that 
erythrocytes may contribute to reverse cholesterol transport, but factors influencing 
the binding of lipoproteins to erythrocytes need yet to be determined [12]. Therefore, 
the focus of this thesis is on postprandial lipemia and the interplay between lipids and 
circulating blood cells in relation to atherosclerosis.
Triglycerides and atherosclerosis
One of the first reports linking hypertriglyceridemia to cardiovascular disease is the 
description by Nicolaes Tulp (1593-1674), who was immortalized in the “Anatomical les-
son” by Rembrandt, describing a patient with severe hypertriglyceridemia who probably 
died from a seizure [13]. Since the mid-twentieth century several publications appeared 
showing that patients with coronary heart disease have increased postprandial lipemia 
[14-16]. Convincing evidence establishing the role of postprandial hyperlipidemia and 
TG-rich lipoproteins in atherosclerosis was provided by research coming from different 
groups in the last three decades [17-20]. 
Recently large, prospective epidemiological studies have shown that a single 
measurement of non-fasting TG is associated with an increased risk of cardiovascular 
disease independent from classical risk factors [3,5]. For every 1 mmol/l increase in 
non-fasting TG a significant increase of death was found with multifactorially adjusted 
hazard ratios of 1.2-1.8 for men and 1.3-3.3 for women. Similar significant trends were 
found for myocardial infarction and ischemic heart disease in both men and women [5]. 
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Therefore, it was suggested that non-fasting TG are stronger predictors of cardiovascu-
lar disease than fasting TG [3,5]. Abnormalities in TG reflect metabolic derangements 
and may be used as biomarkers for cardiovascular risk because of their strong relation 
with atherogenic remnant lipoproteins (chylomicron remnants and hepatic derived 
VLDL-remnants) [21]. Chapter 2 provides an overview from the literature regarding the 
interpretation of elevated TG and subsequent treatment of hypertriglyceridemia with 
clear instructions for physicians.
Triglycerides and postprandial lipemia
Atherosclerosis is a chronic disease which takes years to develop, but endothelial func-
tion is already transiently impaired after a single high-fat meal and is associated with 
an abnormal postprandial TG response [9,10,22]. Most of the postprandial studies are 
performed using experimental situations where participants undergo standardized oral 
fat loading tests. However, these tests are not suitable to screen large populations or to 
use as a diagnostic tool for clinical practice. They are laborious, require a metabolic ward 
and are inconvenient for subjects, who need to fast for a long period and to be hospital-
ized during the test. Work from our laboratory described the technique of self-measured 
capillary TG to determine postprandial lipemia in individual subjects without the need 
for laborious and time-consuming oral fat loading tests. Daytime triglyceridemia mea-
sured in this way is also increased in patients with premature cardiovascular disease 
compared to healthy controls [23-27]. The intra-individual variability in fasting TG is ap-
proximately 20-25%, but variation in TG and postprandial lipemia between individuals 
is even higher [28-33]. However, little is known about the variability of non-fasting TG, 
which may affect the clinical usability of non-fasting TG in clinical practice. Chapter 3 
describes the results from a study, which investigated the intra-individual variability of 
diurnal TG using the technique of self-measured capillary TG.
Postprandial lipemia and leukocyte activation
As mentioned before, atherosclerosis is in part an inflammatory disease. Many inflam-
matory markers such as C-reactive protein (CRP), leukocyte count and complement 
component 3 (C3) have been associated with cardiovascular disease [34-39]. Several 
studies with animal models showed a reduction in atherosclerotic plaque formation 
[40,41] and prevention of endothelial dysfunction [42], when adherence of leukocytes to 
the endothelium was prevented. These findings support the theory that atherogenesis, 
in part, starts with leukocyte-endothelium interaction and adherence. Obligatory for 
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Figure 1: Concept of the initiation of atherosclerosis by remnant lipoproteins: Remnants enter the 
subendothelial space via non-specific transcytotic processes. This is often a non-pathologic process, 
because the remnants leave the subendothelial space again via the vasa vasorum. However, retention of 
remnants may occur in the presence of proteoglycans and excess extracellular matrices. Remnants can 
be easily taken up by macrophages, in contrast to LDL, which need to become modified first. Circulating 
remnants themselves also contribute to the presence of subendothelial macrophages. Monocytes 
can bind and take up remnants, which stimulate the monocytes to become activated. Subsequently, 
activated monocytes express adhesion molecules on the outer membrane and stimulate the expression 
of endothelial cellular adhesion molecules (CAMs), which allows monocytes to home on the endothelium 
and migrate into the subendothelial space. Finally, the macrophages change into highly atherogenic foam 
cells when lipid uptake exceeds lipid efflux.
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this adherence is a cytokine-controlled sequential upregulation of selectins and adhe-
sion molecules on activated leukocytes and endothelial cells (Figure 1) [43]. 
Van Oostrom et al have shown that postprandially, when TG rise, neutrophil counts 
increase with concomitant production of pro-inflammatory cytokines and oxidative 
stress; and that these changes may contribute to endothelial dysfunction [9,44]. Fur-
thermore, TG are able to induce leukocyte activation, as has been shown in vitro [45,46] 
and ex vivo in hypertriglyceridemic patients [47]. In healthy volunteers and in patients 
with premature cardiovascular disease, postprandial lipemia upregulates leukocyte 
activation markers [48,49]. Leukocytes of fasting patients with cardiovascular disease 
have an increased lipid content, compared to controls and this may be due to uptake 
of chylomicrons [50]. Furthermore, uptake of remnant lipoproteins by primary human 
monocytes has been demonstrated in experiments in vitro [46]. Leukocytes are also 
able to take up retinyl esters, as markers of intestinally derived TG-rich lipoproteins [51]. 
Recently, we have shown that apolipoprotein (apo) B, the structural molecule of the 
atherogenic lipoproteins, binds to neutrophils and monocytes and that postprandial 
leukocytes transport dietary fatty acids [6]. This indicates that activation of leukocytes 
may occur in the circulation by direct interaction with TG-rich lipoproteins. 
Since TG-rich lipoproteins induce leukocyte activation, postprandial lipemia may 
interfere with routine diagnostic procedures used to differentiate leukocytes into 
lymphocytes, monocytes, neutrophils, eosinophils and basophils. The automatic 5-part 
differentiation of leukocytes is performed by automatic cell counters in the labora-
tory using leukocyte cell population data (VCS), which consists of measurements of cell 
volume, conductivity and light scatter. The influence of postprandial lipemia on these 
parameters is described in Chapter 4. 
Vitamin D deficiency has been associated with cardiovascular disease and a po-
tential beneficial effect of vitamin D on cardiovascular disease has been suggested by 
the immunomodulatory effects of vitamin D. In vitro, it has been shown that 1,25-di-
hydroxyvitamin D3, the active metabolite from vitamin D3, reduces the activated state 
of leukocytes as expressed by a reduction in CD11b expression [52]. When 1,25-dihy-
droxyvitamin D3 is present in the culture medium macrophages take up less cholesterol 
with a concomitant reduction in atherogenic foam cell formation [53]. Therefore, we 
investigated the possible immunomodulatory effects of vitamin D on postprandial leu-
kocyte activation in relation to arterial stiffness. The results of this study are described 
in Chapter 5. 
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Erythrocyte-bound apolipoprotein B in relation to atherosclerosis
Every atherogenic lipoprotein contains exactly one apo B molecule and the measure-
ment of apo B provides an indication of the amount of atherogenic lipoproteins. There-
fore, it is not surprising that studies have shown that the concentration of serum apo B 
is a strong predictor of cardiovascular disease [4,54,55]. Lipoproteins are found in fluid 
phase where they are metabolized and transported to specific organs. However, there 
is also evidence of a marginated pool of apo B containing lipoproteins notably attached 
to the endothelium and to circulating blood cells [11,56]. Erythrocytes represent the 
largest blood cell population and make up more than 99% of the total cellular space in 
blood [57]. The exchange of cholesterolesters between LDL and erythrocyte membranes 
may be substantial, which can only be explained by binding of LDL to erythrocytes and 
not by accidental collision [58,59]. In addition, erythrocytes may contribute to reverse 
cholesterol transport and a trend of impaired reverse cholesterol transport was observed 
in anemic mice [12]. 
Binding of atherogenic apo B containing lipoproteins to erythrocytes as a mechanism 
for reverse cholesterol transport may provide an atheroprotective effect of erythrocyte-
bound apo B. In addition, we hypothesized a contributing protective mechanism that 
apo B containing lipoproteins bound to erythrocytes are less likely to interact with the 
endothelium [11]. Chapter 6 presents a pilot study showing that patients with known 
cardiovascular disease have lower values of erythrocyte-bound apo B when compared to 
control subjects without cardiovascular disease. Potential determinants like serum apo 
B concentrations, the use of statins and the ABO blood group in relation to erythrocyte-
bound apo B are explored in Chapter 7.
The complement receptor 1 as a potential mechanism for lipoprotein 
binding to erythrocytes
Another inflammatory pathway related to cardiovascular disease and lipid metabolism 
is the complement system. Serum complement component (C) 3 is a strong predictor of 
myocardial infarction [37] and it has been positively associated with obesity, cardiovas-
cular disease, insulin resistance, the metabolic syndrome, fasting and postprandial TG 
and hypertension [2,37,60]. Chylomicrons are the strongest in vitro and in vivo stimula-
tors of adipocyte C3 production via activation of the alternative complement cascade 
[39,61]. A postprandial increase in serum C3 after a fat meal has been shown in healthy 
subjects, in patients with cardiovascular disease and in patients with familial combined 
hyperlipidemia [2,36,39]. Moreover, this postprandial increment has been related to TG 
and FFA metabolism [62]. 
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The complement receptor 1 (CR1) is known for its capacity to bind C3b-opsonized 
immune complexes and pathogens. CR1 is present on monocytes and neutrophils as 
well as on erythrocytes. In leukocytes CR1 internalizes C3b-opsonized immune com-
plexes and pathogens for phagocytosis, whereas CR1 can not be internalized by eryth-
rocytes. Therefore, erythrocytes use CR1 as a transport mechanism of C3b-opsonized 
immune complexes called immune adherence [63-65]. We hypothesized that CR1 may 
be involved in the binding and transportation of apo B containing lipoproteins by eryth-
rocytes. Chapter 8 presents in vitro experiments, investigating the binding capacity of 
LDL and modified LDL to CR1.
Summary
The topics in the upcoming chapters will slowly shift from a more clinical perspective to 
a more fundamental level of research. The up to date literature regarding the treatment 
of hypertriglyceridemia is reviewed in Chapter 2. Chapter 3 focuses on determinants 
regarding the intra-individual variability in fasting and non-fasting plasma triglycer-
ides. The effects of postprandial lipemia and subsequent leukocyte activation on the 
automated 5-part leukocyte differentiation by a hematology analyzer are described 
in Chapter 4. The effects of vitamin D3 supplementation on postprandial leukocyte 
activation and arterial stiffness are investigated in Chapter 5. The association between 
erythrocyte-bound apo B and cardiovascular disease, serum apo B, the use of statins and 
ABO blood group are described in Chapters 6 and 7. Finally, a potential contribution of 
the complement receptor 1 to bind lipoproteins as a model for cellular binding of LDL 
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A physician’s guide for the management 
of hypertriglyceridemia: the 









Hypertriglyceridemia is a common lipid disorder associated to different, highly prevalent 
metabolic derangements like diabetes mellitus, the metabolic syndrome and obesity. The 
choice of treatment depends on the underlying pathogenesis and the consequences for 
atherosclerosis or pancreatitis. A family history, physical examination and analysis of the 
lipid profile including measurement of apolipoprotein B or non-HDL-C are necessary to 
establish the underlying primary or secondary cause. Due to physiological diurnal varia-
tions of triglycerides (TG), the time of measurement (fasting or postprandial) should be 
taken into account when evaluating TG values. Increased awareness arises concerning 
the impact of postprandial hypertriglyceridemia on the development of atherosclerosis. 
Hypertriglyceridemia is strongly associated to postprandial hyperlipidemia, remnant 
accumulation, increased small dense LDL concentrations, low HDL-C, increased oxida-
tive stress, endothelial dysfunction, leukocyte activation and insulin resistance. All these 
factors are strongly linked to the development of atherosclerosis. Treatment should be 
aimed at reducing the secretion of triglyceride-rich lipoproteins, increasing intravascu-
lar lipolysis and reducing the number of circulating remnants. The main intervention is 
a change of lifestyle with decreased alcohol consumption, increased physical activity, 
dietary changes and, if applicable, adaptation of used medication. Fibrates, fish oil and 
nicotinic acid are the first choice of treatment in sporadic and familial hypertriglyc-
eridemia to reduce the risk of pancreatitis, whereas high dose statins, sometimes in 
combination with fibrates, nicotinic acid, or fish oil capsules, are indicated for familial 
combined hyperlipidemia. Statins are necessary to reach low LDL-C concentrations in 
patients with type 2 diabetes mellitus and statin dosage should be increased when 
hypertriglyceridemia is present to reach secondary treatment targets for apolipoprotein 
B or non-HDL-C. Finally, family screening is mandatory to detect familial lipid disorders 
for early intervention in other family members.
Management of hypertriglyceridemia 25
Introduction
Hypertriglyceridemia is a common lipid disorder associated with an increased risk for 
cardiovascular disease and pancreatitis, especially at higher triglyceride (TG) concentra-
tions. Approximately one third of the adult US population has TG concentrations above 
1.70 mmol/l (150 mg/dl) and a total of 18% of the population showed marked hypertri-
glyceridemia with TG concentrations above 2.25 mmol/l (200 mg/dl) [1]. Nevertheless, 
only 3.6% percent of the population with TG concentrations above 2.25 mmol/l used 
medication for hypertriglyceridemia [1]. Treatment strategies for hypertriglyceridemia 
strongly depend on the etiology of the hypertriglyceridemia and the relation to compli-
cations. Plasma TG concentrations are determined by the production of TG-rich lipopro-
teins (VLDL, chylomicrons and their respective remnants), the intravascular lipolysis of 
TG-rich lipoproteins (TRLs) and, finally, the hepatic uptake of TRLs. Hypertriglyceridemia 
can be subdivided into primary and secondary causes. Therefore, physicians should 
search for the underlying cause(s) in patients with hypertriglyceridemia, because it in-
fluences treatment strategy, cardiovascular risk assessment and, potentially, the neces-
sity to screen families for familial lipid disorders [2]. This review provides an overview of 
the current evidence how to correctly diagnose hypertriglyceridemia, to search for the 
underlying etiology in individual cases and how to choose the appropriate treatment 
strategy. 
Triglyceride metabolism
A schematic overview of TG metabolism is shown in Figure 1. TG are a major energy 
source for the body. After ingestion of food containing fat, TG are hydrolyzed in the 
intestinal lumen into free fatty acids (FFA) and 2-monoacylglycerols (MAG) and taken 
up by enterocytes through passive diffusion and specific proteins, like CD36 and vari-
ous fatty acid transport proteins [3]. Once inside the endoplasmatic reticulum of the 
enterocyte, FFA and MAG are assembled into TG again and packed with cholesterol, 
phospholipids and apolipoproteins (apo) B48 and A-IV to form chylomicrons [4,5]. In this 
process, the microsomal triglyceride transfer protein and the editing ezyme complex are 
paramount factors [6,7]. Especially the latter is crucial for the synthesis of apo B48, the 
structural protein of chylomicrons. After assembling, the chylomicrons are secreted into 
the lymphatics and finally enter the circulation through the thoracic duct. Within the 
circulation apo A-IV is exchanged for two other apolipoproteins, namely apo C-II and 
apo E [8]. 
In fasting physiological conditions, plasma TG are mainly determined by VLDL 













































Figure 1: A schematic representation of triglyceride (TG) hydrolysis. Very low density lipoproteins (VLDL) 
are secreted by the liver and contain apolipoprotein (apo) B100. In contrast, the small intestine secretes 
chylomicrons, which contain apo B48. Both VLDL and chylomicrons contain high concentrations of 
TG and hydrolysis is necessary for the delivery of free fatty acids (FFA) to muscular and adipose tissue 
for energy expenditure or storage. Lipoprotein lipase (LPL) has a central role in the hydrolysis of TG. 
LPL is mainly produced by myocytes and adipocytes and transported to the subendothelial space by 
heparan sulphate proteoglycans (HSPG). Finally, LPL is transported towards the capillary lumen by 
glycosylphosphatidylinositol-anchored high-density-binding protein 1 (GPIHBP1). LPL becomes activated 
by apo C-II, which is available on both chylomicrons and VLDL. In addition, apo A-V is involved in the TG 
hydrolysis as well. The TG are hydrolyzed into FFA, which are taken up from the circulation by specific 
receptors like CD36 or via non-specific proteins like albumin. Chylomicrons and VLDL shrink in size and 
become denser as hydrolysis continues. The remaining remnants are taken up by the liver via multiple 
receptors like the LDL-related protein receptor (LRP), several proteoglycans (HSPG) and a small proportion 
by the LDL-receptor (LDL-R).
Within the circulation, chylomicrons and VLDL interact with HDL by cholesterylester-transfer protein (CETP), 
which exchanges cholesterylesters (CE) for TG. In case of hypertriglyceridemia, CETP increases cholesterol 
content of TG-rich lipoproteins in combination with a decrease in HDL-cholesterol. This explains the inverse 
relationship between TG and HDL-C. Moreover, apo E is transferred from HDL to chylomicrons and VLDL, 
which is necessary for the hepatic removal of the remnants.
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increases postprandially when food derived TG and FFA reach the liver. The VLDL assem-
bly resembles chylomicron synthesis, but in this case, apoB100 is the structural protein 
of VLDL [7]. 
Both, chylomicrons and VLDL are essential for the delivery of FFA to mainly the 
heart, skeletal muscle and adipose tissue for energy expenditure or storage. Hydrolysis 
of TG in the circulation is the main determinant of FFA delivery to tissues.  Many proteins 
are involved in the hydrolysis of TG and lipoprotein lipase (LPL) and its co-factor apo 
C-II are the most important. LPL is mainly synthesized by myocytes and adipocytes, 
which secrete LPL into the surrounding interstitial spaces. LPL is transported from the 
interstitial space to the capillary lumen by binding to heparan sulphate proteoglycans. 
Recently it was discovered that LPL anchors on glycosylphosphatidylinositol-anchored 
high-density-binding protein 1 (GPIHBP1) at the endothelial cell surface of small 
capillaries, where LPL serves as a docking station for TG-rich lipoproteins [9-11]. Apo 
C-II, which is carried by chylomicrons and VLDL, serves as a co-factor for LPL activity, 
whereas apoC-III serves as an inhibitor of LPL [10,12,13]. Furthermore, apo A-V is also 
a major determinant of TG hydrolysis [14]. FFA are internalized by the endothelium via 
cell surface receptors like CD36 and via other processes such as non-specific carriers like 
albumin [15,16]. Lipolysis results in TG depleted chylomicrons and VLDL, which shrink in 
diameter and become enriched with cholesterol due to the action of cholesterol ester 
transfer protein (CETP) and other transfer proteins [17], resulting in chylomicron and 
VLDL remnants, respectively. Finally, the remnants are taken up by the liver via multiple 
receptor pathways including the LDL-receptor, heparan sulphate proteoglycans and the 
LDL receptor-related protein [12].
Within the circulation TG-rich lipoproteins interact with HDL by CETP, which ex-
changes cholesterylesters for TG (Figure 1). Therefore, cholesterol content of TG-rich 
lipoproteins increases, HDL-C decreases and small dense LDL become more abundant 
in the case of hypertriglyceridemia [17]. This close metabolic connection between TRLs 
and HDL, reflects the difficulty to distinguish hypertriglyceridemia as a cardiovascular 
risk factor independently from low HDL-C concentrations [18]. Apo E is transferred from 
HDL to chylomicrons and VLDL, where apoE is involved in multiple processes. Apo E has 
an inhibitory effect on the hydrolysis of TG within the circulation and secondly apo E 
binds to the LDL receptor, LDL receptor-related protein and heparan sulfate proteogly-
cans for adequate hepatic removal of remnants [12,19,20].
Fasting versus non-fasting triglycerides
Fasting TG levels below 1.70 mmol/l are considered desirable and hypertriglyceridemia is 
present when TG levels are above 1.70 mmol/l [18,21]. Current guidelines recommend to 
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measure TG in the fasting state since TG concentrations increase during the day [18,21]. 
However, most patients visit the hospital in the non-fasting state and it would be more 
convenient for both, patients and doctors, to measure non-fasting lipid profiles. Prospec-
tive studies have shown that also non-fasting TG predict cardiovascular disease in the 
non-fasting state [22,23] and it has been suggested that non-fasting TG are even a stron-
ger predictor of cardiovascular disease than fasting TG [24,25]. Moreover, non-fasting TG 
are strongly correlated to fasting TG concentrations [26] and increase approximately 0.5 
mmol/l in females and 1.0 mmol/l in males during the day [27,28]. These values can be 
used to compose normal ranges for non-fasting TG levels since mean diurnal increase in 
TG is similar between normotriglyceridemic and hypertriglyceridemic individuals [28]. 
Intra-individual variability of TG does not significantly increase in females during the 
day and not in males during daylight hours [28]. In summary, non-fasting TG can be used 
in clinical practice as long as an average TG increase of 0.5 mmol/l in females and 1.0 
mmol/l in males is considered.
One of the inconveniences of measuring non-fasting lipid profiles is the fact that 
LDL-C calculations need fasting samples to be accurate. Non-fasting samples can lead 
to lower LDL-C values. It has been suggested that LDL-C is approximately 0.3-0.6 mmol/l 
lower in the non-fasting state [29]. In our opinion, the falsely decreased LDL-C is prob-
ably negligible in non-fasting normotriglyceridemic subjects. 
Apo B and non-HDL-C can be used as an alternative for LDL-C. Apo B represents 
the number of circulating atherogenic lipoproteins containing apo B (LDL, VLDL, 
chylomicrons and their respective remnants) [30]. In contrast, non-HDL-C reflects the 
cholesterol concentration of both LDL and TRLs [31]. A post-hoc analysis of two combined 
prospective studies has shown that non-HDL-C and apo B are better predictors for future 
cardiovascular events than LDL-C in subjects receiving statin therapy [32]. High non-
HDL-C levels predict cardiovascular disease independently from LDL-C concentrations 
[33]. In addition, apoB and non-HDL-C levels remain unchanged in the non-fasting state 
[34]. Normal values for non-HDL-C are 0.8 mmol/l above the normal ranges for LDL-C 
and the normal value for apoB ranges from 0.8-1.0 g/l [21].
The evaluation of the patient with hypertriglyceridemia
Whether hypertriglyceridemia alone initiates and accelerates atherosclerosis is an on-
going discussion, but hypertriglyceridemia surely is a marker of metabolic abnormalities 
[13]. Hypertriglyceridemia is often secondary to inappropriate dietary habits, obesity, 
diabetes, chronic kidney disease, end-stage liver disease or use of certain medications 
[2,30,35-37]. Besides secondary causes, hypertriglyceridemia can be caused by mono-
genic or polygenic diseases, which can have different associations with cardiovascular 
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disease. A list of diseases and factors causing hypertriglyceridemia is shown in Table 1. 
An adequate diagnosis for the cause of hypertriglyceridemia is of importance to deter-
mine the exact treatment strategy for each individual patient.
The evaluation of the hypertriglyceridemic patient starts with the family history, 
specifically aimed to identify lipid disorders and premature cardiovascular disease in 
first degree relatives. Secondly, potential secondary causes of hypertriglyceridemia 
should be identified. Therefore, other factors like the patient’s medical history, use of 
medication, dietary pattern and smoking history are also relevant. Physical examination 
should at least include the body mass index and waist circumference. The presence of 
xanthomas, which are usually not present in moderate hypertriglyceridemia, does not 
help to identify the underlying hypertriglyceridemic cause [2]. Laboratory screening 
should include a lipid profile (fasting or non-fasting) containing total cholesterol, LDL-C, 
HDL-C, TG and preferably apo B. Non-HDL-C concentrations can be easily calculated 
without additional costs as an alternative for apo B. In addition, creatinine levels reflect-
ing kidney function, TSH levels, and glucose or glycated haemoglobin A(1c) and “liver 
function” tests should be measured to search for renal failure, hypothyroidism, diabetes 
and liver disease, respectively. An apo E genotyping can be performed when the diag-
nosis of familial dysbetalipoproteinemia is considered.
Table 1: Primary and secondary causes of hypertriglyceridemia
Primary hypertriglyceridemia Secondary hypertriglyceridemia
Familial combined hyperlipidemia Obesity
Familial hypertriglyceridemia Diabetes mellitus
Familial dysbetalipoproteinemia Dietary patterns
Smoking
Very rare primary causes: Excessive alcohol intake
Tangier disease Hypothyroidism
Lipoprotein lipase deficiency End stage kidney disease
GP1HBP1 deficiency End stage liver disease
Apolipoprotein A-V deficiency Human Immunodeficiency Virus
Apolipoprotein C-II deficiency Use of medication
(estrogens, androgens, glucocorticoids, 
cyclosporines, tacrolimus, β-blockers, thiazide 
diuretics, synthetic retinoids, valproate and related 
drugs)[2,35,37]
GPIHBP1 = glycosylphosphatidylinositol-anchored high-density-binding protein 1
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Primary causes of hypertriglyceridemia
The three most common primary causes of hypertriglyceridemia are familial combined 
hyperlipidemia (FCH), familial hypertriglyceridemia and familial dysbetalipoprotein-
emia, which all affect approximately 1% of the population [2,35,38-40]. Besides the 
three most common primary hypertriglyceridemias, severe hypertriglyceridemia can 
already present during childhood due to very rare genetic disorders like LPL deficiency, 
apo A-V deficiency or apo C-II deficiency. Recently, the first human case with a GPIHBP1 
deficiency showing marked hypertriglyceridemia was published [41]. However, these 
rare disorders are beyond the scope of this review.
FCH is characterized by increased TG, LDL-C and apo B in combination with the 
presence of premature cardiovascular disease in at least one first degree relative [42,43]. 
Multiple genes are involved in FCH leading to an increased hepatic production of VLDL 
together with a decreased clearance of circulating remnants [43-50]. Insulin resistance 
often coincides with FCH [51]. The presence of small, dense LDL is another characteristic 
of FCH [52]. Cardiovascular risk is substantially increased in FCH [38-40] and it has even 
been suggested that approximately 10% of the patients with a myocardial infarction 
below the age of 60 years have FCH [53].
In contrast, familial hypertriglyceridemia (FHTG) is not associated with an increased 
risk of cardiovascular disease [38] and is characterized by an impaired catabolism of TRLs 
[35]. The exact genetic disorder is unknown, but several candidate genes have been 
postulated [54]. Lipid profiles from patients with FHTG typically show increased TG con-
centrations above 5.0 mmol/l, with decreased LDL-C and normal apo B concentrations. 
FHTG may not be accompanied by premature atherosclerosis, but chylomicronemia 
syndrome (TG > 20.00 mmol/l) can develop when FHTG is accompanied by other fac-
tors, which can raise TG levels substantially. Highly increased TG levels can cause acute 
pancreatitis, making treatment imperative [55-57].
Familial dysbetalipoproteinemia (FD), also called “remnant removal disease” or type 
III hyperlipoproteinemia according to the Fredrickson classification, is most frequently 
caused by homozygosity for an isoform of apo E, namely apo E2 [12]. Additional genetic 
or environmental factors such as obesity or diabetes are needed besides the apo E2/
E2 genotype for the development of hyperlipidemia, since only 10% of the subjects 
with the apo E2/E2 genotype develop hyperlipidemia [12]. For example estrogens may 
protect subjects with the apo E2/E2 genotype, since women do not develop type III 
hyperlipoproteinemia before the menopause, whereas males are already susceptible 
after adolescence [58]. Apo E2 has less affinity for the LDL-receptor, heparan sulfate 
proteoglycans and LDL receptor-related protein compared to the wild type apo E3, 
which leads to decreased hepatic removal of remnants [12,59]. In addition, the wild type 
apo E3 enhances the hydrolysis of TG compared to an inhibitory effect on the hydrolysis 
Management of hypertriglyceridemia 31
by apo E2 [60,61]. FD is typically characterized by TG levels above 3.5 mmol/l and total 
cholesterol levels above 7.5 mmol/l in combination with normal ranges for apo B and 
LDL-C and is associated with an increased cardiovascular risk [12,18,62].
Secondary causes of hypertriglyceridemia
Genetic defects can cause hypertriglyceridemia, but dietary habits and other abnormali-
ties can also contribute (Table 1). The most frequent cause of hypertriglyceridemia is 
obesity, a growing problem in Western countries [63]. Obesity has been associated with 
an increased mortality, largely by an increased risk of cardiovascular disease, which can 
be attributed by an increment of obesity related risk factors like hypertriglyceridemia 
[64]. Mildly obese subjects already have an impaired postprandial TG response, despite 
having normal fasting TG concentrations [65]. The mechanism of hypertriglyceridemia 
in the case of obesity has been linked to insulin resistance with an increased flux of 
FFA from the abdominal fat to the liver leading to increased hepatic VLDL produc-
tion [51,66]. Triglyceridemia increases even more because competition for clearance 
between VLDL and chylomicrons occur, since both share the same catabolic processes 
[65,67]. However, not all obese subjects develop hypertriglyceridemia, which is the main 
lipid disorder in obesity. A recent study has shown that increased plasma apo C-III, which 
inhibits hydrolysis, significantly contributes to the development of the hypertriglyceri-
demic waist [68,69]. Obesity can lead to insulin resistance and subsequently to type 2 
diabetes mellitus (T2DM). Lipid abnormalities are common in T2DM, which significantly 
add to the increased cardiovascular risk of patients with T2DM [70]. Very often TG are 
increased in patients with T2DM despite adequate treatment of the T2DM, probably 
because T2DM coexists with other disorders like obesity, smoking, alcohol consumption 
or the apo E2/E2 genotype [35].
Epidemiologic evidence is inconsistent on the effects of chronic alcohol consump-
tion on TG concentrations. In the fasting state, both unchanged and increased TG have 
been described in relation to increased alcohol consumption [71-74]. However, in 
postprandial studies high alcohol intake has been related to elevated TG in contrast to 
low and moderate consumption [26,74-76]. It has been proposed that alcohol impairs 
oxidation of FFA by mitochondria, which accelerates TG synthesis leading to an increased 
hepatic secretion of VLDL [77,78]. Low to moderate alcohol consumption (1-3 consump-
tions per day) would probably not have major effects on TG, whereas excessive intake 
can cause hypertriglyceridemia. Besides alcohol, smoking has especially an effect on 
postprandial lipemia [26]. Smokers showed a postprandial increase in chylomicrons and 
their respective remnants characterized by increased postprandial apo B48 concentra-
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tions. The increased number of chylomicrons and chylomicron remnants is probably due 
to a decreased clearance of chylomicron remnants [79].
Untreated hypothyroidism is frequently accompanied by hypercholesterolemia and 
possibly hypertriglyceridemia with increased concentrations of VLDL, LDL and also HDL 
[80]. Hypothyroidism leads to a reduced number of LDL receptors, which decreases the 
catabolism and turnover of mainly LDL and in part TRLs [81]. Hormone replacement 
therapy resulted in normalisation of total cholesterol and LDL-C, but TG concentrations 
remained unchanged [82,83]. However, it should be noted that the study groups were 
small and mean TG concentrations were normal at baseline.
Increased TG concentrations also occur in poorly controlled HIV infections together 
with decreased LDL-C and HDL-C concentrations. HIV-associated hypertriglyceridemia 
is caused by a combination of hepatic VLDL overproduction and reduced TG clearance 
[84]. In addition, antiretroviral therapy leads to lipodystrophy in 10 to 80 percent of the 
treated patients. The lipodystrophy impairs the storage of FFA in adipose tissue, which 
further increases the HIV-related hypertriglyceridemia [84].
TG concentrations are also frequently elevated in patients with end stage kidney 
disease, but cholesterol levels are mostly normal or even decreased. Secondly, the 
composition of the lipoproteins is also altered in end stage kidney disease. For example 
VLDL contains relatively more cholesterol and less TG in patients with end stage kidney 
disease. Moreover, clearance and hydrolysis of TRLs is altered by multiple mechanisms, 
which are reviewed in detail elsewhere [85,86].
Treatment of hypertriglyceridemia by diet and lifestyle
The non-pharmacological treatment with diet and increased physical activity is the most 
important strategy in reducing hypertriglyceridemia and is applicable on all patients 
with hypertriglyceridemia regardless the cause. In recent years, it has become clear that 
lifestyle factors including type of dietary fats, proteins, fibers, micronutrients, alcohol 
consumption, exercise, obesity and smoking have a strong impact on triglyceridemia 
[36]. Since all these factors can be altered via improved lifestyle behaviour, hypertri-
glyceridemia and subsequently reducing cardiovascular risk can be partly reduced by 
non-pharmacological strategies [87].
The average Western style meal contains 20-40 g of fat and a postprandial rise in TG 
is already evident after the ingestion of 30 g of fat. Postprandial triglyceridemia is likely 
to be present most of the day, because people typically eat 3 to 4 meals a day [26]. The 
amount of dietary fat remains the most important determinant of postprandial lipemia 
[36], but the type of dietary fat influences triglyceridemia as well. Postprandial lipemia is 
most pronounced after ingestion of saturated fatty acids (SFA), which are found in high 
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amounts in animal fat, followed by monounsaturated fatty acids (MUFA), the main fatty 
acids in olive oil. In contrast, dietary polyunsaturated fatty acids (PUFA), which are mainly 
found in vegetables (n-6 PUFA) and fish oils (n-3 PUFA), show the smallest postprandial 
increase in TG [36,88]. Obese subjects probably experience more beneficial effects of 
a diet rich in PUFA and MUFA and low on SFA compared to lean subjects. Chylomicron 
remnant concentrations were reduced after a meal with olive oil (22% SFA, 38% MUFA, 
4% PUFA) compared to a meal with butter (35% SFA, 22% MUFA, 4% PUFA), but only in 
obese subjects and not in lean subjects [89].
Besides dietary fats, carbohydrates may influence TG concentrations as well. Re-
duced postprandial TG responses have been observed with lean red meat, soy protein, 
casein and whey protein [36,90,91]. In addition, indigestible carbohydrates like oat 
bran, wheat fiber, wheat germ and psyllium husk also have beneficial effects on TG 
concentrations [36,92,93]. In contrast, fructose, which is abundant in soft drinks, may 
enhance postprandial lipemia when consumed more than 50 g per day [94]. Moreover, 
micronutrients like vitamins and polyphenols found in fruit and beverages like green tea 
are believed to reduce postprandial lipemia [95,96]. It was recently shown for the first 
time that a high intake of fruit and vegetables was indeed significantly associated with 
a reduced risk of cardiovascular disease [87].
Obesity is a strong determinant for hypertriglyceridemia as well and obese patients 
should be urged to lose weight regardless of the hypertriglyceridemic cause. Moderate 
weight loss induced by a diet low on carbohydrates and SFA combined with a slight in-
crease in physical activity resulted in a 27%-46% reduction in postprandial TG responses 
[97]. Moderate weight loss normalized postprandial lipemia, despite persisting obesity. 
Regular physical activity does reduce weight, but acute exercise bouts alone also re-
duced postprandial lipemia by 24% to 35% by an increase in LPL activity [36]. However, 
exercise needs to be done on a regular basis, because the improved clearance of TG-rich 
lipoproteins already attenuates after 2 to 3 days [98]. 
In addition to weight loss and exercise, smoking increases TG, postprandial chy-
lomicrons and their remnants suggesting a beneficial effect of smoking cessation on 
TG. However, a meta-analysis could not confirm a TG lowering effect from cessation 
of smoking [99]. Nevertheless, smoking cessation should be promoted for improving 
cardiovascular health and many other reasons [36].
Mechanisms of triglyceride lowering pharmacotherapy
Isolated hypertriglyceridemia can be present, but hypertriglyceridemia is more fre-
quently present in combination with other lipid abnormalities like increased LDL-C or 
decreased HDL-C depending on the underlying etiology. The four main pharmacological 
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agents used to treat hypertriglyceridemic disorders, either isolated or in combination 
with other lipid abnormalities, are fibrates, statins, nicotinic acid and omega-3 fatty 
acids. Each of them has different mechanisms of action to modify TG synthesis and clear-



































Figure 2: Schematic representation of triglyceride (TG) lowering mechanisms by different pharmacological 
agents: fibrates, nicotinic acid, statins and omega-3 fatty acids (Ω-3). Fibrates increase transcription of LPL 
and decrease transcription of apo C-III, which all improves TG clearance from plasma. Nicotinic acid reduces 
the lipolysis of adipocytes leading to reduced hepatic TG synthesis. Moreover, niacin has the potential to 
increase apoB100 degradation in hepatocytes. Statins have only a modest effect on TG and inhibit the 
enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is the rate limiting step of 
the hepatic cholesterol synthesis. Reduction in the endogenous cholesterol synthesis leads to upregulation 
of the LDL receptor (LDL-R) and subsequently increased hepatic uptake of LDL. Omega-3 fatty acids have 
multiple effects on TG metabolism. First of all, omega-3 fatty acids lower gene transcription of sterol 
regulatory element-binding protein-1c leading to decreased hepatic synthesis of fatty acids and thus TG 
synthesis. In addition, TG clearance from VLDL and chylomicrons is stimulated by omega-3 fatty acids, 
because it is a ligand for the farnesoid X receptor, which suppresses apo C-III gene expression and induces 
apo C-II gene expression. Hydrolysis of VLDL and chylomicrons is also increased by omega-3 fatty acids, 
potentially via increased lipoprotein lipase (LPL) gene expression in adipose tissue.
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Fibrates (fibric acid derivatives) are synthetic ligands that bind to the peroxisome 
proliferator-activated receptor (PPAR)-α and are known for their TG-lowering and HDL-C 
increasing effect. Activation of PPAR-α modulates many genes affecting TG metabolism 
including LPL, APOC3 and APOA5 [100]. Fibrates increase transcription of LPL and de-
crease transcription of apo C-III, which favours TG clearance from plasma [101,102]. Most 
studies investigating the effect of fibrates on apo B metabolism reported increased VLDL 
apo B100 clearance and in some subjects reduced VLDL apo B100 secretion in patients 
with hypertriglyceridemia [100]. Treatment with fenofibrate also resulted in reduced apo 
B48 secretion in two subjects with a rare combination of heterozygous familial hyper-
cholesterolemia combined with dysbetalipoproteinemia [103]. In addition, the catabolic 
rate of chylomicrons is increased by fenofibrate in hypertriglyceridemic subjects with 
T2DM [104].
Statins mainly reduce LDL-C, non-HDL-C and apoB concentrations, but statins 
modestly lower TG levels in hypertriglyceridemic subjects as well [105]. The TG lowering 
effect of the different statins is comparable with the percentage of cholesterol lowering 
effect and is probably a reflection of reduced cholesterol content of the TRLs since TG 
strongly correlate with cholesterol concentrations in the TRLs [25]. Statins inhibit the 
enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is the 
rate limiting step of the hepatic cholesterol synthesis. Reduction of the endogenous 
cholesterol synthesis leads to upregulation of the LDL receptor and subsequently in-
creased hepatic uptake of LDL. When hepatic uptake of LDL is increased, LDL-C and apo 
B concentrations decrease.
Nicotinic acid has multiple effects on serum lipoprotein levels by raising HDL-C, 
lowering LDL-C and decreasing TG by 13-50% [106-108]. Nicotinic acid inhibits the 
lipolysis in adipocytes accompanied by a drop in FFA by binding of nicotinic acid to the 
nicotinic acid receptor [109]. This reduces the supply of FFA and subsequently hepatic 
TG synthesis and VLDL formation [110,111]. In addition, an in vitro study has shown the 
potential of nicotinic acid to degrade intracellular apo B100 [112]. The HDL-C raising 
property of nicotinic acid is probably a result of decreased TG concentrations. When TG 
levels are lowered, cholesterylesters are less transferred from VLDL to HDL in exchange 
for TG by CETP. 
Omega-3 fatty acids are PUFA obtained from fatty fish or fish-oil supplements and 
consist of α-linoleic acid (ALA, 18:3n-3), eicosapentaenoic acid (EPA, 20:5n-3) and doco-
sahexaenoic acid (DHA, 22:6n-3) [113]. Humans are unable to synthesize omega-3 fatty 
acids and only a small percentage of ALA is converted to EPA [113]. Therefore, supply of 
EPA and DHA depends on dietary intake. Fatty acids with multiple double bonds, like 
omega-3 fatty acids, are essential to increase cell membrane fluidity for improved recep-
tor functions and signalling pathways [113]. Studies have shown that omega-3 fatty 
acids lower TG by reducing hepatic TG synthesis and VLDL secretion and enhancing TG 
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clearance from circulating chylomicrons and VLDL. However, animal studies investigat-
ing the exact mechanisms were not always consistent or physiologically relevant [114]. 
It has been shown that omega-3 fatty acids lower gene transcription of sterol regulatory 
element-binding protein-1c (SREBP-1c), which stimulates the hepatic synthesis of fatty 
acids and thus TG synthesis [115]. In addition, TG clearance from VLDL and chylomicrons 
is stimulated by DHA, because it is a ligand for the farnesoid X receptor (FXR), which sup-
presses apo C-III gene expression and induces apo C-II gene expression [113,116,117]. 
Hydrolysis of TRLs is even more stimulated by omega-3 fatty acids via increased LPL 
gene expression in adipose tissue [118,119].
Treatment targets
Treatment of hypertriglyceridemia is complex due to the multifactorial basis of this lipid 
abnormality. Lifestyle changes including weight loss, physical exercise and a healthy 
diet should be advised to all patients with hypertriglyceridemia. The importance of 
lifestyle changes is clear, but different opinions exist about the pharmacological treat-
ment of hypertriglyceridemia. Some pharmacological agents are more appropriate than 
others in certain cases of hypertriglyceridemia but evidence is often lacking (Table 2). 
The recent ESC/EAS guidelines advise treatment targets of LDL-C < 1.8 mmol/l and < 
2.5 mmol/l in subjects with very high and high cardiovascular risk, respectively [21]. 
Non-HDL-C is advised as a secondary treatment target in case of hypertriglyceridemia, 
which treatment target is 0.8 mmol/l higher than the corresponding LDL-C target [21]. 
Moreover, apo B can be used as a treatment target, because it reflects the number of 
Table 2: Choosing the right pharmacological agent depends on the underlying hypertriglyceridemic 
cause. Lifestyle changes are always important besides pharmacological therapy.
Etiology of 
hypertriglyceridemia
Choice of pharmacological 
treatment in specific situations




High dose statins, sometimes in 




· Diet low on fat and SFA and 
rich in dietary fibres, soy, ca-
sein, whey and lean red meat 
and PUFA.
· Reducing alcohol
· Cessation of smoking
Familial hypertriglyceridemia Fibrates, nicotinic acid 
Familial dysbetalipoproteinemia Statins + fibrate when lifestyle 
changes are insufficient
Obesity None
Type 2 diabetes mellitus High dose statins
Hypothyroidism Adequate treatment with thyroid 
hormone
Note: do not combine gemfibrozil with a statin. Instead ciprofibrate, bezafibrate or fenofibrate can be 
combined with a statin
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atherogenic particles. Treatment targets of apo B are 0.8 g/l and 1.0 g/l for subjects with 
very high and high cardiovascular risk, respectively [21]. No specific treatment targets 
are available for TG or for the addition of a secondary agent on top of statin therapy 
to treat the residual cardiovascular risk associated with hypertriglyceridemia. However, 
more evidence is becoming available on efficacy and safety concerning combination 
therapies [120]. 
Pharmacological treatment for different causes of 
hypertriglyceridemia
Statins are the first choice of treatment for FCH since it is characterised by increased 
hepatic VLDL production, small dense LDL and substantially increased cardiovascular 
risk [52,121]. Although no specific studies exist on the long-term effects of treatment 
of FCH, results can be extrapolated from subjects with combined hyperlipidemia. High 
dosages of statins are advised to further reduce apo B and non-HDL-C, because of the 
increased remnant cholesterol in subjects with FCH. Lowering non-HDL-C results in a 
linear reduction of cardiovascular risk [122] and non-HDL-C is the strongest predictor 
of the residual cardiovascular risk in subjects already on statin therapy [32]. When statin 
related myopathy occurs, a combination of fenofibrate and ezetimibe, an intestinal cho-
lesterol absorption inhibitor, can be prescribed. This combination decreases cholesterol 
in both VLDL and LDL and reduces the amount of small dense LDL particles [123].
Treatment of FHTG should not be aimed at reducing cardiovascular risk, but to 
reduce the risk of hypertriglyceridemia associated pancreatitis [120]. Medical treat-
ment with a fibrate should be initiated when TG are > 10.00 mmol/l to reduce the risk 
of pancreatitis [2], but the threshold for developing pancreatitis could be much higher 
[2,57]. A common side effect of fibrates is an increase in serum creatinine, which is often 
reversible [124]. Nicotinic acid can be used as an alternative when fibrates can not be 
prescribed, because nicotinic acid has a strong TG lowering capacity of 30-50% as well 
[125]. Patients receiving nicotinic acid should be warned for the frequent occurring side 
effect of severe flushing, which lasts for approximately 30 to 90 minutes after intake 
[109].
The most optimal pharmacological treatment of FD is controversial since FD seems 
to improve by all available interventions. It should be noted that most subjects with 
the apo E2/E2 genotype have normal lipid parameters. Pharmacological treatment is 
indicated when lifestyle changes and treatment of other secondary causes have not 
improved the combined hyperlipidemia [126]. Both statins and fibrates have been 
investigated in relation to FD, but studies on clinical outcomes are unavailable. Statins 
reduce mainly LDL-C, whereas fibrates lower mainly TG in subjects with FD [62,127]. In 
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addition, both bezafibrate 400 mg daily and atorvastatin 10 mg show both a reduction 
in non-HDL-C of approximately 45% [62]. Combination therapy with a statin and fibrate 
may be considered in therapy refractory subjects [126,128,129].
Post hoc subgroup analyses showed that fibrates reduce cardiovascular risk sub-
stantially in subjects with characteristics of the metabolic syndrome [130-132]. However, 
results could not always be replicated. Treatment of patients with T2DM with fenofibrate 
alone or on top of statin therapy did not result in a reduction of cardiovascular events 
[133,134]. It seems that gemfibrozil has more potential to reduce cardiovascular risk in 
subjects with the metabolic syndrome compared to bezafibrate, possibly by decreased 
concentrations of small dense LDL particles [135,136]. However, statins are the first 
choice of treatment for diabetic dyslipidemia and gemfibrozil should not be combined 
with a statin, because of an increased risk of rhabdomyolysis [102,120]. Targets for 
patients with T2DM are LDL-C concentrations < 1.8 mmol/l, but often diabetic patients 
have elevated TG as well [21]. In the case of hypertriglyceridemia, statin therapy should 
be intensified to further reduce non-HDL-C concentrations < 2.6 mmol/l [21].
Omega-3 fatty acids reduce TG levels but are insufficient as monotherapy. However, 
they can be safely combined with other drugs to further decrease TG concentrations 
[113]. Drugs like cholesterol absorption inhibitors (ezetimibe) or bile acid sequestrants, 
have no place in the specific treatment of hypertriglyceridemia and the latter are even 
contraindicated since these agents can increase TG concentrations.
Conclusion
Hypertriglyceridemia is common and can be caused by primary lipid disorders like 
familial combined hyperlipidemia, familial hypertriglyceridemia and familial dysbet-
alipoproteinemia or by secondary causes, mainly obesity and T2DM. It is often possible 
to diagnose the underlying hypertriglyceridemic cause with a family history, physical 
examination and lipid profile including apo B. Treatment should always include lifestyle 
changes and different pharmacological treatment options exist aiming at different 
pathways within the vast lipid metabolism. Pharmacological agents reduce the TG-rich 
lipoprotein secretion, increase lipolysis of TG-rich lipoproteins or reduce remnant cho-
lesterol levels. Multiple agents can be used when monotherapy is insufficient to reach 
treatment targets. In addition, families should be screened for lipid abnormalities in case 
of a familial lipid disorder.
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Abstract
Background: Triglyceride (TG) levels measured in either the fasting or non-fasting state 
predict the risk of cardiovascular disease (CVD). Since CVD risk assessment is affected 
by variability in TG, the aim of the study was to investigate intra-individual variability of 
non-fasting TG. 
Methods: Capillary triglyceride (cTG) levels were measured in 246 free-living individuals 
at six time-points during the day on three separate occasions. Intra-individual variability 
in cTG was assessed by calculating the standard deviation of three measures at each 
time-point. Subjects were analyzed by gender and by fasting TG level.
Results: In the fasting state, intra-individual variability was similar in males and females 
(0.28 and 0.35 mmol/l, respectively), but increased significantly in male but not in female 
subjects during the day, i.e., 0.28 to 0.69, and 0.35 to 0.36 mmol/l, resp. Subjects with 
higher fasting TG levels had greater absolute variability in both fasting and non-fasting 
TG. 
Conclusions: The variability in non-fasting TG is greater in males and in individuals with 
higher levels of TG. Since greatest variability in non-fasting TG occurs very late in the day, 
it is unlikely to affect the assessment of CVD risk, which is based on a blood sample taken 
during daylight hours.
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Introduction
Blood triglyceride (TG) concentration increases during the day and decreases overnight 
in human subjects [1-4]. Men have higher fasting and postprandial levels of TG than 
women [5]. Their TG levels increase by about 75% during the day, while women have 
a more modest increase, i.e., around 25% [6]. Due to the diurnal changes in blood TG 
levels, TG measurements are usually carried out in the fasting state for cardiovascular 
risk assessment [5]. However, most patients visit the hospital in the non-fasting state and 
are therefore compelled to have their blood taken on a different occasion. Furthermore, 
prospective studies have shown that non-fasting TG levels are associated with increased 
risk of cardiovascular disease (CVD) [6,7] and it has been suggested that non-fasting TG 
levels are a stronger predictor of cardiovascular disease than fasting TG levels [8,9]. 
Even without the influence of sequential meals, fasting TG levels have a high intra-
individual day-to-day variability of 15% to 30% [10-15]. Only a limited number of studies 
have investigated the variability of non-fasting TG levels and this has been restricted 
to a relatively small number of individuals [11,15,16]. The purpose of the present study 
was to determine differences in intra-individual variability in fasting compared to non-
fasting TG levels. Our aim was: 1) to quantitate the extent to which TG increase in differ-
ent subjects during the day, 2) to study the extent to which intra-individual variability 
in TG vary between males and females, and 3) to determine if intra-individual variability 
in TG differ between normotriglyceridemic and hypertriglyceridemic subjects. These 
questions were addressed by analyzing data obtained from previous studies always 
using the same protocol, in which a hand-held point-of-care testing device was used 
to determine capillary TG concentrations (cTG) during the day, in free-living male and 
female individuals [16-21]. 
Material and methods
Subjects and capillary measurements
Subjects were healthy volunteers or patients with hyperlipidemia or a known medical 
history of CVD or type 2 diabetes mellitus (T2DM) that had participated in clinical studies 
aimed to investigate factors influencing postprandial lipemia [16-21]. Males and females 
were aged 18-80 years. Exclusion criteria were renal, liver or thyroid disease and/or the 
use of lipid lowering drugs. Participants using lipid lowering drugs were investigated 
after withdrawal of these drugs during 4 weeks. Briefly, subjects visited the department 
after a 12-hour overnight fast. Height, weight, blood pressure and waist circumference 
were measured. Self-measurement of cTG was performed with a triglyceride-specific 
point-of-care testing device (Accutrend GCT®, Roche Diagnostics, Germany) [22,23]. Sub-
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jects were instructed to measure their cTG on three different days (preferably Monday, 
Wednesday and Friday - not weekend days) at the following six time-points: fasting, 
before and three hours after lunch, before and three hours after dinner, and at bedtime. 
The three-hour postprandial measurements were performed exactly three hours after 
the meals, regardless of intake of snacks. Subjects were requested to refrain from heavy 
physical activity, although normal daily activities such as riding a bike to work were 
allowed. Subjects did not receive recommendations concerning the frequency and 
composition of meals and were requested to follow their normal diet during the study. 
Alcohol consumption was recorded in a diary. The diaries were evaluated by a trained 
physician together with each subject. 
The measurement range for cTG was 0.80 to 6.86 mmol/l. When cTG levels were 
below 0.80 mmol/l or above 6.86 mmol/l the Accutrend registered a cTG level of 0.80 
and 6.86 mmol/l respectively. Besides this limitation, the TG-analyser detects TG reli-
ably, regardless of the type of lipoprotein carrying the TG in the blood sample (e.g., 
chylomicron or VLDL) [22]. In a previous study, variation coefficients for different cTG 
concentrations were 3.3% for high TG (6.12 mmol/l) and 5.3% for low TG (1.81 mmol/l) 
[23]. The correlation coefficient between cTG measurements with the TG-analyser and 
plasma measurements according to enzymatic methods is 0.94 [23]. Similar results have 
been obtained in our laboratory [16,17]. Capillary TG concentrations are generally 0.2-
0.3 mmol/l higher than TG concentrations in venous plasma [16-20,22,23], which may 
reflect differences between capillary and venous samples or differences in methodology. 
Analytical determinations 
Fasting blood was collected at inclusion after a 12 h fast for measurement of lipids, 
apolipoproteins and insulin from plasma. Cholesterol and TG in plasma and HDL choles-
terol (obtained after precipitation with dextransulphate/MgCl2), were determined using 
a Vitros 250 analyzer (Johnson & Johnson Rochester, NY, USA). Plasma apolipoprotein 
(apo) B was measured by nephelometry using apo B monoclonal antibodies (Behring 
Diagnostics NV, OSAN 14/15). Plasma apo AI was measured by nephelometry using apo 
AI monoclonal antibodies (Behring Diagnostics NV, OUED 14/15). Insulin was measured 
by competitive radio immunoassay with polyclonal antibodies. LDL cholesterol was 
calculated using the Friedewald calculations (if fasting TG were below 4.6 mmol/l). For 
estimation of the insulin sensitivity, the HOMA-IR index (= glucose (mmol/l) * insulin 
(mU/l) / 22.5) was calculated.
Statistics
Data are given as mean ± standard deviations. Intra-individual variability in cTG are 
given as medians with interquartile ranges (IQR), because of their skewed distribution. 
Capillary TG measurements of 0.80 mmol/l were excluded from the analysis of intra-
Diurnal triglyceride variability 53
individual cTG variability, since these measures reflected the lower limit of the point-
of-care testing device. Absolute intra-individual variation in cTG (SD) was assessed by 
calculating the standard deviation for the three cTG measurements obtained at each 
specific time-point. The relative intra-individual variation in cTG was assessed for each 
individual at every time-point by calculating the coefficient of variation (CV). The formula 
to calculate the CV for cTG was the standard deviation divided by mean cTG at a specific 
time-point multiplied by 100 [16]. Subjects were also divided into tertiles based on their 
three-day average fasting cTG levels. Ranges were calculated for males and females 
separately, because TG levels are lower in females [18,21]. The TG ranges for tertiles were 
respectively 1.03 – 1.62 mmol/l for males and 0.98 – 1.49 mmol/l for females. Differences 
between two groups were tested by Student’s t-test or Chi-square test where appropri-
ate. Comparisons between multiple groups were performed using one-way ANOVA with 
Bonferroni correction for numerical data and Chi-square test or Fisher’s exact test for 
categorical data. For ANOVA analysis cTG, SD and CV were logarithmically transformed 
to obtain a normal distribution. The Pearson’s correlation was used to test for associa-
tions between the SD and different variables. Statistical analyses were performed using 
PASW statistics version 18.0. Statistical significance was defined as P < 0.05.
Results
Baseline characteristics of male (n = 125) and female subjects (n = 121) are shown in 
Table 1. The participants had an average age of 40 years and a mean BMI of 25. About 
one-fifth of the subjects had a history of CVD and only six subjects had been diagnosed 
with T2DM. Nearly one-third of the subjects were smokers. Average lipid and apoli-
poprotein levels are shown in Table 1, and significant differences between males and 
females are indicated.
The capillary TG concentration in the fasting state was not significantly different 
between males and females (Table 2). However, after lunch and for the rest of the 
day, cTG was significantly higher in males. In both male and female subjects, cTG rose 
significantly during the day, with a maximum increase of 1.05 ± 0.87 mmol/l in males, 
which occurred at bedtime, and 0.53 ± 0.69 mmol/l in females, which occurred after 
dinner. cTG levels were significantly higher in males compared to females after lunch 
until bedtime (P < 0.001).
The absolute and relative intra-individual variability in cTG for males and females in 
the fasting state and at time-points during the day are shown in Table 3. Median values 
are given since the data were skewed. In the fasting state, the intra-individual variability 
was similar in males and females (0.28 and 0.35 mmol/l, respectively), representing on 
average a relative variability of 21%. This variability increased as the day progressed in 
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Table 1: Baseline characteristics of female and male subjects. 
Females
 (n = 121)
Males
 (n = 125)
P-value
Age (years) 41.3 ± 13.3 39.4 ± 13.4 NS
BMI (weight/height2) 25.5 ± 5.2 24.5 ± 3.5 NS
History of CVD (n, %) 17 (18.1%) 25 (23.6%) NS
History of T2DM (n, %) 3 (2.7%) 3 (2.5%) NS
HOMA-IR 2.97 ± 3.07 2.13 ± 1.79 P = 0.001
Smokers (n, %) 36 (31.3%) 32 (26.4%) NS
Alcohol intake (g/day) 7.6 ± 11.5 17.8 ± 20.9 P < 0.001
Use of aspirin (n, %) 5 (6.7%) 11 (10.8%) NS
Use of ß-blockers (n, %) 9 (7.9%) 13 (10.8%) NS
Use of ACE-inhibitors (n, %) 3 (2.6%) 7 (5.8%) NS
Use of diuretics (n, %) 3 (2.6%) 3 (2.5%) NS
Use of calcium-antagonists (n, %) 5 (4.1%) 5 (4.2%) NS
Use of oral contraceptives (n, %) 30 (51.7%) 0 (0.0%) P < 0.001
Fasting plasma TG (mmol/l) 1.23 ± 0.74 1.33 ± 0.78 NS
Total cholesterol (mmol/l) 5.0 ± 1.2 5.2 ± 1.0 NS
LDL-C (mmol/l) 3.4 ± 1.1 3.8 ± 1.0 P = 0.009
HDL-C (mmol/l) 1.42 ± 0.40 1.21 ± 0.30 P < 0.001
Apo B (g/l) 0.85 ± 0.26 0.99 ± 0.25 P < 0.001
Apo A-I (g/l) 1.50 ± 0.32 1.32 ± 0.21 P < 0.001
Data are given as mean ± standard deviation unless stated otherwise.
Table 2: Mean capillary triglyceride concentration (cTG) and mean increase in cTG at time-points 












Mean increase in 
cTG from fasting
(mmol/l)
Fasting 1.48 ± 0.80 - 1.54 ± 0.77 -
Before lunch 1.61 ± 0.85 0.13 ± 0.44 1.68 ± 0.82 0.14 ± 0.63
After lunch 1.82 ± 1.05 0.34 ± 0.63 2.08 ± 0.95 * a 0.54 ± 0.67 *
Before dinner 1.75 ± 1.01 0.28 ± 0.50 1.96 ± 0.93 * a 0.43 ± 0.62 *
After dinner 2.00 ± 1.14 a 0.53 ± 0.69 2.53 ± 1.16 ** a 0.99 ± 0.87 **
Bedtime 1.92 ± 1.08 a 0.45 ± 0.75 2.59 ± 1.16 ** a 1.05 ± 0.87 **
Data represent means ± SD for female (n = 121) and male (n = 125) subjects.
*  Significantly different from corresponding value in females (P < 0.05).
** Significantly different from corresponding value in females (P < 0.001).
a Significantly different from fasting (P < 0.01).
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males but not in females. The absolute variability was significantly greater after dinner 
and at bedtime (0.64 and 0.69 mmol/l) compared to the beginning of the day (0.28 
mmol/l) in males and it was also significantly greater at the end-of-day time-points 
compared to female subjects. 
Subjects were divided into tertiles based on their three-day average fasting cTG 
concentration. Baseline characteristics from tertile data by gender are shown in Table 4. 
Both females and males with the highest levels of triglyceridemia were older and showed 
increased BMI, HOMA-IR, total cholesterol and apo B. Moreover, males with the highest 
level of triglyceridemia were more frequently smokers, had a higher prevalence of CVD, 
and presented with increased fasting plasma TG and decreased HDL-C concentrations. 
At all time-points, cTG was significantly higher in females and males in the second 
tertile compared to subjects in the first tertile, and as expected subjects in the third 
tertile showed the highest cTG concentrations. Surprisingly, no differences were found 
in mean increase in diurnal cTG between the tertiles in both females and males (Tables 5 
and 6). Fasting and non-fasting absolute intra-individual variability was increased in fe-
males and males with the highest level of triglyceridemia compared to subjects from the 
lowest tertile (Tables 7 and 8). However, statistical significance was not reached for males 
at time-points before dinner and at bedtime. In contrast, the relative intra-individual 
variability was mostly unchanged between the tertiles, except for the first male tertile 
in the fasting state, which was significantly lower compared to the second and third 
Table 3: Intra-individual variability in capillary triglyceride levels at time-points during the day in female 

















Fasting 0.35 (0.19-0.54) 20.5 (12.9-27.8) 0.28 (0.13-0.67) 21.0 (9.7-35.3)
Before lunch 0.28 (0.13-0.53) 17.6 (8.6-25.6) 0.35 (0.18-0.61) 19.7 (10.8-33.6)
After lunch 0.40 (0.18-0.67) 22.3 (12.8-32.4) 0.41 (0.19-0.75) 21.4 (9.9-33.2)
Before dinner 0.33 (0.16-0.56) 18.1 (12.4-32.4) 0.41 (0.23-0.69) * 23.2 (13.3-34.9)
After dinner 0.44 (0.20-0.71) 21.3 (12.4-27.7) 0.64 (0.32-0.98) ** a 25.5 (14.4-36.8)
Bedtime 0.36 (0.18-0.79) 21.6 (11.0-37.4) 0.69 (0.39-1.00) ** b 27.3 (17.3-41.7) *
Intra-individual variability is given in absolute terms (mmol/l) as a standard deviation for cTG (SD) measured 
on three separate occasions, and in relative terms (%) as a coefficient of variation for cTG measured on three 
occasions. Data are given as medians with interquartile ranges (IQR) for females (n = 121) and males (n = 
125).
* Significantly different from corresponding value in female subjects (P < 0.05).
** Significantly different from corresponding value in female subjects (P < 0.01).
a Significantly different from fasting (P < 0.01).
b Significantly different from fasting (P < 0.001).
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 (n = 40)
Second 
tertile
  (n = 41)
Third 
tertile
 (n = 40)
First 
tertile
 (n = 42)
Second 
tertile
  (n = 41)
Third 
tertile
 (n = 42)
Age (years) 37.1 ± 12.5 41.1 ±10.9 45.9 ± 
15.6 *




BMI (kg/m2) 23.1 ± 3.1 24.6 ± 3.4 28.8 ± 6.6 
***
22.6 ± 2.3 24.0 ± 3.1 26.8 ± 3.5 
***
History of CVD (n, %) 2 (7.1%) 7 (20.6%) 8 (25%) 2 (6.1%) 7 (17.1%) 16 (47.1%) 
***
History of T2DM (n, %) 0 (0%) 0 (0%) 3 (8.6%) 0 (0%) 0 (0%) 3 (7.5%)
HOMA-IR 1.89 ± 0.75 2.47 ±1.18 4.56 ± 4.82 
***




Smokers (n, %) 9 (23.1) 12 (30.8%) 15 (40.5%) 7 (17.5%) 9 (22.0%) 16 (39%) *
Alcohol intake (g/day) 8.8 ± 9.8 6.7 ± 7.4 7.5 ± 16.1 13.8 ± 17.8 20.7 ± 
22.5
18.8 ± 22.0
Use of aspirin (n,%) 0 (0.0%) 2 (9.1%) 3 (13.0%) 1 (2.4%) 4 (11.1%) 6 (24.0%) *
Use of ß-blockers (n, %) 1 (2.6%) 5 (12.5%) 3 (8.3%) 1 (2.4%) 4 (10.0%) 8 (20.5%) *
Use of ACE-inhibitors (n, %) 1 (2.6%) 1 (2.5%) 1 (2.8%) 0 (0.0%) 1 (2.5%) 6 (15.4%) *
Use of diuretics (n, %) 1 (2.6%) 1 (2.4%) 2 (5.4%) 0 (0.0%) 1 (2.5%) 2 (5.1%)
Use of calcium-antagonists 
(n, %) 
2 (5.0%) 3 (7.5%) 2 (5.4%) 0 (0.0%) 3 (7.5%) 2 (4.8%)
Use of oral contraceptives 
(n, %)
8 (40.0%) 13 (56.5%) 6 (60%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Fasting plasma TG (mmol/l) 0.75 ± 0.31 1.06 ± 0.53 1.92 ± 0.76 1.01 ± 0.41 1.06 ± 
0.35
1.91 ± 1.02 
***
Total cholesterol (mmol/l) 4.5 ± 0.9 5.0 ± 1.1 5.7 ± 1.2 
***
4.8 ± 0.9 5.3 ± 1.07 5.5 ± 1.08 *
LDL-C (mmol/l) 2.9 ± 0.8 3.4 ± 1.0 4.1 ± 1.1 3.3 ± 0.9 3.8 ± 1.09 4.2 ± 1.0
HDL-C (mmol/l) 1.50 ± 0.34 1.48 ± 0.37 1.28 ± 0.47 1.31 ± 0.30 1.28 ± 
0.24
1.03 ± 0.27 
***
Apo B (g/l) 0.70 ±0.16 0.85 ± 
0.25 *
1.01 ± 0.25 
***




Apo A-I (g/l) 1.50 ± 0.37 1.56 ± 0.25 1.44 ± 0.37 1.35 ± 0.21 1.36 ± 
0.18
1.24 ± 0.24 
**
Data represent means ± SD for females (n = 121) and males (n = 125) divided into tertiles based on their 
three-day average fasting cTG. 
* Significantly different from corresponding value in subjects from first tertile (P < 0.05).
** Significantly different from corresponding value in subjects from second tertile (P < 0.05).
*** Significantly different from corresponding value in subjects from first and second tertile (P < 0.05).
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Table 5: Mean capillary triglyceride concentration (cTG) and mean increase in cTG at time-points during the 































Fasting 0.84 ± 0.06 * - 1.21 ± 0.16 * - 2.39 ± 0.77 * -
Before lunch 0.99 ± 0.21 * 0.15 ± 0.21 1.35 ± 0.36 * 0.14 ± 0.36 2.51 ± 0.88 * 0.11 ± 0.65
After lunch 1.08 ± 0.28 * b 0.24 ± 0.27 1.61 ± 0.70 * 0.40 ± 0.72 2.78 ± 1.11 * 0.39 ± 0.79
Before dinner 1.04 ± 0.23 * a 0.21 ± 0.23 1.54 ± 0.57 * 0.33 ± 0.56 2.69 ± 1.13 * 0.29 ± 0.62
After dinner 1.20 ± 0.41 * b 0.36 ± 0.41 1.80 ± 0.76 * b 0.59 ± 0.76 3.02 ± 1.23 * 0.63 ± 0.80
Bedtime 1.27 ± 0.37 * b 0.43 ± 0.38 1.67 ± 0.62 * a 0.46 ± 0.63 2.84 ± 1.30 * 0.45 ± 1.09
Data represent means ± SD for female subjects (n = 121) divided into tertiles based on their three-day 
average fasting cTG.
* Significantly different between corresponding values of all three tertiles (all P < 0.001)
a Significantly different from fasting (P < 0.05)
b Significantly different from fasting (P < 0.001)
Table 6: Mean capillary triglyceride concentration (cTG) and mean increase in cTG at time-points during the 































Fasting 0.90 ± 0.07 * - 1.30 ± 0.19 * - 2.40 ± 0.72 * -
Before lunch 1.13 ± 0.37 * a 0.23 ± 0.36 1.54 ± 0.54 * 0.24 ± 0.54 2.35 ± 0.90 * -0.05 ± 0.86
After lunch 1.35 ± 0.45 * b 0.45 ± 0.46 2.00 ± 0.57 * b 0.69 ± 0.55 2.88 ± 1.00 * 0.48 ± 0.90
Before dinner 1.31 ± 0.34 * b 0.41 ± 0.34 1.81 ± 0.53 * b 0.51 ± 0.52 2.77 ± 1.04 * 0.36 ± 0.89
After dinner 1.74 ± 0.60 * b 0.84 ± 0.57 2.46 ± 0.86 * b 1.16 ± 0.86 3.39 ± 1.26 * a 0.99 ± 1.10
Bedtime 1.84 ± 0.66 * b 0.94 ± 0.64 2.46 ± 0.84 * b 1.16 ± 0.80 3.47 ± 1.25 * b 1.06 ± 1.12
Data represent means ± SD for male subjects (n = 125) divided into tertiles based on their three-day average 
fasting cTG.
* Significantly different between corresponding values of all three tertiles (all P < 0.01)
a Significantly different from fasting (P < 0.05)









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































tertiles and for the second tertile in females after dinner, which was significantly higher 
compared to the first tertile (Tables 7 and 8). 
Similarly to the total female group, the variability did not increase significantly as 
the day progressed when females were divided into tertiles, except for the absolute 
intra-individual variability after dinner, which was significantly higher in the second 
tertile compared to the first tertile (Table 7). In males, the variability increased as the day 
progressed, except in the highest tertile. In male subjects from the first tertile, the abso-
lute and relative variability were increased before dinner, after dinner and at bedtime. 
In males from the second tertile, only the absolute variability was increased after dinner 
and at bedtime, but the relative variability remained unchanged (Table 8). 
Significant correlations were found between fasting cTG and fasting absolute intra-
individual variability in both females and males (r: 0.459; P < 0.001 and r: 0.759; P < 0.001, 
respectively) and between cTG at bedtime and the absolute intra-individual variability 
at bedtime in both females and males (r: 0.523; P < 0.001 and r: 0.362; P < 0.001, respec-
tively). No significant correlations were found between the absolute intra-individual TG 
variability and age, BMI or HOMA-IR during fasting or at bedtime. 
Discussion
The present study confirms our previous work showing that: 1) cTG increases during 
the course of the day, and 2) daytime increase in cTG is greater, and thus non-fasting 
cTG levels are higher, in male compared to female subjects [24]. While intra-individual 
variability in fasting cTG levels was found to be similar in males and females (0.28 and 
0.35 mmol/l, i.e., 21.0% and 20.5%, respectively), the intra-individual variability in non-
fasting cTG levels was found to increase during the day (i.e., 2-fold) in males but not in 
females. When subjects were divided into tertiles on the basis of their fasting cTG levels, 
the daytime increase in cTG was similar in all three groups, and subjects with higher 
levels of cTG had a greater absolute intra-individual variability in both fasting and most 
non-fasting time points. Our data are consistent with the concept that TG concentra-
tions in the blood tend to increase throughout the day and are dependent on: 1) the 
size, composition and frequency of fat-containing meals, 2) the levels of stress and ex-
ercise, and 3) hormonal and metabolic factors. Numerous environmental and metabolic 
parameters thus contribute to the variability of non-fasting TG levels, which tends to be 
greater in male subjects and in individuals with higher levels of circulating TG.
The ability of blood TG levels to predict or diagnose the presence of cardiovascular 
disease depends on the stability of the TG concentration over time. Current guidelines 
thus recommend the measurement of TG levels after an eight to twelve hour fast in 
order to reduce day-to-day variability [5]. However, even in the fasted state, blood TG 
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levels vary considerably. For example, in 44 healthy women, aged 18-35 years, plasma TG 
had an intra-individual variance of 22% [12]. In a group of 83 healthy men and women, 
the biological variability in fasting capillary TG was found to be 14.7% and did not differ 
from venous samples [25]. In patients with T2DM treated with either simvastatin or ator-
vastatin, the biological variability in fasting serum TG was 12.1% and 19.7%, respectively 
[26]. A meta-analysis of 30 studies published from 1970 to 1992 found the overall aver-
age intra-individual biological variability to be 22.6% [11]. This coefficient of variation 
is relatively similar to the CV of 21.0% in males and 20.5% in females in the fasted state 
observed in the current study, confirming that our mixed group of healthy volunteers 
and patients is representative of other cohorts. 
We had assumed that the intra-individual variability in cTG would be greater in non-
fasting than in fasting samples, however somewhat surprisingly, this was only found 
to be the case in males but not in females. The intra-individual variability in daytime 
non-fasting cTG levels thus increased significantly from 0.28 to 0.69 mmol/l in males, 
and was 0.35 and 0.36 mmol/l in females. Greater intra-individual variability in cTG in 
males in the non-fasting state could in part be due to the beneficial effects of estrogens 
in females which tends to reduce fluctuations in TG levels [17,21,27]. In a separate study, 
diurnal variation in serum TG was determined by measuring blood samples taken at 9:00 
a.m. (fasting), 11.00 a.m., 3.00 p.m. and at 8.00 p.m. (after dinner). Women were found 
to have a diurnal variability of 23.8% and men had 35.7% [15]. Generally these data are 
consistent with the concept that male individuals who tend to have higher levels of 
blood TG in the non-fasting state, have greater diurnal as well as day-to-day variability 
in their circulating TG levels.
The absolute intra-individual TG variability was higher in females and males with 
elevated TG levels (third tertile). This is most probably a physiological phenomenon. It 
must be acknowledged, however, that the intra-individual variability in subjects with 
low levels of triglyceridemia may have been partly affected by technical limitations of 
the point-of-care testing device. This device had a limit of sensitivity of 0.80 mmol/l, and 
therefore gave a reading of 0.80 mmol/l whenever cTG was 0.80 mmol/l or below. Cor-
rections were attempted by disregarding measurements that were equal to 0.80 mmol/l, 
however this could still have reduced the variability of cTG measurements artificially 
at this lower end of detection. Of greater clinical relevance is the finding that subjects 
with higher levels of cTG (i.e., the third tertile) had the highest intra-individual TG vari-
ability. These individuals could potentially be diagnosed as being normotriglyceridemic, 
and subsequently be categorized in a lower cardiovascular risk category. This concern 
pertains to both fasting and non-fasting blood samples since intra-individual variabil-
ity in cTG was high at all time-points. As expected, subjects with the highest levels of 
triglyceridemia had a significantly higher age, BMI, HOMA-IR and higher prevalence of 
CVD. The variability correlated strongly with cTG concentrations but not with age, BMI or 
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HOMA-IR. Therefore, it seems likely that TG variability is more influenced by the degree 
of triglyceridemia than factors as age, BMI or HOMA-IR.
Langsted et al. have recently shown using cross-sectional data that in both diabetic 
and non-diabetic individuals [28], plasma triglyceride concentration differs very little 
(i.e., 0.2-0.3 mmol/l) when measured in fasting and non-fasting samples. They have thus 
concluded that plasma TG levels change minimally in response to normal food intake 
in individuals in the general population. This is however an erroneous extrapolation of 
the population data, as evidenced by the present results in male and female individuals, 
showing that non-fasting TG levels actually increase by 0.5 to 2.0 mmol/l during the 
day. The majority of this increase is at the end of the day however, as is the increase in 
intra-individual variability, leading us to suggest that the accuracy of TG measurements 
for cardiovascular risk assessment is likely to be minimally affected if non-fasting blood 
samples are drawn during daylight hours.
It is generally believed that the postprandial period is more atherogenic, and it 
therefore seems logical to try to establish new standards for non-fasting lipid measure-
ments. Large epidemiological studies have shown that increased non-fasting TG are 
a risk factor for cardiovascular disease independent from other well established risk 
factors [8,9,29] and evidence has been presented suggesting that non-fasting TG is an 
even stronger predictor of cardiovascular disease than fasting TG [6,8]. In the future, 
measurement of non-fasting TG could replace fasting TG once reference values for non-
fasting TG have been established [30]. In a pilot study with limited numbers of healthy 
males and females, an attempt was made to describe reference values for diurnal TG in 
Dutch subjects [21]. Similar studies need to be done in other populations taking into 
consideration, age, gender and race. 
In conclusion, TG levels increase throughout the day by an average of 0.53 mmol/l in 
females and 1.05 mmol/l in males. Non-fasting TG show the greatest variability in males, 
especially in those with hypertriglyceridemia. Since the greatest postprandial variability 
occurs very late in the day (around dinner time and bedtime), this is unlikely to affect the 
assessment of cardiovascular risk, which is usually made with a daytime blood sample. 
In view of the fact that non-fasting TG levels are likely to be used in the future to assess 
the individual risk of cardiovascular disease, future studies are required to determine 
normal ranges for non-fasting TG levels.
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Abstract
Introduction: Changes in leukocyte cell population data have been reported in various 
infectious diseases, but little is known in other inflammatory conditions such as the 
postprandial state. We investigated whether leukocyte cell population data change dur-
ing postprandial leukocyte activation.
Methods: Healthy volunteers underwent a standardized oral fat loading test (OFLT). 
Flowcytometric quantification of leukocyte activation markers CD11b, CD66b, CD35 and 
CD36, together with leukocyte cell population data from LH750 hematology analyzers 
were measured fasting and at 4 and 8 hours postprandially. 
Results: Twelve volunteers were included. Postprandial leukocyte activation was 
confirmed by increased expression of CD11b by monocytes (+11.7%) and neutrophils 
(+15.0%) and by increased expression of CD66b (+14.7%) and CD35 (+16.6%) by neu-
trophils at T = 4h. The mean scatter from neutrophils, reflecting granularity, significantly 
decreased at T = 4h (P < 0.05) and returned to baseline at T = 8h (P-ANOVA = 0.048). The 
mean volume of monocytes increased significantly at T = 4h (P < 0.001) and returned to 
baseline at T = 8h (P-ANOVA = 0.0008). At T = 4h CD11b expression on neutrophils was 
associated with a reduction in mean scatter of neutrophils (Pearson’s r: -0.677, P = 0.016).
Conclusion: Postprandial leukocyte activation is accompanied by temporary changes 
in leukocyte cell population data, similar to changes observed during various infections, 
but to a lesser extent. 
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Introduction
Triglyceride-rich lipoproteins are abundant in the postprandial phase and are able to 
induce an inflammatory response, which includes postprandial leukocyte activation 
[1]. Neutrophils are recruited within two hours after the ingestion of fat and/or glucose 
together with concomitant impairment of vessel dilatation [2,3]. In vitro experiments 
have shown that chylomicron remnants activate monocytes and neutrophils [4,5]. 
Moreover, postprandial leukocyte activation is observed in vivo after the ingestion 
of a fat-containing meal, which directly correlates with the postprandial increase in 
triglycerides (TG) [5-7]. Postprandial activated monocytes can adhere on endothelial 
cells by increased expression of adhesion molecules, mainly CD11c/CD18 [7], which may 
facilitate subendothelial migration of monocytes, with risk of foam cell formation and 
subsequently the development of atherosclerosis [1].
Changes in leukocyte cell population data have been reported in various infec-
tious diseases. Monocyte and neutrophil volume temporarily increases combined with 
decreased light scatter by neutrophils during bacterial infections or sepsis [8-10]. In 
contrast, little is known about changes in leukocyte cell population data during other 
non-infectious inflammatory conditions like the inflammatory postprandial state. Leu-
kocyte cell population data are acquired during the 5-part leukocyte differentiation 
by automatic cell counters in clinical laboratories. The LH750 hematology analyzer 
(Beckman Coulter, Miami, USA) uses Volume Conductivity Scatter (VCS) technology to 
perform the 5-part leukocyte differential count. Different parameters of VCS-data reflect 
the granularity and activation state of leukocytes. Over 8000 cells are measured using 
direct current impedance to measure cell volume (V). A radio frequency probe mea-
sures conductivity (C) that reflects nuclear shape, lobularity and nuclear/cytoplasmic 
ratio. Finally, laser light scatter (S) quantifies cellular granularity [11,12]. Together, these 
leukocyte cell population data are used to identify the different leukocytes for the 5-part 
differential count. Recently, it has been suggested that leukocyte cell population data 
may also be a clinical useful indicator for acute bacterial infections [8,10], postoperative 
infections [13], malaria [14] and as a discriminator between fungemia and bacteremia 
[15].
Since postprandial lipemia is one of the most physiological stimuli for leukocyte 
activation, our aim was to study whether changes in leukocyte cell population data 




Subjects and study design
Male and female volunteers were recruited by advertisement. Subjects had to be healthy 
and aged between 18 and 50 years. Exclusion criteria were the use of any medication or 
the presence of hypertriglyceridemia (fasting TG > 2.00 mmol/l). Participants visited the 
hospital after a 10h overnight fast. Anthropometric characteristics like length, weight, 
body mass index, waist circumference and blood pressure were measured. A fasting 
venous blood sample was drawn (T = 0h) and subjects were given an oral fat load using 
fresh cream (Fresh cream, Albert Heijn, Zaandam, the Netherlands) in a dosage of 50g 
of fat per square meter body surface at 9:00 AM. During the oral fat loading test (OFLT) 
participants were not allowed to smoke, eat or drink (except water) and participants 
refrained from physical activity. Venous blood samples were taken at 4 (T = 4h) and 8 
hours (T = 8h) after the ingestion of the oral fat load. The time-points T = 4h and T = 8h 
were chosen since postprandial triglyceridemia in healthy subjects is maximal at T = 4h 
and TG return to fasting levels at T = 8h. In addition, it has been shown that postprandial 
leukocyte activation is highest at T = 4h [5]. The study was approved by the independent 
Regional Medical Ethical Committee Rotterdam (Maasstad Hospital, the Netherlands) 
and all subjects gave written informed consent.
Clinical chemistry
All clinical chemistry measurements were carried out on freshly drawn blood in the 
department of Clinical Chemistry, Sint Franciscus Gasthuis, Rotterdam. Baseline renal 
function, C-reactive protein, glucose, plasma cholesterol, HDL-C and triglycerides were 
measured using the LX20 or DxC analyzers (Beckman Coulter, Miami, USA). LDL-C values 
were calculated using the Friedewald formula. Apolipoprotein A-Ι and apo B were de-
termined by nephelometry using an IMAGE instrument with commercially available kits 
(Beckman Coulter). 
Leukocyte VCS-data
Blood cell counts and 5-part leukocyte differentiation were determined automatically 
using LH750 analyzers (Beckman Coulter) within 45 minutes after venipuncture. VCS-
data were obtained from lymphocytes, monocytes and neutrophils. These data were 
generated by optical and electronic measurements of individual cells by the LH750 
analyzers during generation of the automated leukocyte 5-part differential count. The 
parameters include the mean channel and standard deviation of volume (V), conductiv-
ity (C) and light scatter (S) for lymphocytes, monocytes and neutrophils. Using a normal 
blood sample that was measured 10 consecutive times on the LH750 we established the 
coefficient of variation (CV) for each of these parameters. With the exception of lympho-
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cyte conductivity (CV: 1.41%) all CV’s were below 1%. This indicates that VCS-data are 
robust and have very little analytical variation, as was also reported by others [10].
CD11b, CD66b, CD35 and CD36 as markers for in vivo leukocyte activation
Blood samples for the determination of leukocyte activation markers CD11b, CD66b, 
CD35 and CD36 were collected in tubes containing 5.4mg K2 EDTA (Becton Dickinson, 
Plymouth, United Kingdoms) at baseline and at four and eight hours after ingestion 
of the oral fat load. The method has been described in detail before [5,6]. Briefly, the 
staining procedure was started within 15 minutes after venipuncture. All measurements 
were carried out in triplicate. Separate tubes were prepared: 1) a combination of fluo-
rescein isothiocynate (FITC) conjugated CD66b, phycoerythrin (PE) conjugated CD11b 
and phycoerythrin-Texas Red-X (ECD) conjugated CD45 and 2) a combination of FITC 
conjugated CD36, PE conjugated CD35 and ECD conjugated CD45. All antibodies were 
from Beckman Coulter, except for CD35-PE (BD Biosciences, Franklin Lakes, NJ, USA). A 
total of 20 µl of whole blood was added to each tube and incubated for 15 minutes in the 
dark on room temperature. Erythrocytes were lysed by addition of 500µl lysis solution 
(1.5 M ammonium chloride, 100 mM potassium hydrogen carbonate, 0.82 mM EDTA, 
pH7.4) followed by 15 min of incubation in the dark. The samples were measured on a 
Navios flow cytometer (Beckman Coulter). Samples were measured for a maximum of 
five minutes or until at least 2000 monocytes were acquired. Lymphocytes, monocytes 
and neutrophils were identified in the side scatter versus CD45 dot plot. The fluorescence 
intensity of each cell type was expressed as the mean fluorescence intensity (MFI) of the 
triplicate measurements. Before each use, the optics and settings of the flow cytometer 
were checked with Flow-Check Pro and Flow-Set Pro beads (Beckman Coulter). Identi-










FITC CD66b NA 1.8% (0.4-9.5) 20x 80H3 0531 BC
FITC CD36 5.6% (1.0-17.0) NA 5x FA6.152 PN IM07664 BC
PE CD35 4.4% (0.6-11.1) 4.0% (1.9-7.0) 1x E11 559872 BD
PE CD11b 2.5% (0.2-6.3) 2.5% (0.8-6.3) 10x Bear1 PN IM2581 BC
ECD CD45 NA NA 5x J33 A07784 BC
The intra-assay variation is shown in relative terms (%) as the coefficient of variation of the triplicate 
measurements of the respective antibody and cell type in the fasting state. The mean and range of all 
subjects is given.
Abbreviations: fluorescein isothiocynate (FITC), phycoerythrin (PE), phycoerythrin-Texas Red-X (ECD), not 
applicable (NA), Beckman Coulter (BC), Becton Dickinson Biosciences (BD).
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cal instrument settings were used for the complete study. An overview of the antibody 
information and the intra-assay variation of the respective in vivo leukocyte activation 
markers is given in Table 1.
Statistical analysis
Data are given as mean ± SD in the text and tables and as mean ± SEM in the figures 
unless stated otherwise. The relative intra-assay variation in markers for in vivo leukocyte 
activation by flow cytometry was assessed by calculating the coefficient of variation (CV) 
of the triplicate measurements in the fasting state of the respective marker for each sub-
ject. The CV was calculated for each specific marker and cell type as: (standard deviation 
/ mean MFI) * 100. Postprandial time effects were analyzed using repeated measures 
ANOVA with Dunnett’s Multiple Comparison Test as post hoc analysis. VCS-data of one 
time-point (t = 8h) was missing in two volunteers and these data were imputed by using 
the mean of the respective individual. Correlations were calculated using the Pearson’s 
correlation coefficient. PRISM version 5.0 (Graph Pad Software, San Diego, USA) and 
PASW 18.0 (IBM, New York, USA) were used for statistical analyses. Statistical significance 
was set at P < 0.05 (two-sided).
Table 2: Characteristics of the subjects. Data are given as mean ± standard deviation, unless stated otherwise.
n = 12
Age (years) 35.3 ± 12.7
Male gender (n, %) 6 (50)
Body mass index (kg/m2) 21.9 ± 2.1
Systolic blood pressure (mmHg) 110.5 ± 9.1
Diastolic blood pressure (mmHg) 65.1 ± 8.8
Leucocyte count (*109/l) 6.1 ± 1.1
Absolute lymphocyte count (*109/l) 1.7 ± 0.3
Absolute monocyte count (*109/l) 0.46 ± 0.13
Absolute neutrophil count (*109/l) 3.8 ± 0.9
C-reactive protein (mg/l) 1.4 ± 0.7
Total cholesterol (mmol/l) 4.6 ± 0.6
LDL-C (mmol/l) 2.7 ± 0.6
HDL-C (mmol/l) 1.63 ± 0.39
Triglycerides (mmol/l) 0.71 ± 0.24
Apolipoprotein B (g/l) 0.78 ± 0.14
Apolipoprotein A-I (g/l) 1.88 ± 0.35
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Table 3: Postprandial changes in triglycerides and absolute counts for total leukocytes, lymphocytes, 
monocytes and neutrophils after a standardized oral fat load (n = 12). Data are given as mean ± standard 
deviation.
T = 0h T = 4h T = 8h P-ANOVA
Triglycerides (mmol/l) 0.71 ± 0.24 1.62 ± 0.70*** 0.81 ± 0.57 <0.001
Total leucocyte count (*109/l) 6.1 ± 1.1 6.7 ± 1.5 7.5 ± 2.0*** 0.0017
Absolute lymphocyte count (*109/l) 1.8 ± 0.3 2.0 ± 0.4* 2.4 ± 0.6*** <0.001
Absolute monocyte count (*109/l) 0.46 ± 0.13 0.45 ± 0.14 0.54 ± 0.15*** 0.002
Absolute neutrophil count (*109/l) 3.8 ± 0.9 4.3 ± 1.4 4.4 ± 1.9 0.26
Relative lymphocyte count (%) 28.3 ± 4.8 29.5 ± 6.5 33.1 ± 8.6* 0.04
Relative monocyte count (%) 7.6 ± 1.9 7.0 ± 1.8 7.3 ± 1.8 0.17
Relative neutrophil count (%) 62.5 ± 6.3 61.8 ± 8.3 57.6 ± 10.4 0.06
* Significantly different from corresponding value at T = 0h (P < 0.05)
*** Significantly different from corresponding value at T = 0h (P < 0.001)
Table 4: Postprandial changes in VCS-data after a standardized oral fat loading test (n = 12). Data represent 
the mean ± standard deviation.
T = 0h T = 4h T = 8h P-ANOVA
Lymphocytes
V-MN 81.2 ± 2.7 81.5 ± 2.3 80.5 ± 2.5 0.35
V-SD 13.7 ± 0.8 13.5 ± 1.2 13.2 ± 0.8 0.24
C-MN 114.0 ± 1.6 114.1 ± 1.9 116.0 ± 2.3* 0.009
C-SD 10.5 ± 1.6 9.8 ± 1.1 9.9 ± 1.2 0.22
S-MN 67.3 ± 3.1 67.7 ± 3.2 67.6 ± 4.3 0.87
S-SD 16.3 ± 1.4 16.1 ± 1.8 15.9 ± 1.7 0.69
Monocytes
V-MN 162.4 ± 4.3 165.0 ± 4.8*** 163.5 ± 4.2 0.0008
V-SD 17.2 ± 2.0 17.1 ± 1.6 17.3 ± 1.6 0.96
C-MN 123.4 ± 3.0 122.5 ± 3.2 124.8 ± 3.0 0.022
C-SD 4.5 ± 0.7 4.4 ± 0.4 4.5 ± 0.5 0.76
S-MN 90.0 ± 3.5 88.7 ± 2.7 89.5 ± 2.2 0.22
S-SD 9.6 ± 0.7 9.5 ± 0.7 9.4 ± 1.1 0.65
Neutrophils
V-MN 140.8 ± 2.7 142.3 ± 3.8 140.9 ± 4.6 0.27
V-SD 18.4 ± 0.6 19.0 ± 0.9 18.9 ± 1.4 0.30
C-MN 146.4 ± 2.8 146.1 ± 3.5 148.8 ± 3.6* 0.0064
C-SD 5.6 ± 0.9 5.7 ± 0.7 5.6 ± 0.6 0.79
S-MN 147.5 ± 4.7 145.4 ± 5.0* 146.4 ± 6.3 0.048
S-SD 10.7 ± 1.2 11.0 ± 1.0 10.8 ± 1.2 0.53
* Significantly different from corresponding value at T = 0h (P < 0.05)
*** Significantly different from corresponding value at T = 0h (P < 0.001)
Abbreviations: mean (MN), standard deviation (SD), volume (V), conductivity (C), scatter (S). 
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Results
A total of 12 healthy subjects, 6 males and 6 females, were included in the study. Sub-
jects were lean, normotensive and showed a normal lipid profile, leukocyte concentra-
tion and automated 5-part leukocyte differentiation (Table 2). Plasma TG increased by 
0.91 ± 0.53 mmol/l (P < 0.001) four hours postprandially and returned to baseline at T 















































































































Figure 1: The mean (± SEM) changes in activation markers of monocytes and neutrophils after the ingestion 
of a standardized oral fat loading test (n = 12): Expression of CD11b by monocytes (A) and neutrophils 
(B) was significantly increased postprandially (P-ANOVA 0.004 and 0.024, respectively). CD36 expressed 
by monocytes (C) remained unchanged, but the degranulation marker CD66b increased significantly on 
neutrophils (D) postprandially (P-ANOVA 0.007). Furthermore, CD35 was significantly more expressed by 
monocytes (E) and neutrophils (F) postprandially (P-ANOVA 0.021 and 0.016, respectively). Abbreviations: 
cluster of differentiation (CD), monocytes (MO), neutrophils (NE). *P < 0.05 and **P < 0.01 when compared 
to T = 0h.
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at the end of the OFLT, whereas absolute lymphocyte count gradually increased during 
the OFLT. The absolute neutrophil count increased gradually during the OFLT, but did 
not reach statistical significance (Table 3). The expression of CD11b on monocytes and 
CD11b, CD66b and CD35 on neutrophils increased significantly at T = 4h and declined 
thereafter. In addition, monocytes showed a trend of a postprandial increase in CD35 
expression, whereas the expression of CD36 by monocytes remained unchanged (Figure 
1).
The mean volume of monocytes increased significantly from 162.4 ± 4.3 a.u. to 165.0 
± 4.8 a.u. at t = 4h (P < 0.001) and returned to 163.5 ± 4.2 a.u. at T = 8h (P-ANOVA 0.0008). 
The mean volume of lymphocytes and neutrophils remained unchanged postprandially. 
The mean conductivity of lymphocytes, monocytes and neutrophils increased at the 
end of the OFLT (T = 8h) (Table 4). The mean scatter of neutrophils decreased signifi-
cantly from 147.5 ± 4.7 to 145.4 ± 5.0 (P < 0.05) at T = 4h and returned to 146.4 ± 6.3 at 
T = 8h (P-ANOVA 0.048). The mean scatter from lymphocytes and monocytes remained 
unchanged postprandially. No significant postprandial changes were observed in the 
standard deviations of the VCS-data.
At T = 4h, CD11b expression on neutrophils was negatively correlated with the mean 
scatter of neutrophils (Pearson’s r: -0.677, P = 0.016) and CD36 expression on monocytes 
was positively correlated with the mean conductivity of monocytes (Pearson’s r: 0.606, 
P = 0.037). No other correlations were found between activation markers on monocytes 
and neutrophils with corresponding VCS-parameters at the postprandial peak.
Discussion
To our knowledge this is the first report on postprandial changes in leukocyte cell 
population data. Our study illustrates that leukocyte cell population data are influenced 
by non-infectious inflammatory conditions like physiological postprandial leukocyte 
activation. As reported earlier [5,6], postprandial leukocyte activation was confirmed 
by an increased expression of CD35, CD11b and CD66b on neutrophils and CD11b on 
monocytes at the postprandial peak. Postprandial TG increased by 0.91 mmol/l, which 
is comparable with a physiological diurnal increase in TG, since TG normally increase 
approximately 0.5-1.0 mmol/l during the day [16]. 
The mean monocyte volume was increased four hours postprandially. This result 
is in concordance with others who reported increased mean volume of monocytes in 
bacteremia [10,15], fungemia [15], hepatitis B infection [17] and malaria infection [14]. 
Our study also observed a postprandial decrease in mean scatter of neutrophils, which 
correlated with the postprandial expression of CD11b on neutrophils. These results were 
expected since neutrophils become activated postprandially. Similar changes in mean 
76 Chapter 4
scatter of neutrophils, albeit with a stronger magnitude, have been observed during 
systemic infection or sepsis [8,15] and after activation of neutrophils with granulocyte 
colony-stimulating factor (G-CSF) [18]. Neutrophil activation leads to degranulation and 
thus to a decrease in mean scatter. Upon activation, the secretory vesicles of neutrophils 
are fused with the plasma membrane and are exocytosed. These secretory vesicles are 
the main reservoir for CD35 and membrane proteins CD11b and CD66b [19]. Therefore, 
leukocyte activation leads to increased membrane expression of CD11b, CD66b and 
CD35.
The observed postprandial changes in mean volume of monocytes and mean scat-
ter of neutrophils we observed were 1.7% and 1.4% compared to reported changes of 
4.1 - 11.2% in infectious conditions [9,10,14,15]. The postprandial state may theoretically 
influence the usability of leukocyte cell population data as a diagnostic tool for infection 
detection. However, the postprandial changes in leukocyte cell population were rather 
small, which probably limits the clinical relevance of these postprandial changes in 
mean volume of monocytes and mean scatter of neutrophils. Nevertheless, our results 
confirm that leukocyte cell population data are already affected by a physiological 
postprandial inflammatory reaction. We hypothesize that these morphological changes 
are due to internalization of TG-rich lipoproteins by monocytes and neutrophils [5,7,20]. 
The question remains whether subjects with hypertriglyceridemia or diabetes will show 
similar changes in postprandial leukocytes.
A left shift of neutrophils may occur with the presence of band forms and immature 
neutrophils during an acute bacterial infection, which can lead to an increased stan-
dard deviation in volume of neutrophils [9,15]. However, here we did not observe any 
postprandial changes in the standard deviation of VCS parameters, nor did the LH750 
flag any of the samples for immature neutrophils. We did observe a significant increase 
in total leukocyte count, lymphocyte and monocyte count during the OFLT, whereas 
neutrophils tended to increase postprandially without reaching statistical significance. 
These results are in concordance with previous reports, which showed increases in 
leukocyte count and absolute lymphocyte and neutrophil counts during comparable 
experiments [2,3,21]. Recently lymphocyte counts were shown to decrease one to two 
hours after a light mixed meal with normalization at four hours postprandially [22]. Here 
we have studied four and eight hours postprandially aimed at detecting leukocyte ac-
tivation postprandially. We observed an increase in lymphocyte count, especially eight 
hours postprandially. Therefore, we could have missed an initial decrease in lymphocyte 
counts during the first two to four hours of the OFLT. Comparing both studies is difficult 
since different meals were used (a mixed meal versus a fat load) and the addition of 
glucose to a fat load has been shown to reduce the postprandial increase in TG [23].
In conclusion, monocytes and neutrophils of healthy adults become activated after 
the ingestion of a fat-containing meal, which temporarily affects leukocyte cell popula-
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tion data in a similar way as in certain infectious diseases. However, the magnitude of 
these changes is limited. Therefore, the postprandial changes in leukocyte cell popula-
tion data probably do not affect the clinical use of leukocyte cell population data as a 
diagnostic tool for infection detection. 
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Abstract
Background: The postprandial phase is considered pro-atherogenic, in part due to 
triglyceride-rich lipoprotein mediated inflammation. Vitamin D has been proposed to 
reduce inflammation and to improve arterial elasticity. We hypothesized that vitamin 
D3 could improve postprandial arterial elasticity by modulation of leukocyte activation.
Methods: Healthy volunteers underwent two oral fat loading tests (OFLT). Arterial 
elasticity by augmentation index (AIx) and flowcytometric quantification of leukocyte 
activation markers CD11b, CD66b, CD35 and CD36 were measured. After the first OFLT 
a dose of 100000 IU of vitamin D3 was administered and a second OFLT was carried out 
seven days later. 
Results: Six men and 6 women were included. 25-Hydroxyvitamin D3 levels rose from 
63.0 ± 28.8 nmol/l to 98.5 ± 26.8 nmol/l after vitamin D3 supplementation (P < 0.001). 
Baseline arterial elasticity did not change postprandially, but a significant favourable 
reduction in AIx was found after vitamin D3 supplementation (P = 0.042) in both men 
and women. After vitamin D3, exclusively in women a reduction in the area under the 
postprandial curve for monocyte CD11b and CD35 by 10.5% (P = 0.016) and 12.5% (P = 
0.04) and neutrophil CD11b by 17.0% (P = 0.014) was observed.
Conclusions: Vitamin D3 probably increased postprandial arterial elasticity, but vitamin 
D3 reduced postprandial leukocyte activation exclusively in women.
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Introduction
In the past 20 years, the diagnosis of vitamin D deficiency has increased to epidemic 
proportions, mainly due to obesity, lack of sun exposure and increased screening for 
vitamin D deficiency [1]. Vitamin D has not only been related to bone mineralization and 
the metabolism of calcium and phosphate, but also to numerous other physiological 
processes [1,2]. The vitamin D receptor has been identified on multiple cell types, in-
cluding immunological and endothelial cells [3-5]. Several studies have shown that low 
vitamin D concentrations are associated with endothelial dysfunction, increased arterial 
stiffness, increased carotid intima media thickness, hypertension, the metabolic syn-
drome and an increased risk for cardiovascular disease [6-13]. Endothelial function and 
arterial elasticity can improve after vitamin D supplementation in vitamin D deficient 
subjects as shown in two different studies using cut-off points for vitamin D deficiency 
of 25 nmol/l and 75 nmol/l, respectively [14,15]. The exact mechanisms of the beneficial 
effects of vitamin D on cardiovascular disease and arterial stiffness are still unknown.
The immunological effects of vitamin D may be the key link between vitamin D and 
cardiovascular disease, since inflammation is highly involved in the development of im-
paired vascular function and atherosclerosis [16]. In vitro experiments have shown that 
the active metabolite of vitamin D, 1,25-dihydroxyvitamin D3, decreased the expres-
sion of CD11b on monocytes and their phagocytic capacity [17]. CD11b is an integrin 
expressed on monocytes and neutrophils, which improves the binding of monocytes 
and neutrophils to the endothelium, thereby facilitating subendothelial migration 
[18,19]. 1,25-Dihydroxyvitamin D3 reduces the uptake of cholesterol by macrophages 
with inhibition of macrophage differentiation into atherogenic foam cells [20]. Gender 
differences have been described concerning the activation of leukocytes mediated by 
sex steroids with a potential functional synergy between 1,25-dihydroxyvitamin D3 and 
estradiol [21,22]. Since acute inflammatory changes as well as vascular dysfunction oc-
cur in the postprandial state [18,19,23,24], the postprandial state can be considered an 
adequate physiological model to further investigate the relationships between vitamin 
D, postprandial leukocyte activation and arterial stiffness in vivo. Therefore, the aim of 
the present study was to investigate if vitamin D3 can reduce leukocyte activation and 
improve arterial elasticity postprandially in both genders. 
Materials and methods
Subjects and study design
The study was designed as a non-randomized cross-over study of healthy males and 
females. Measurements were performed before and after the intervention i.e. supple-
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mentation of vitamin D3; participants served as their own controls. Male and female 
volunteers were recruited by advertisement between March 2011 and October 2011. 
Included were healthy subjects between 18 and 50 years of age. Exclusion criterion was 
the use of any medication except oral contraceptives. At day one participants visited 
the hospital after a 10h overnight fast. Anthropometric characteristics (length, weight, 
body mass index, waist circumference) and blood pressure were measured. At baseline, 
arterial elasticity was determined by augmentation index (AIx), which was measured 
at the radial artery according to standard operating procedures (Sphygmocor, AtCor 
Medical, Sydney, Australia) in duplicate after a 5 minute rest in a supine position [25]. 
The AIx was corrected for a heart rate of 75/min. A fasting venous blood sample was 
drawn and subjects received an oral fat load using fresh cream (Albert Heijn, Zaandam, 
the Netherlands) in a dose of 50g of fat per square meter body surface. This method 
reflects the physiological diurnal increase in triglycerides. During the oral fat loading 
test participants were not allowed to eat or drink except water and they were asked 
to refrain from physical activity. Blood pressure, AIx and venous blood sampling were 
repeated at two hourly intervals until eight hours. At the end of the first oral fat loading 
test participants received 100000 IU of vitamin D3 dissolved in water (cholecalciferol, 
50000 IU/ml). Since 25-hydroxyvitamin D3 reaches its highest serum concentration after 
7 days [26,27], the second oral fat loading test was performed exactly seven days later. 
The procedure and measurements of the second oral fat loading test were identical to 
the first. All subjects gave written informed consent and the study was approved by 
the independent Regional Medical Ethical Committee Rotterdam, Maasstad Hospital, 
the Netherlands (NL3372110110). The study protocol was prospectively registered at 
EudraCT (2010-024182-44).
Laboratory measurements
All clinical chemistry and hematology measurements were carried out on freshly drawn 
blood at the Department of Clinical Chemistry, Sint Franciscus Gasthuis, Rotterdam. 
Baseline C-reactive protein, plasma cholesterol, HDL-C and triglycerides were measured 
using the LX20 or DxC analyzers (Beckman Coulter, Miami, USA). LDL-C values were 
calculated using the Friedewald formula. Apolipoprotein A-Ι and apo B were determined 
by nephelometry using an IMMAGE instrument with commercially available kits (Beck-
man Coulter). Blood cell counts and 5-part leucocyte differentiation were determined 
automatically using LH750 analyzers (Beckman Coulter). The vitamin D status was de-
termined by measuring 25-hydroxyvitamin D3 on serum that had been stored at -70°C 
(Liaison, DiaSorin, Saluggia, Italy).
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CD11b, CD66b, CD35 and CD36 as markers for in vivo leukocyte activation
Blood samples for the determination of leukocyte activation markers CD11b, CD66b, 
CD35 and CD36 were collected in tubes containing 5.4mg K2 EDTA (Becton Dickinson, 
Plymouth, United Kingdoms) at baseline and at four and eight hours postprandially. 
The method has been described in detail before [18,28]. Briefly, the staining procedure 
was started within 15 minutes after venipuncture. All measurements were carried out 
in triplicate to reduce variability. Two separate tubes were prepared: 1) a combination 
of fluorescein isothiocynate (FITC) conjugated CD66b, phycoerythrin (PE) conjugated 
CD11b and phycoerythrin-Texas Red-X (ECD) conjugated CD45 and 2) a combination 
of FITC conjugated CD36, PE conjugated CD35 and ECD conjugated CD45. All antibod-
ies were from Beckman Coulter, except for CD35-PE (BD Biosciences, Franklin Lakes, 
NJ, USA). A total of 20 µl of whole blood was added to each tube and incubated for 
15 minutes in the dark at room temperature. Erythrocytes were lysed by addition of 
500µl lysis solution (1.5 M ammonium chloride, 100 mM potassium hydrogen carbonate, 
0.82 mM EDTA, pH 7.4) followed by 15 min of incubation in the dark. The samples were 
measured on a Navios flow cytometer (Beckman Coulter). Samples were measured for a 
maximum of five minutes or until at least 2000 monocytes were acquired. Lymphocytes, 
monocytes and neutrophils were identified in the side scatter versus CD45 dot plot. The 
fluorescence intensity of each cell type was expressed as the mean fluorescence inten-
sity (MFI) of the triplicate measurements. Before each use, the optics and settings of the 
flow cytometer were checked with Flow-Check Pro and Flow-Set Pro beads (Beckman 
Coulter). Identical flow cytometric settings were used for the complete study.
Statistical analysis
Data are given as mean ± SD in the text and tables and as mean ± SEM in the figures. 
Differences between the first oral fat load and the second were tested using the paired 
Student’s t-test in case of normally distributed variables or by the non-parametric Wil-
coxon matched pairs signed ranks test in case of skewed variables. Differences were 
tested for the total group and for men and women seperately. All statistical analyses 
were performed using PASW statistics version 18.0 (IBM SPSS Statistics, New York, United 
States). The total area under the postprandial curve (AUC) was calculated with PRISM 




Cholesterol, apolipoproteins and postprandial lipemia after vitamin D3
A total of 6 men and 6 women were included. Oral contraceptives were used by three 
women. The baseline characteristics for the total group and for each gender are shown in 
Table 1. No significant differences were observed between genders. Seven days after the 
administration of 100000 IU of vitamin D3, serum 25-hydroxyvitamin D3 concentrations 
increased significantly from 63.1 ± 28.8 nmol/l to 98.5 ± 26.8 nmol/l for the total group (P 
< 0.001), from 49.9 ± 25.2 nmol/l to 88.2 ± 22.1 nmol/l for men (P < 0.001) and from 76.2 
± 27.9 nmol/l to 108.7 ± 28.9 nmol/l for women (P = 0.001). Only one male participant 
had an initial 25-hydroxyvitamin D3 serum concentration below 30.0 nmol/l in contrast 
Table 1: Characteristics in the fasting state at baseline (control) and after vitamin D3 supplementation. 
Results are shown for the total group and for men and women separately.
Total group (n = 12) Men (n = 6) Women (n = 6)
Control Vitamin D3 Control Vitamin D3 Control Vitamin D3
Age (years) 35.3 ± 12.7 - 34.5 ± 12.3 - 36.2 ± 14.1 -
Body mass index (kg/m2) 21.9 ± 2.1 - 21.1 ± 2.6 - 22.7 ± 0.9 -
Systolic blood pressure 
(mmHg)
110.5 ± 9.1 108.2 ± 10.6 111.3 ± 10.1 108 ± 13.8 109.7 ± 8.9 108.3 ± 7.4
Diastolic blood pressure 
(mmHg)
65.1 ± 8.8 65.8 ± 7.1 67.2 ± 11.3 65.3 ± 9.0 63.0 ± 5.8 66.3 ± 5.4
Augmentation Index (%) 14.8 ± 11.7 14.0 ± 12.4 7.9 ± 12.0 10.3 ± 9.2 20.1 ± 11.9 17.5 ± 15.5
25-hydroxyvitamin D3 
(nmol/l)
63.1 ± 28.8 98.5 ± 
26.8**
49.9 ± 25.2 88.2 ± 
22.1**
76.2 ± 27.9 108.7 ± 
28.9*
Leukocyte count (*109/l) 6.1 ± 1.1 5.8 ± 1.4 5.8 ± 1.2 5.9 ± 1.1 6.3 ± 1.0 5.8 ± 1.8
Absolute lymphocyte 
count (*109/l)
1.68 ± 0.33 1.76 ± 0.38 1.65 ± 0.40 1.82 ± 0.48 1.70 ± 0.27 1.70 ± 0.28
Absolute monocyte count 
(*109/l)
0.46 ± 0.13 0.43 ± 0.12 0.52 ± 0.15 0.45 ± 0.14 0.40 ± 0.09 0.40 ± 0.11
Absolute neutrophil count 
(*109/l)
3.83 ± 0.87 3.49 ± 1.15 3.50 ± 0.80 3.45 ± 0.87 4.15 ± 0.88 3.53 ± 1.46
C-reactive protein (mg/l) 1.42 ± 0.67 1.67 ± 1.72 1.17 ± 0.41 1.17 ± 0.41 1.67 ± 0.82 2.2 ± 2.4
Total cholesterol (mmol/l) 4.6 ± 0.6 4.6 ± 0.8 4.5 ± 0.6 4.9 ± 0.8 4.8 ± 0.7 4.3 ± 0.7
LDL-C (mmol/l) 2.7 ± 0.6 2.7 ± 0.6 2.7 ± 0.5 2.6 ± 0.5 2.7 ± 0.7 2.7 ± 0.7
HDL-C (mmol/l) 1.63 ± 0.39 1.58 ± 0.45 1.52 ± 0.32 1.65 ± 0.31 1.75 ± 0.46 1.52 ± 0.59
Triglycerides (mmol/l) 0.71 ± 0.24 0.70 ± 0.30 0.71 ± 0.22 0.73 ± 0.28 0.72 ± 0.28 0.67 ± 0.34
Apolipoprotein B (g/l) 0.78 ± 0.14 0.77 ± 0.18 0.76 ± 0.14 0.75 ± 0.17 0.79 ± 0.14 0.78 ± 0.20
Apolipoprotein A-I (g/l) 1.88 ± 0.35 1.75 ± 0.28 1.79 ± 0.34 1.86 ± 0.28 1.97 ± 0.38 1.63 ± 0.26
* Significantly different from corresponding control value (P = 0.001)
** Significantly different from corresponding control value (P < 0.001)
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to none in the females. No significant changes were observed in leukocyte counts, 
absolute lymphocyte, monocyte and neutrophil counts, lipids or arterial stiffness in the 
fasting state after vitamin D3 supplementation (Table 1). The postprandial triglyceride 
response was similar before and seven days after supplementation of vitamin D3 for the 
total group (Figure 1A) and for men and women separately (Figure 1B). As expected, 
women tended to have lower fasting and postprandial triglycerides when compared to 
men, but statistical significance was not reached. The AUC for triglycerides for the total 
group and for men and women separately remained unchanged after vitamin D3 (Table 
2).
Postprandial leukocyte activation after vitamin D3 supplementation
Postprandial leukocyte activation before and after supplementation of vitamin D3 
is shown for men and women in Figure 2. In the fasting state, integrin expression on 
monocytes tended to be higher in women in contrast to the expression on neutrophils. 
Both in men and in women, the expression of integrins on monocytes and on neutro-
phils increased postprandially at T = 4h and returned to baseline at T = 8h.
In the fasting state, no changes in integrin expression for both monocytes and 
neutrophils in males and females were observed after vitamin D3 supplementation. 
After vitamin D3 supplementation the reduction of the AUC for CD11b expression 
on monocytes was 6.9% (P = 0.043) and on neutrophils 8.9% (P = 0.019) for the total 
group (Table 2). A similar trend was observed for the CD35 expression on neutrophils. 
In females, the AUC for CD11b expression on monocytes and neutrophils and for CD35 
expression on monocytes was significantly reduced together with a similar trend for the 



























Figure 1: Mean ± SEM postprandial changes in plasma triglycerides (TG) for the total group (n = 12) before 
(open diamonds, ◊) and seven days after the administration of 100000 IU of vitamin D3 (closed diamonds, 
♦) (A). Postprandial changes in plasma TG were separated by gender (B). Men (n = 6) before (open square, □) 
and after vitamin D3 administration (closed square, ■) and women (n = 6) before (open circle, ○) and after 
vitamin D3 administration (closed circle, ●) are shown.
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CD35 and CD66b expression on neutrophils and CD36 expression on monocytes, while 
no changes were observed in men (Table 2).
Arterial stiffness after vitamin D3 supplementation
Women tended to have a higher AIx when compared to men. The AIx did not change 
postprandially during the first oral fat load in contrast to the situation after supplemen-






































































































Figure 2: Mean ± SEM postprandial changes in mean fluorescence intensity (MFI) of CD11b expression on 
monocytes (MO) (A) and neutrophils (NE) (D), CD35 expression on monocytes (B) and neutrophils (E), CD36 
expression on monocytes (E) and CD66b expression on neutrophils (F) before (open squares, □, for men 
and open bullets, ○, for women) and seven days after the administration of 100000 IU of vitamin D3 (closed 
squares, ■, for men and closed bullets, ●, for women).
























































































































































































































































































































































































































































































































































































































total group (Figure 3A) and in both genders separately (Figure 3B). This resulted in a 
significant reduction of the AUC for AIx for the total group after vitamin D3 supplemen-
tation (107.5 ± 93.6 %*h vs 88.7 ± 98.3 %*h, P = 0.042), which was observed in both 
genders (Table 2).
Discussion
Multiple studies have demonstrated the association between vitamin D deficiency 
and a subsequent increased cardiovascular risk [6,12,13], but the exact mechanism is 
not clearly understood. The atheroprotective effect of vitamin D may be attributed to 
beneficial modulation of the immune system [29]. The present study shows that a single 
high dose of vitamin D3 reduced postprandial leukocyte activation only in women, 
whereas the improvement in postprandial arterial elasticity was observed in both men 
and women. Serum 25-hydroxyvitamin D3 concentrations increased substantially in 
all our subjects seven days after a single dose of 100000 IU of vitamin D3. However, 
it should be noted that higher serum 25-hydroxyvitamin D3 concentrations do not 
necessarily translate into increased 1.25-dihydroxyvitamin D3 serum concentrations 
[30]. Nevertheless, it is generally accepted that 1.25-dihydroxyvitamin D3 will be higher 
when 25-hydroxyvitamin D3 serum concentrations rise.
The postprandial CD11b expression on monocytes and neutrophils was significantly 
reduced after vitamin D3 supplementation. However, this effect was mainly observed 
in women. Others have shown that 1,25-dihydroxyvitamin D3 reduced the CD11b 
expression on monocytes with a concomitant reduction in the phagocytic capacity in 
vitro [17]. On the contrary, 1,25-dihydroxyvitamin D3 upregulates the CD11b gene in 























Figure 3: Mean ± SEM postprandial changes in augmentation index (AIx) for the total group (n = 12) before 
(open diamonds, ◊) and seven days after the administration of 100000 IU of vitamin D3 (closed diamonds, 
♦) (A). Postprandial changes in AIx were separated by gender (B). Men (n = 6) before (open square, □) and 
after vitamin D3 administration (closed square, ■) and women (n = 6) before (open circle, ○) and after 
vitamin D3 supplementation (closed circle, ●) are shown.
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leukocytes [31]. Since in vitro 1,25-dihydroxyvitamin D3 reduced the CD11b expression 
on monocytes despite a contradictory upregulation of the CD11b gene, vitamin D may 
have differential effects on leukocyte CD11b regulation.
We hypothesize that sex steroids may have influenced the vitamin D3 effects on the 
expression of integrins like CD11b. It has been demonstrated that estradiol reduces the 
CD11b expression on monocytes in vitro [21], whereas testosterone potentiates neutro-
phil activation [32]. Animal studies showed that the CD11b expression on neutrophils is 
also regulated by estradiol, which limits the entry of calcium into cells, thereby blunting 
neutrophil activation [32,33]. This may explain the observed trend to lower fasting and 
postprandial CD11b, CD35 and CD66b expressions on neutrophils in women compared 
to men in the present study. 
Another explanation for the gender differences observed here may be related to an 
interaction between estrogen and vitamin D. Others have shown that women have fewer 
CYP24A1 transcripts, encoding the 1,25-dihydroxyvitamin D3-inactivating enzyme, 
when compared to men [22]. Therefore, binding and cellular accumulation of 1,25-dihy-
droxyvitamin D3 is increased in women with a subsequent increased anti-inflammatory 
effect on T-lymphocytes and macrophages [22]. The ex vivo addition of estradiol to male 
T-lymphocytes and macrophages reproduced these effects, suggesting a synergistic ef-
fect between 1,25-dihydroxyvitamin D3 and estradiol [22]. Therefore, vitamin D induced 
reductions in postprandial leukocyte activation may be dependent on estrogen.
We observed that the relative change in 25-hydroxyvitamin D3 was greater in men 
compared to women, but all subjects reached levels that were well above generally 
accepted normal concentrations. In contrast, females showed higher absolute serum 
25-hydroxyvitamin D3 concentrations after supplementation, probably because of 
higher initial levels. The results may have been influenced by the wide variation in 
25-hydroxyvitamin D3 concentrations between subjects, especially in males, which may 
also have contributed to the observed gender differences. In vitro a clear dose response 
relationship between a reduction in CD11b expression on monocytes with increasing 
concentrations of 1,25-dihydroxyvitamin D3 has been demonstrated [17]. Future studies 
including primarily vitamin D deficient subjects are needed to evaluate whether vitamin 
D3 supplementation in vitamin D deficiency is beneficial in reducing postprandial leu-
kocyte activation.
The postprandial CD36 expression on monocytes was reduced by 9.3% in women 
after vitamin D3 supplementation. CD36 is a scavenger receptor facilitating the uptake 
of free fatty acids and oxidized LDL by macrophages with subsequent risk of foam cell 
formation. In vitro, macrophages showed less cholesterol uptake and foam cell forma-
tion, with suppression of the CD36 expression when 1,25-dihydroxyvitamin D3 was 
present in the culture medium [20,34]. Recently, comparable results were obtained in 
a vitamin D-deficient mouse model [35]. However, it should be noted that this mouse 
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model included both male and female animals. Therefore, our results showing a blunted 
postprandial response in leukocyte activation by vitamin D3 in females are partly in line 
with previous publications.
We did not observe any effect of vitamin D3 on postprandial lipemia and these re-
sults are comparable to previous reports [36,37]. Therefore, the observed effects on leu-
kocyte activation and arterial stiffness we found could not be attributed to postprandial 
lipid changes. Although it should be noted that triglycerides reflect total postprandial 
response of both very low density lipoproteins and chylomicrons and that we did not 
differentiate between them using specific antibodies against apo B-100 and apo B-48.
Low 25-hydroxyvitamin D3 levels have been associated with increased arterial 
stiffness [38] and vitamin D supplementation improved endothelial function, which was 
determined with flow mediated vasodilatation, in asymptomatic subjects [14] and in 
patients with type 2 diabetes mellitus [39]. In addition, vitamin D3 supplementation can 
reduce arterial stiffness during childhood (14-18 years of age) [15]. All these interven-
tional studies were performed in both genders and the beneficial effects of vitamin D3 
supplementation on arterial elasticity were observed in both [14,15,39]. In addition, the 
association between 25-hydroxyvitamin D3 and arterial stiffness was independent from 
gender status [38]. Our data extend those observations showing similar effects in both 
genders. Since we observed a reduction in postprandial leukocyte activation solely in 
women, the improved postprandial arterial elasticity after vitamin D3 in both genders 
can not be explained by the reduction in postprandial leukocyte activation after vitamin 
D3 supplementation. Therefore, a direct effect of vitamin D on the arterial wall may have 
played a role. In vitro 1,25-dihydroxyvitamin D3 inhibited vascular cellular adhesion mol-
ecule-1 and interleukin-8 production in human arterial endothelial cells [40]. However, 
a placebo controlled randomized trial was unable to show any changes in circulating 
vascular cell adhesion molecules after vitamin D2 supplementation [41].
In our study women tended to have a higher AIx, which is in line with a recent 
community-based cohort study with 983 participants showing that women have a 
higher degree of arterial stiffness and concomitant AIx compared to men [42]. We did not 
observe any changes in AIx postprandially during the first oral fat load, whereas the AIx 
was temporarily reduced in the postprandial state after vitamin D3 supplementation. A 
postprandial improvement in arterial elasticity has been observed by others during the 
first 120 minutes after the ingestion of a mixed meal [43]. These authors suggested that 
postprandial changes in autonomic function could be responsible for temporary post-
prandial improvements in arterial elasticity. We did not measure parameters like heart 
rate variability to investigate changes in autonomic function in the postprandial state or 
after vitamin D3 supplementation. It has been reported that vitamin D3 may alter the 
autonomic nervous system [44]. In vitro 1,25-dihydroxyvitamin D3 stimulates myocytes 
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in a similar way as the beta-adrenergic agonist isoproterenol [45]. Moreover, vitamin D3 
maintained the expression of cholinergic receptors in rats with diabetes mellitus [46].
In conclusion, a single dose of 100000 IU of vitamin D3 increased postprandial 
arterial elasticity in healthy men and women probably by a direct effect on the arte-
rial wall. Vitamin D3 reduced postprandial leukocyte activation exclusively in women 




1. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-281
2. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, et al. Vitamin D and hu-
man health: Lessons from vitamin D receptor null mice. Endocr Rev 2008;29:726-776
3. Bell DS. Protean manifestations of vitamin D deficiency, part 3: Association with cardiovascular 
disease and disorders of the central and peripheral nervous systems. South Med J 2011;104:340-
344
4. Bell DS. Protean manifestations of vitamin D deficiency, part 1: The epidemic of deficiency. South 
Med J 2011;104:331-334
5. Lavie CJ, Lee JH, Milani RV. Vitamin D and cardiovascular disease will it live up to its hype? J Am 
Coll Cardiol 2011;58:1547-1556
6. Hosseinpanah F, Yarjanli M, Sheikholeslami F, Heibatollahi M, Eskandary PS, Azizi F. Associations 
between vitamin D and cardiovascular outcomes; Tehran Lipid and Glucose Study. Atherosclero-
sis 2011;218:238-242
7. Carrelli AL, Walker MD, Lowe H, McMahon DJ, Rundek T, Sacco RL, et al. Vitamin D deficiency 
is associated with subclinical carotid atherosclerosis: The Northern Manhattan Study. Stroke 
2011;42:2240-2245
8. Pacifico L, Anania C, Osborn JF, Ferraro F, Bonci E, Olivero E, et al. Low 25(OH)D3 levels are as-
sociated with total adiposity, metabolic syndrome, and hypertension in caucasian children and 
adolescents. Eur J Endocrinol 2011;165:603-611
9. Zagura M, Serg M, Kampus P, Zilmer M, Eha J, Unt E, et al. Aortic stiffness and vitamin D are inde-
pendent markers of aortic calcification in patients with peripheral arterial disease and in healthy 
subjects. Eur J Vasc Endovasc Surg 2011;42:689-695
10. Al Mheid I, Patel R, Murrow J, Morris A, Rahman A, Fike L, et al. Vitamin D status is associated with 
arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol 2011;58:186-192
11. Lee JI, Oh SJ, Ha WC, Kwon HS, Sohn TS, Son HS, et al. Serum 25-hydroxyvitamin D concentration 
and arterial stiffness among type 2 diabetes. Diabetes Res Clin Pract 2011
12. Schottker B, Haug U, Schomburg L, Kohrle J, Perna L, Muller H, et al. Strong associations of 25-hy-
droxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease 
mortality in a large cohort study. Am J Clin Nutr 2013;97:782-793
13. Wang L, Song Y, Manson JE, Pilz S, Marz W, Michaelsson K, et al. Circulating 25-hydroxy-vitamin D 
and risk of cardiovascular disease: A meta-analysis of prospective studies. Circ Cardiovasc Qual 
Outcomes 2012;5:819-829
14. Tarcin O, Yavuz DG, Ozben B, Telli A, Ogunc AV, Yuksel M, et al. Effect of vitamin D deficiency 
and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab 
2009;94:4023-4030
15. Dong Y, Stallmann-Jorgensen IS, Pollock NK, Harris RA, Keeton D, Huang Y, et al. A 16-week ran-
domized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 
25-hydroxyvitamin D, adiposity, and arterial stiffness. J Clin Endocrinol Metab 2010;95:4584-4591
16. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999;340:115-126
17. Spittler A, Willheim M, Leutmezer F, Ohler R, Krugluger W, Reissner C, et al. Effects of 1 alpha,25-
dihydroxyvitamin D3 and cytokines on the expression of MHC antigens, complement receptors 
and other antigens on human blood monocytes and U937 cells: Role in cell differentiation, activa-
tion and phagocytosis. Immunology 1997;90:286-293
Vitamin D3 on postprandial leukocyte activation 95
18. Alipour A, van Oostrom AJ, Izraeljan A, Verseyden C, Collins JM, Frayn KN, et al. Leukocyte activa-
tion by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol 2008;28:792-797
19. Gower RM, Wu H, Foster GA, Devaraj S, Jialal I, Ballantyne CM, et al. CD11c/CD18 expression is up-
regulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular 
cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2011;31:160-166
20. Oh J, Weng S, Felton SK, Bhandare S, Riek A, Butler B, et al. 1,25(OH)2 vitamin D inhibits foam 
cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes 
mellitus. Circulation 2009;120:687-698
21. Cutini PH, Campelo AE, Agriello E, Sandoval MJ, Rauschemberger MB, Massheimer VL. The 
role of sex steroids on cellular events involved in vascular disease. J Steroid Biochem Mol Biol 
2012;132:322-330
22. Correale J, Ysrraelit MC, Gaitan MI. Gender differences in 1,25 dihydroxyvitamin D3 immunomod-
ulatory effects in multiple sclerosis patients and healthy subjects. J Immunol 2010;185:4948-4958
23. Klop B, Castro Cabezas M. Chylomicrons: A key biomarker and risk factor for cardiovascular 
disease and for the understanding of obesity. Curr Cardiovasc Risk Rep 2012;6:27-34
24. van Oostrom AJ, Sijmonsma TP, Verseyden C, Jansen EH, de Koning EJ, Rabelink TJ, et al. Post-
prandial recruitment of neutrophils may contribute to endothelial dysfunction. J Lipid Res 
2003;44:576-583
25. Berry SE, Tucker S, Banerji R, Jiang B, Chowienczyk PJ, Charles SM, et al. Impaired postprandial 
endothelial function depends on the type of fat consumed by healthy men. J Nutr 2008;138:1910-
1914
26. Heaney RP, Armas LA, Shary JR, Bell NH, Binkley N, Hollis BW. 25-hydroxylation of vitamin D3: Rela-
tion to circulating vitamin D3 under various input conditions. Am J Clin Nutr 2008;87:1738-1742
27. Ilahi M, Armas LA, Heaney RP. Pharmacokinetics of a single, large dose of cholecalciferol. Am J Clin 
Nutr 2008;87:688-691
28. van Oostrom AJ, Rabelink TJ, Verseyden C, Sijmonsma TP, Plokker HW, De Jaegere PP, et al. Activa-
tion of leukocytes by postprandial lipemia in healthy volunteers. Atherosclerosis 2004;177:175-
182
29. Takeda M, Yamashita T, Sasaki N, Nakajima K, Kita T, Shinohara M, et al. Oral administration of an 
active form of vitamin D3 (calcitriol) decreases atherosclerosis in mice by inducing regulatory 
T cells and immature dendritic cells with tolerogenic functions. Arterioscler Thromb Vasc Biol 
2010;30:2495-2503
30. Biancuzzo RM, Clarke N, Reitz RE, Travison TG, Holick MF. Serum concentrations of 1,25-dihy-
droxyvitamin D2 and 1,25-dihydroxyvitamin D3 in response to vitamin D2 and vitamin D3 
supplementation. J Clin Endocrinol Metab 2013;98:973-979
31. Moeenrezakhanlou A, Shephard L, Lam L, Reiner NE. Myeloid cell differentiation in response to 
calcitriol for expression CD11b and CD14 is regulated by myeloid zinc finger-1 protein down-
stream of phosphatidylinositol 3-kinase. J Leukoc Biol 2008;84:519-528
32. Deitch EA, Ananthakrishnan P, Cohen DB, Xu da Z, Feketeova E, Hauser CJ. Neutrophil activation 
is modulated by sex hormones after trauma-hemorrhagic shock and burn injuries. Am J Physiol 
Heart Circ Physiol 2006;291:H1456-1465
33. Faas MM, Moes H, van der Schaaf G, Heineman MJ, de Vos P. Monocyte activation, but not granu-
locyte activation, is inhibited in the presence of developing ovarian follicles. J Reprod Immunol 
2006;70:21-32
34. Riek AE, Oh J, Bernal-Mizrachi C. 1,25(OH)2 vitamin D suppresses macrophage migration and 
reverses atherogenic cholesterol metabolism in type 2 diabetic patients. J Steroid Biochem Mol 
Biol 2013;136:309-312
35. Weng S, Sprague JE, Oh J, Riek AE, Chin K, Garcia M, et al. Vitamin D deficiency induces high blood 
pressure and accelerates atherosclerosis in mice. PLoS One 2013;8:e54625
36. Ponda MP, Dowd K, Finkielstein D, Holt PR, Breslow JL. The short-term effects of vitamin D 
repletion on cholesterol: A randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol 
2012;32:2510-2515
37. Wood AD, Secombes KR, Thies F, Aucott L, Black AJ, Mavroeidi A, et al. Vitamin D3 supplementa-
tion has no effect on conventional cardiovascular risk factors: A parallel-group, double-blind, 
placebo-controlled RCT. J Clin Endocrinol Metab 2012;97:3557-3568
38. Giallauria F, Milaneschi Y, Tanaka T, Maggio M, Canepa M, Elango P, et al. Arterial stiffness and vita-
min D levels: The Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2012;97:3717-
3723
39. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial func-
tion in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet Med 2008;25:320-
325
40. Kudo K, Hasegawa S, Suzuki Y, Hirano R, Wakiguchi H, Kittaka S, et al. 1alpha,25-dihydroxyvitamin 
D(3) inhibits vascular cellular adhesion molecule-1 expression and interleukin-8 production in 
human coronary arterial endothelial cells. J Steroid Biochem Mol Biol 2012;132:290-294
41. Sokol SI, Srinivas V, Crandall JP, Kim M, Tellides G, Lebastchi A, et al. The effects of vitamin D reple-
tion on endothelial function and inflammation in patients with coronary artery disease. Vasc Med 
2012;17:394-404
42. Russo C, Jin Z, Palmieri V, Homma S, Rundek T, Elkind MS, et al. Arterial stiffness and wave re-
flection: Sex differences and relationship with left ventricular diastolic function. Hypertension 
2012;60:362-368
43. Morioka N, Funada J, Takata Y, Hashida H, Iwata T, Higaki J, et al. Influence of meal intake on pulse 
wave indices in type 2 diabetes. Hypertens Res 2010;33:743-747
44. Sternberg Z. Autonomic dysfunction: A unifying multiple sclerosis theory, linking chronic cere-
brospinal venous insufficiency, vitamin D(3), and epstein-barr virus. Autoimmun Rev 2012;12:250-
259
45. Santillan GE, Vazquez G, Boland RL. Activation of a beta-adrenergic-sensitive signal transduction 
pathway by the secosteroid hormone 1,25-(OH)2-vitamin D3 in chick heart. J Mol Cell Cardiol 
1999;31:1095-1104
46. Peeyush Kumar T, Paul J, Antony S, Paulose CS. Expression of cholinergic, insulin, vitamin D recep-
tors and GLUT 3 in the brainstem of streptozotocin induced diabetic rats: Effect of treatment with 
vitamin D(3). Neurochem Res 2011;36:2116-212
Chapter 6
Erythrocyte-associated apolipoprotein 













Jan Willem F. Elte
Manuel Castro Cabezas
Eur J Clin Invest 2012;42:365-70
98 Chapter 6
Abstract
Objectives: Apolipoprotein (apo) B containing lipoproteins are closely linked to ath-
erogenesis. These lipoproteins are transported in plasma and are also associated with 
blood leukocytes. Our aim was to investigate whether apoB-containing lipoproteins are 
also present on the surface of erythrocytes and investigate the relationship with the 
presence of atherosclerosis. 
Methods and results: Erythrocyte-bound apo B (ery-apoB) was measured by flowcy-
tometry in subjects with (CAD+) and without coronary artery disease (CAD-), based on 
coronary angiography or on a history of cardiovascular disease. Intima media thickness 
(IMT) measurements were carried out using B-mode ultrasound. The relationship be-
tween ery-apoB and clinical and subclinical atherosclerosis was evaluated with binary 
logistic regression. A total of 166 subjects were included (40 CAD+ and 126 CAD-). Apo 
B was detected on freshly isolated erythrocytes (range: 0.1 to 5.5 a.u.; mean ± SEM 0.86 
± 0.09 a.u.) in all but nine subjects (4 CAD+ and 5 CAD-). Ery-apoB was lower in CAD+ 
(0.62 ± 0.09 a.u.) compared to CAD- (1.18 ± 0.10 a.u.; P < 0.001). Higher ery-apoB was 
associated with a lower risk of CAD (adjusted OR: 0.003 (95% CI: 0.001 - 0.08; P < 0.001), 
but the protective effect was diminished with increasing age (adjusted OR: 1.10 (95% CI: 
1.04 - 1.16; P < 0.001). IMT was increased in CAD+ subjects (0.77 ± 0.13 mm) compared to 
CAD- (0.57 ± 0.14 mm; P < 0.001). A significant negative correlation was found between 
ery-apoB and IMT (Beta=-0.214: 95%CI -0.284 to -0.145; P<0.001). There was no associa-
tion between ery-apoB with plasma apo B (Pearson’s r: -0.45; P = 0.57).
Conclusions: Human erythrocytes carry apo B-containing lipoproteins. Subjects with 
atherosclerosis have lower ery-apoB. High ery-apoB may be protective against athero-
sclerosis, and may reflect an alternative blood cell-mediated lipoprotein transport system 
in the circulation, in which these lipoproteins less likely interact with the endothelium.
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Introduction
All atherogenic lipoproteins carry apolipoprotein (apo) B as structural apolipoprotein 
[1,2,3]. Increased concentrations of plasma apo B have been identified as strong predic-
tors of cardiovascular disease [4-8].
The classical concept of lipoprotein transport in the circulation suggests that lipo-
proteins in plasma are modified by a series of enzymatic reactions [1,2]. Earlier studies 
from our group suggested the presence of a marginated pool of apo B-containing lipo-
proteins possibly attached to the endothelium or to other cells [9]. More recently, it has 
been demonstrated that apo B-containing lipoproteins can bind to blood leukocytes 
and that dietary fatty acids may be taken up by these cells in the circulation [10,11]. Oth-
ers have provided evidence suggesting that human erythrocytes also bind LDL [12,13]. 
The clinical and pathophysiological consequences of these observations are have not 
been established yet. 
In this study we measured apo B attached to human erythrocytes (ery-apoB) and 
evaluated the relationship with clinical and subclinical atherosclerosis.
Materials and methods
Subjects 
Participants were recruited from the outpatient clinic of the Diabetes Vascular Center 
from the Department of Internal Medicine, and from the outpatient clinic of the De-
partment of Cardiology of the Sint Franciscus Gasthuis, Rotterdam, the Netherlands. 
Subjects were divided into patients with and without atherosclerosis (CAD+ and CAD-, 
respectively). CAD+ patients were defined as patients with CAD established by coronary 
angiography or with a history of cardiovascular disease, as described in the International 
Classification of Disease (ICD-10, codes 100 - 199) [14]. CAD- patients were subjects with 
angiographically established absence of coronary atherosclerosis or without clinical 
signs and without a history of clinical atherosclerosis. Exclusion criteria were aberra-
tions in liver and thyroid function and the use of any experimental medication within 6 
months before participation. Written informed consent was obtained from each subject. 
Anthropometric characteristics e.g., weight, length, BMI, waist circumference and blood 
pressure measurements were recorded. The study was approved by the independent 
Regional Medical Ethical Committee Rotterdam, Maasstad Hospital, the Netherlands.
Intima media thickness (IMT) of the carotid arteries
Carotid ultrasound scans were carried out using the ART-LAB (Esaote, Italy) by trained 
and experienced sonographers, who were unaware of the patient’s medical history. 
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Ultrasound scans were performed with the patients lying in a supine position with the 
head resting comfortably and the neck slightly hyperextended and rotated in the op-
posite direction of the probe. The ultrasound images were obtained of the distal 1 cm of 
the far wall of each common carotid artery (CCA) using B-mode ultrasound producing 
two echogenic lines. These lines represent the combined thickness of the intima and 
media layers of the arterial wall. Each CCA was imaged in three different projections: 
CCA right side 90 – 120 - 150 and CCA left side 210 – 240 - 270 degrees. The segments 
were measured semi-automated in triplicate. 
Analytical Methods
All clinical chemistry measurements were performed on freshly drawn blood samples. 
Baseline renal function, glucose, plasma cholesterol, HDL-C and TG were measured us-
ing the LX 20 analyzer (Beckman Coulter, Miami, FL, USA). LDL-C values were calculated 
using the Friedewald formula. Apo A-Ι and apo B were determined by nephelometry 
using an IMMAGE instrument with commercially available kits (Beckman Coulter). Blood 
cell counts and 5-part leukocyte differentiation were determined automatically using 
LH 750 analyzers (Beckman Coulter). Thyroid function (TSH) was determined by TSH 
measurement (Immulite 2500, Siemens, Healthcare Diagnostics, Deerfield, IL, USA). 
Apo B on erythrocytes 
Blood samples for the determination of binding of apo B on erythrocytes were obtained 
in tubes containing 5.4 mg K2 EDTA (Becton Dickinson, Plymouth, UK). The staining 
procedure for apoB was started within one hour after venipuncture. The method has 
been described in detail previously [10]. To avoid interference of serum lipoproteins 
the samples were washed three times in PBS supplemented with 0.5% bovine serum 
albumin (PBS-BSA). The erythrocytes were incubated with a polyclonal goat antibody 
directed against human apo B (Millipore, Billerica, MA, USA) for 30 minutes in the dark 
on ice. Subsequently, the erythrocytes were washed with PBS-BSA and incubated with 
a rabbit anti-goat (RAG) antibody conjugated with FITC (Nordic Immunological Labora-
tories, Tilburg, the Netherlands) for another 30 minutes in the dark on ice. As a control 
for background staining each sample was simultaneously stained in parallel without 
anti-apoB antibodies, but with RAG-FITC. Samples were kept in the dark on ice until 
measurement. A total of 5000 erythrocytes per sample were analyzed by flowcytometry 
using an Epics XL-flowcytometer (Beckman Coulter). 
Statistical analysis
The binding of apo B on erythrocytes was expressed as the mean difference between 
fluorescence intensity of apo B-staining and aspecific staining. For statistical analysis 
IMT was defined as the mean of the six individual measurements. Differences in baseline 
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characteristics between the CAD+ and CAD- groups were tested by Chi-square test (or 
Fisher’s Exact test, where indicated) for nominal variables, by Student’s t-test for continu-
ous variables which were approximately Gaussian distributed, and by Mann-Whitney-U 
test for skewed variables. Correlation matrix of CAD+ and CAD- was carried out using 
Pearson Correlation. 
The association between ery-apoB and the presence of CAD adjusted for other 
covariables was evaluated with multiple binary logistic regression (backwards stepwise 
analysis). The following variables were entered into the model: gender, age, waist, apo 
A-I, apo B and ery-apoB. For methodological reasons, age was entered into the model 
as an interaction effect but not as main effect. The effect of age in the multiple binary 
logistic regression model is presented graphically for fixed values of gender, waist, apo 
AI and apo B. The association between ery-apoB and IMT as an estimate of subclinical 
atherosclerosis adjusted for other covariables was evaluated with multiple linear regres-
sion, entering the same variables as described earlier. 




The study group consisted of 166 subjects, 40 CAD+ and 126 CAD- subjects. The CAD+ 
subjects were on average older than the CAD- subjects. BMI, diastolic blood pressure and 
plasma triglycerides were similar between the groups. CAD+ subjects had a significantly 
higher waist circumference, systolic blood pressure, glucose level and reported more 
frequently the use of lipid lowering drugs and other medication. IMT was increased in 
CAD+ subjects compared to CAD- subjects (P < 0.001).
Erythrocyte-bound apo B and clinical and subclinical atherosclerosis
In all but nine subjects (4 CAD+ and 5 CAD-; 7.5%) ApoB was detected on freshly isolated 
erythrocytes (mean ± SEM: 0.86 ± 0.09 a.u.; range: 0.1 to 5.5 au). CAD+ subjects showed 
a lower mean erythrocyte bound apo B (0.60±0.09 au) compared to CAD- subjects (1.12 
± 0.12 a.u.; P < 0.001) (Figure 1). 
Table 2 shows the associations between ery-apoB, CAD and IMT. Higher ery-apoB 
was associated with a lower risk of CAD (adjusted OR: 0.003, 95% CI 0.001 - 0.08), but 
the protective effect was diminished with increasing age (adjusted OR: 1.10, 95% CI 
1.04 – 1.16). Figure 2 illustrates our model of multiple binary logistic regression from 
Table 2 showing the decrease in protective effect of ery-apoB on CAD with increasing 




















Figure 1: Mean ± SEM expression of apolipoprotein B on erythrocytes in with and without coronary artery 
disease (CAD+ and CAD-, respectively). Expression of ery-apoB is shown as mean fluorescence intensity 
(MFI) in arbitrary units (a.u.).






Age (years) 51 (22-81) 73 (35-85) <0.001
Diabetes mellitus (n, %) 6 (4.8%) 13 (32.5%) 0.002
Male gender (n, %) 37 (44.0%) 28 (71.8%) <0.001
Waist (cm) 90 ±12 99 ±12 <0.001
Body mass index (kg/m2) 26 ±4.4 27 ±4.2 0.1
Intima media thickness (mm) 0.57±0.13 0.77±0.13 <0.001
Systolic blood pressure (mmHg) 125 ±13 136 ±16 <0.001
Diastolic blood pressure (mmHg) 77 ±9 77 ±11 0.92
Glucose (mmol/l) 5.5 ±1.3 6.6 ±2.0 <0.001
Triglycerides (mmol/l) (median, range) 1.19 (0.34-3.89) 1.36 (0.54-4.66) 0.12
Cholesterol (mmol/l) 5.5 ±1.2 4.4 ±0.7 <0.001
LDL-cholesterol (mmol/l) 3.3 ±1.0 2.5 ±0.7 <0.001
HDL-cholesterol (mmol/l) 1.50 ±0.4 1.20 ±0.3 <0.001
Apolipoprotein B (g/l) 0.99 ±0.3 0.87 ±0.2 0.005
Apolipoprotein AI (g/l) 1.61 ±0.3 1.38 ±0.2 <0.001
No. of medications (median, range) 0 (0-6) 4 (1-7) <0.001
Data are expressed as mean ± SD unless stated otherwise.
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teraction effect between gender and age, nor between gender and ery-apoB. Ery-apoB 
was negatively associated with IMT (beta: -0.215, adjusted R² = 0.249; P < 0.001). The 
interaction effect between age and ery-apoB for IMT was significant and positive (beta: 
0.004), suggesting that the negative association between ery-apoB and IMT was also 
partially diminished with age. Ery-apoB was not associated with plasma apo B (Pearson’s 
r = -0.45; P = 0.57). 
















Figure 2: The relationship between ery-apoB and the risk for coronary artery disease (CAD) by age, based 
on the regression results from Table 2, for females with an apo AI level of 1.55 mmol/l, apo B of 0.96 g/l and 
waist of 95.7 cm. Expression of ery-apoB is shown as mean fluorescence intensity in arbitrary units (a.u.).
Table 2: Impact of ery-apoB on the presence of clinical atherosclerosis (CAD) and subclinical atherosclerosis 
(IMT). The impact of ery-apoB on CAD was evaluated by multiple logistic regression analysis (backward 
stepwise analysis). The impact of ery-apoB on IMT was evaluated with multiple linear regression analysis 
(backward stepwise analysis).
Parameter Presence of CAD IMT *
Adjusted OR (95% CI) P-value Beta (95% CI) P-value
Constant 37.37 0.21 0.377 (0.213; 0.541) 0.083
Female gender 0.24 (0.09;  0.67) 0.006 ― ―
Waist circumference 1.031 (0.99; 1.072) 0.13 0.003 (0.001; 0.004) 0.001
Apo A-I 0.05 (0.004; 0.57) 0.016 ― ―
Apo B 0.10 (0.012; 0.83) 0.032 ― ―
Ery-apoB 0.003 (0.001; 0.08) 0.001 -0.214 (-0.284; -0.145) 0.035
Age x ery-apoB 1.10 (1.04; 1.17) 0.001 0.004 (0.003; 0.005) 0.001
* R²a = 0.2
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Discussion
This is the first study showing the binding of apo B on human erythrocytes and its rela-
tion to clinical and subclinical atherosclerosis. Flowcytometric measurement of apoB on 
erythrocytes is technically feasible and can be used as a tool in mechanistic and clinical 
studies of cellular transport of lipoproteins. In 7.5% of all subjects no signal of ery-apoB 
was found, but this occurred equally between CAD- and CAD+ subjects. Ery-apoB did 
not correlate with plasma apo B concentrations and therefore, ery-apoB does not seem 
to be a mere reflection of plasma apo B concentrations. These results support the con-
cept of different pools of apo B containing lipoproteins in the circulation and different 
pathways for atherogenic lipoprotein transport in humans [9], as “free” lipoproteins in 
the plasma compartment and bound to blood cells. So far, we have not been able to 
quantify the contribution of the cell-bound fraction and this is one of the limitations 
of the present study. For this purpose, other types of experiments should be designed, 
most likely using labelled lipoproteins.  
As expected, CAD+ subjects in our study were on average older and age was also 
positively associated with higher IMT. The fact that ery-apoB interacted with age, sug-
gests that binding of apoB-containing lipoproteins to erythrocytes may be a physiologi-
cal process that becomes less efficient with increasing age (see Table 2, Figure 2), similar 
to the decreasing hepatic LDL-receptor effect on LDL metabolism with increasing age. 
No difference in ery-apoB was found when comparing males and females, although apo 
B metabolism is different between genders resulting in lower apoB plasma concentra-
tions in women [15,16].
Previous studies demonstrated that LDL can be attached to erythrocytes [12], but 
the clinical relevance of this observation was not investigated. In theory, LDL, VLDL, 
chylomicrons and their remnants could be bound to erythrocytes. We did not investi-
gate the nature of the apo B-containing lipoproteins attached to the erythrocytes and 
at this stage we have no data concerning the specific type of lipoproteins detected on 
the erythrocyte surface, except that erythrocytes carry apo B. We do not know if the 
decrease in quantity of ery-apoB and the protective effect on CAD with increasing age 
can be linked to a change in different types of apo B-containing lipoproteins bound to 
erythrocytes. The general consensus is that all apo B-containing lipoproteins are athero-
genic, although we agree that there may be functional differences between lipoproteins.
Earlier studies suggested that the LDL-receptor is not involved in binding of LDL 
to erythrocytes [13]. Recently we proposed a mechanism involving the complement 
receptor on human erythrocytes and complement activation on the surface of apo B 
containing lipoproteins [17]. In our view, the binding of apo B-containing lipoproteins to 
erythrocytes may have some similarities to the binding of immune complexes (“immune 
adherence”) to erythrocytes and clearance from the circulation by the liver [18,19,20]. 
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Therefore, higher concentrations of apo B-containing lipoproteins on erythrocytes will 
result in less (free) apo B-containing particles migrating to the subendothelium which 
can stimulate foam cell formation. This theory remains speculative and ongoing studies 
in our laboratory will address this issue. The current paper, however, provides further 
support to explore this phenomenon by showing a close association with clinical and 
subclinical atherosclerosis. 
One of the mechanisms by which binding of apo B-containing lipoproteins to 
erythrocytes could protect the endothelium is by impeding the interaction between 
these atherogenic lipoproteins and the endothelial cells. If this mechanism is correct 
and ery-apoB appears to be a stable parameter and able to predict cardiovascular risk 
prospectively in relation to classical and recently described risk factors, ery-apoB could 
become a novel cardiovascular biomarker [21]. The power of this potential risk identifier 
should be weighed against other atherosclerotic risk factors, like plasma apo A-I, apo 
B, total cholesterol/HDL and the combination of biomarkers, like N-terminal pro-brain 
natriuretic peptide, troponin I, cystatin C and C-reactive protein [22,23,24]. For this 
purpose large prospective cohort studies will be necessary. 
In conclusion, high apo B bound to erythrocytes in the circulation may be protective 
against atherosclerosis, and may reflect an alternative blood cell-mediated lipoprotein 
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Introduction: Erythrocytes carry apolipoprotein B on their membrane, but the deter-
mining factors of erythrocyte-bound apolipoprotein B (ery-apoB) are unknown. We 
aimed to explore the determinants of ery-apoB to gain more insight into potential 
mechanisms.
Methods: Subjects with and without CVD were included (n = 398). Ery-apoB was 
measured on fresh whole blood samples using flow cytometry. Subjects with ery-apoB 
levels ≤ 0.20 a.u. were considered deficient. Carotid intima media thickness (CIMT) was 
determined as a measure of (subclinical) atherosclerosis.
Results: Mean ery-apoB value was 23.2% lower in subjects with increased CIMT (0.80 ± 
0.09 mm, n = 140) compared to subjects with a normal CIMT (0.57 ± 0.08 mm, n = 258) (P 
= 0.007, adjusted P < 0.001). CIMT and ery-apoB were inversely correlated (Spearman’s 
r: -0.116, P = 0.021). A total of 55 subjects (13.6%) were considered ery-apoB deficient, 
which was associated with a medical history of CVD (OR: 1.86, 95% CI 1.04 – 3.33; ad-
justed OR: 1.55; 95% CI 0.85 – 2.82). Discontinuation of statins in 54 subjects did not 
influence ery-apoB values despite a 58.4% increase in serum apolipoprotein B. Subjects 
with blood group O had significantly higher ery-apoB values (1.56 ± 0.94 a.u.) when 
compared to subjects with blood group A (0.89 ± 1.15 a.u), blood group B (0.73 ± 1.12 
a.u.) or blood group AB (0.69 ± 0.69 a.u.) (P-ANOVA = 0.002).
Conclusion: Absence or very low values of ery-apoB are associated with clinical and 
subclinical atherosclerosis. While serum apolipoprotein B is not associated with ery-
apoB, the ABO blood group seems to be a significant determinant.
Ery-apoB, atherosclerosis, lipids and blood group 111
Introduction
The cardiovascular complications of atherosclerosis remain a major health problem in 
the general population. Atherosclerosis is a slowly progressive disease, induced by nu-
merous risk factors contributing to lipid deposition, inflammation and atherothrombosis 
[1]. Apolipoprotein (apo) B is the structural protein of the atherogenic lipoproteins in-
cluding chylomicrons and their remnants, VLDL, IDL and LDL. Large studies have shown 
that the concentration of serum apo B is a strong predictor of CVD [2-4]. Lipoproteins are 
found in the fluid phase where they are metabolized and transported to specific organs. 
However, there is also evidence of a marginated pool of apo B containing lipoproteins 
attached to the endothelium and to circulating blood cells [5,6]. Close interaction exists 
between circulating leukocytes and apo B containing lipoproteins as has been demon-
strated in human studies [7-9]. 
Erythrocytes represent the largest blood cell population and make up more than 
99% of the total cellular space in blood [10]. It has been suggested that the exchange of 
cholesterolesters between LDL and erythrocyte membranes may be substantial, which 
can only be explained by binding of LDL to erythrocytes and not by accidental collision 
[11,12]. Recently, it was shown that erythrocytes may contribute to reverse cholesterol 
transport with impairment of reverse cholesterol transport in anemic mice [13]. In a 
relatively small pilot study, binding of apolipoprotein (apo) B containing lipoproteins to 
erythrocytes (ery-apoB) was proposed as a protective factor for cardiovascular disease 
(CVD) [14]. In this study no clear correlation was observed between serum apo B con-
centrations and ery-apoB and no significant determinants of ery-apoB were detected. 
We investigated the association of ery-apoB with carotid intima media thickness 
(CIMT) and CVD in a larger study population. In addition, we tested whether statins and 
serum apo B concentrations influence ery-apoB values in a separate group of subjects. 




Participants were recruited from the outpatient clinics of the Diabetes Vascular Center 
and the department of Cardiology, Sint Franciscus Gasthuis in Rotterdam, for the mea-
surement of ery-apoB. The inclusion was carried out between July 2009 and February 
2013. Both subjects with and without a history of CVD were included since we expected 
an atheroprotective effect from ery-apoB. A history of CVD was defined as the presence of 
at least one of the following conditions before inclusion: a myocardial infarction, angina 
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pectoris based on clinical characteristics, documented coronary artery disease based on 
a coronary angiogram, a cerebral infarction or the presence of peripheral artery disease. 
Exclusion criteria were age <18 years or the use of any experimental medication within 
6 months before participation. Anthropometric characteristics, e.g. weight, length, BMI, 
waist circumference and blood pressure measurements were recorded. Carotid ultra-
sound scans were carried out to measure carotid intima media thickness (CIMT) using 
the ART-LAB (Esaote, Italy), which has been described in detail previously [14].
ABO blood groups were obtained from the clinical registry system and if not avail-
able, participants were asked to have their ABO blood group determined in our hospital 
on a separate occasion.
A separate group of subjects who used statins for primary cardiovascular preven-
tion discontinued their statin therapy to investigate the effect of statins and subsequent 
changes in serum apo B concentrations on ery-apoB values. Participants using statins, 
but not other lipid lowering drugs, visited the outpatient clinic for baseline measure-
ments including ery-apoB and they were asked to discontinue statin therapy for 6 weeks 
followed by a second visit including a second blood draw with the measurement of 
ery-apoB. The subjects were fasting during both visits. This substudy was registered at 
Clinicaltrials.gov (NCT01634906).
All subjects provided written informed consent. The studies were approved by the 
independent Regional Medical Ethical Committee Rotterdam, Maasstad Hospital, the 
Netherlands.
In vivo measurement of ery-apoB
Blood samples for the determination apo B bound to erythrocytes were obtained 
in tubes containing 5.4 mg K2 EDTA (Becton Dickinson, Plymouth, UK). The staining 
procedure was started within one hour after venipuncture. The method has been 
described in detail previously [7,14]. To avoid interference of serum lipoproteins, the 
samples were washed three times in PBS supplemented with 0.5% BSA (PBS-BSA). The 
erythrocytes were incubated with a polyclonal goat antibody directed against human 
apo B (catalogue no. AB742; Millipore, Billerica, MA, USA) for 30 minutes in the dark on 
ice. Subsequently, the erythrocytes were washed with PBS-BSA and incubated with a 
rabbit anti-goat (RAG) antibody conjugated with FITC (Nordic Immunological Labora-
tories, Tilburg, the Netherlands) for another 30 minutes in the dark on ice. As a control 
for background staining, each sample was simultaneously stained in parallel without 
anti-apo B antibodies, but with RAG-FITC. Samples were kept in the dark on ice until 
measurement. A total of 5000 erythrocytes per sample were analysed by flow cytometry 
using an Epics XL-flow cytometer (Beckman Coulter, Miami, Florida, USA). An FC500 flow 
cytometer (Beckman Coulter) was used in case of the statin withdrawal sub-study. Before 
each use, the optics and settings of the flow cytometer were checked with Flow-Check 
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and Flow-Set beads (Beckman Coulter). Identical flow cytometric settings were used for 
the complete study.
Laboratory measurements 
All clinical and haematological chemistry measurements were carried out on freshly 
drawn blood samples and analysed in the Department of Clinical Chemistry, Sint Fran-
ciscus Gasthuis. Baseline glucose, plasma cholesterol, HDL-C, triglycerides, C-reactive 
protein, creatine kinase, ALAT and ASAT were measured using the LX20 and DxC analyz-
ers (Beckman Coulter). LDL-C values were calculated using the Friedewald formula. Apo 
A-I and apo B were determined by nephelometry using an IMMAGE instrument with 
commercially available kits (Beckman Coulter). Blood cell counts were determined auto-
matically using LH750 and DxH800 analyzers (Beckman Coulter). Thyroid function (TSH) 
was determined by TSH measurement (Immulite 2500; Siemens, Healthcare Diagnostics, 
Deerfield, Illinois, USA). The ABO blood group was determined by standard procedures 
using agglutination techniques (Galileo Echo; Immucor Gamma, Heppignies, Belgium). 
Statistics 
The binding of apo B on erythrocytes was expressed as the mean difference between 
fluorescence intensity of apo B-staining and control background staining in arbitrary 
units (a.u.). The mean fluorescence intensity reflects the amount of apo B per erythro-
cyte. For statistical analysis, CIMT was defined as the mean of the six individual measure-
ments. Subjects were divided into two groups: a normal CIMT (< 0.70 mm) or increased 
CIMT (≥ 0.70 mm). Linear regression analysis (backward stepwise) was used to test the 
differential impact of ery-apoB on CIMT adjusted for multiple variables. The variables 
included were age, gender, a medical history of CVD, BMI, HDL-C, T2DM and the fol-
lowing interaction effects: CIMT x gender, CIMT x CVD, CIMT x T2DM, CIMT x age, CIMT 
x BMI, CIMT x HDL-C, BMI x HDL-C, BMI x T2DM, CVD x age, T2DM x age, T2DM x HDL-C, 
HDL-C x gender, CVD x HDL-C, CVD x BMI. Subjects with ery-apoB levels ranging from 
undetectable to 0.20 a.u. were considered ery-apoB deficient. Since leukocyte count and 
HDL-C were significantly different between ery-apoB deficient and sufficient subjects, 
the impact of ery-apoB deficiency on CVD risk was adjusted for leukocyte count and 
HDL-C using multiple binary logistic regression analysis. 
A power calculation demonstrated that at least 53 subjects were necessary to dem-
onstrate a significant difference of 0.25 ± 0.64 a.u. in ery-apoB after statin withdrawal 
(power 80%, alpha 0.05 two-sided). The subjects with ABO blood group measurements 
were divided into tertiles based upon their ery-apoB values to test the distribution of 
the ABO blood group between the respective tertiles with the Chi-square test. Differ-
ences in continuous variables between two groups were tested with the independent 
Student’s t-test. One-way ANOVA with LSD as post-hoc analysis was used for comparing 
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multiple groups. The LSD test was not corrected for multiple comparisons. However, we 
performed the LSD test only when the overall ANOVA resulted in a P value less than 0.05.
Skewed variables, which included ery-apoB, triglycerides and C-reactive protein, 
were logarithmically transformed before analysis, but non-transformed data are shown 
in the text and tables. Correlations were obtained using the bivariate Spearman’s cor-
relation. All statistical analyses were performed using PASW statistics version 18.0 (IBM 
SPSS Statistics, New York, United States). A P-value of < 0.05 (two sided) was regarded as 
statistical significant. 
Results
Carotid intima media thickness and ery-apoB 
A total of 409 subjects were included in the study. Levels of ery-apoB were missing in 
11 subjects due to technical failures and they were left out of the analysis. A total of 258 
subjects (64.8%) showed a normal CIMT and 140 (35.2%) had an increased CIMT. Base-
line characteristics of these subjects are shown in Table 1. Subjects with an increased 
CIMT were older and were more frequently male and obese. They had more frequently 
a medical history of CVD and used more often statins. The serum apo B concentration 
was similar between the two groups. Ery-apoB was significantly lower in subjects with 
increased CIMT (0.89 ± 0.83 a.u.) compared to subjects with a normal CIMT (1.16 ± 0.92; P 
= 0.007). The difference between the two groups remained significant after adjustment 
for multiple variables (0.71 ± 0.08 a.u. versus 0.60 ± 0.14 a.u.; P < 0.001). A reverse cor-
relation existed between CIMT and ery-apoB (Spearman’s r: -0.116, P = 0.021). 
Ery-apoB deficiency and CVD risk
A total of 55 subjects (13.8%) were deficient for ery-apoB with undetectable to very low 
(≤ 0.20 a.u.) ery-apoB values. The remaining subjects were classified as ery-apoB suf-
ficient (n = 343). Characteristics of the two groups are shown in Table 1. The two groups 
were comparable, except for a higher leukocyte count and lower HDL-C in the ery-apoB 
deficient group. The risk of CVD was significantly higher in the ery-apoB deficient group 
compared to the ery-apoB sufficient group (60.0% vs 44.6%, P = 0.034). 
Ery-apoB deficiency was associated with an almost two-fold increased prevalence 
of a medical history of CVD (OR 1.86; 95% CI 1.04 – 3.33). However, after adjustment for 
HDL-C and leukocytes the association did not reach statistical significance (adjusted OR 
1.55; 95% CI 0.85 – 2.82).
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The effect of statin use on ery-apoB
The impact of statin withdrawal on serum apo B and ery-apoB values were tested in a 
group of 54 subjects who discontinued their statin therapy for 6 weeks. As expected, 
total cholesterol, LDL-C, triglycerides and serum apo B increased, whereas creatine 
kinase and aspartate aminotransferase decreased 6 weeks after statin withdrawal (Table 
2). Ery-apoB remained unchanged before and after discontinuation with a mean change 
in ery-apoB of -0.04 ± 0.39 (P = 0.49) after statin withdrawal. Ery-apoB at baseline was 
strongly correlated to ery-apoB after discontinuing statin therapy for 6 weeks (Spear-
man r: 0.828; P < 0.001) (Figure 1). Ery-apoB did not correlate with serum apo B before 
(Spearman r: -0.025; P = 0.857) nor after 6 weeks of statin withdrawal (Spearman r: 0.038; 
P = 0.786).
Table 1: Characteristics of subjects based on carotid intima media thickness and on deficiency of ery-apoB 












Age (years) 54.2 ± 11.7 65.8 ± 8.7 <0.001 60.8 ± 13.3 58.0 ± 11.9 0.11
Male gender (n, %) 125 (48.4) 94 (67.1) <0.001 31 (56.4) 187 (54.4) 0.78
History of T2DM 
(n, %)
31 (12.0) 35 (25.0) 0.001 13 (23.6) 58 (16.9) 0.22
History of CVD (n, %) 99 (38.4) 91 (65.0) <0.001 33 (60.0) 153 (44.6) 0.03
Use of statins (n, %) 100 (43.4) 97 (69.3) <0.001 35 (63.6) 173 (50.7) 0.08
BMI (kg/m2) 26.4 ± 4.5 27.9 ± 4.6 0.001 27.5 ± 4.8 27.0 ± 4.6 0.41
CIMT (mm) 0.57 ± 0.08 0.80 ± 0.09 <0.001 0.673 ± 0.132 0.646 ± 143 0.19
Hemoglobin 
(mmol/l)
8.8 ± 0.7 8.8 ± 0.9 0.72 8.8 ± 0.86 8.8 ± 0.7 0.89
Erythrocytes (*1012/l) 4.6 ± 0.4 4.6 ± 0.4 0.33 4.6 ± 0.4 4.6 ± 0.4 0.80
Leukocytes (*109/l) 6.5 ± 1.9 6.9 ± 1.7 0.04 7.2 ± 1.6 6.5 ± 1.8 0.02
Platelets (*109/l) 232 ± 54 237 ± 59 0.47 244 ± 58 232 ± 56 0.13
C-reactive protein 
(mg/l)
2.7 ± 3.0 3.3 ± 3.0 0.10 3.6 ± 3.9 2.7 ± 2.8 0.06
Total cholesterol 
(mmol/l)
4.9 ± 1.2 4.7 ± 1.1 0.12 4.7 ± 1.1 4.9 ± 1.2 0.35
LDL-C (mmol/l) 2.9 ± 1.1 2.7 ± 1.0 0.19 2.7 ± 1.0 2.8 ± 1.1 0.51
HDL-C (mmol/l) 1.44 ± 0.42 1.31 ± 0.38 0.01 1.26 ± 0.36 1.41 ± 0.42 0.01
Triglycerides 
(mmol/l)
1.44 ± 1.01 1.68 ± 0.93 0.03 1.70 ± 0.97 1.50 ± 0.99 0.16
Apo B (g/l) 0.93 ± 0.29 0.93 ± 0.25 0.96 0.92 ± 0.26 0.93 ± 0.27 0.78
Apo AI (g/l) 1.56 ± 0.32 1.50 ± 0.24 0.10 1.48 ± 0.25 1.55 ± 0.31 0.14
Abbreviations: BMI = body mass index; CIMT = carotid intima media thickness; apo = apolipoprotein.
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Table 2: Changes in ery-apoB and other parameters of subjects who discontinued statin therapy for 6 
weeks (n = 54). 
Baseline After 6 weeks of statin 
withdrawal
P-value
Age (years) 58.8 ± 8.7 - -
Male gender (n, %) 29 (53.7%) - -
BMI (kg/m2) 28.5 ± 5.1 28.4 ± 5.1 0.45
Waist (cm) 103.1 ± 13.4 104.3 ± 13.9 0.09
Total cholesterol (mmol/l) 4.6 ± 1.0 6.9 ± 1.4 <0.001
LDL-C (mmol/l) 2.5 ± 0.8 4.6 ± 1.1 <0.001
HDL-C (mmol/l) 1.40 ± 0.41 1.35 ± 0.39 0.08
Triglycerides (mmol/l) 1.72 ± 1.12 2.46 ± 2.49 0.007
Apolipoprotein B (g/l) 0.89 ± 0.26 1.41 ± 0.32 <0.001
Apolipoprotein AI (g/l) 1.41 ± 0.22 1.41 ± 0.23 0.84
Erythrocytes (*1012/l) 4.85 ± 0.46 4.86 ± 0.44 0.83
Leukocytes (*109/l) 6.5 ± 1.7 6.3 ± 1.5 0.27
C-reactive protein (mg/l) 2.60 ± 2.74 3.26 ± 5.18 0.32
ALAT (U/l) 30.6 ± 11.4 28.6 ± 12.6 0.10
ASAT (U/l) 21.8 ± 14.8 19.1 ± 12.3 0.01
Creatine kinase (U/l) 122 ± 76 106 ± 63 0.02
Ery-apoB (a.u.) 1.08 ± 0.68 1.05 ± 0.57 0.49
Abbreviations: ALAT = alanine aminotransferase; ASAT = aspartate aminotransferase; ery-apoB = 
erythrocyte bound apolipoprotein B.






























Figure 1: Erythrocyte-bound apolipoprotein B (ery-apoB) was measured in subjects using statins (n = 54) 
at baseline and after discontinuing statin therapy for 6 weeks. Individual ery-apoB levels remained fairly 
stable during the 6 weeks of follow-up since ery-apoB at baseline was strongly correlated to ery-apoB after 
discontinuing statin therapy for 6 weeks (Spearman r: 0.828; P < 0.001).
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Relationship between ABO blood group and ery-apoB
The ABO blood group was included in the analyses to evaluate factors related to ery-
apoB. The ABO blood group was available in only 104 subjects of the original cohort. 
Subjects were divided into tertiles based on their ery-apoB value. The mean ery-apoB 
value for each of the tertiles were 0.17 ± 0.11 a.u., 0.98 ± 0.36 a.u. and 2.46 ± 0.76 a.u., 
respectively. The prevalence of CVD was lowest in the third tertile (55.9%) when com-
pared to the first (82.3%) and second tertile (82.3%) with a similar trend for the use of 
statins (Table 3). The prevalence of blood group A, B and AB were markedly higher in the 
first tertile when compared to the third tertile, whereas blood group O was much more 














































Figure 2: The prevalence of the ABO blood group phenotypes per tertile are shown (A). Tertiles are based 
upon erythrocyte-bound apolipoprotein B (ery-apoB). The first tertile represents the group with the lowest 
ery-apoB, whereas the third tertile represents the subjects with the highest ery-apoB. The prevalence of ABO 
blood group phenotypes was significantly different between the three groups (P = 0.002). Ery-apoB levels 
were almost two-fold increased in subjects with blood group O when compared to subjects with blood group 
A, B or AB (P-ANOVA < 0.001) (B). *P < 0.05 when compared to subjects with blood group A, B or AB.
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prevalent in the second and third tertile when compared to the first tertile (P = 0.002) 
(Figure 2A). 
Ery-apoB levels were also analyzed when subjects were divided according to the 
ABO blood group phenotype. Subjects with blood group A showed higher LDL-C con-
centrations when compared to subjects with blood group O (Table 4). Mean ery-apoB 
levels were 1.56 ± 0.94 a.u. in subjects with blood group O (n = 51), which was almost 
two-fold higher when compared to subjects with blood group A (n = 39) (0.89 ± 1.15 
a.u.; P < 0.001), blood group B (n = 6) (0.73 ± 1.12 a.u.; P = 0.02) or blood group AB (n = 
8) (0.69 ± 0.69 a.u.; P = 0.015) (Figure 2B).
Table 3: Characteristics of a select group of subjects with measurements of erythrocyte-bound 
apolipoprotein B (ery-apoB) and ABO blood group phenotype. Subjects were divided into tertiles based 








Age (years) 62.8 ± 12.2 61.8 ± 8.9 60.9 ± 8.3 0.75
Ery-apoB (a.u.) 0.17 ± 0.112,3 0.98 ± 0.361,3 2.46 ± 0.761,2 <0.001
Blood group A (n, %) 20 (57.1) 12 (34.3) 7 (20.1)
0.002
Blood group B (n, %) 4 (11.4) 1 (2.9) 1 (2.9)
Blood group AB (n, %) 4 (11.4) 3 (8.6) 1 (2.9)
Blood group O (n, %) 7 (20.0) 19 (54.3) 25 (73.5)
Male gender (n, %) 21 (60.0) 26 (74.3) 16 (47.1) 0.07
History of T2DM (n, %) 9 (25.7) 6 (17.1) 7 (20.1) 0.68
History of CVD (n, %) 29 (82.3) 29 (82.3) 19 (55.9) 0.01
Use of statins (n, %) 29 (82.3) 31 (88.6) 21 (61.8) 0.03
BMI (kg/m2) 27.9 ± 4.4 27.7 ± 4.9 26.0 ± 5.2 0.22
Hemoglobin (mmol/l) 8.9 ± 1.0 8.8 ± 0.7 8.8 ± 0.7 0.98
Erythrocytes (*1012/l) 4.7 ± 0.5 4.6 ± 0.3 4.5 ± 0.4 0.19
Leukocytes (*109/l) 7.3 ± 1.62,3 6.6 ± 1.51 6.2 ± 1.21 0.01
Platelets (*109/l) 236 ± 56 224 ± 55 237 ± 40 0.50
C-reactive protein (mg/l) 3.3 ± 3.33 3.0 ± 3.4 1.7 ± 1.21 0.02
Total cholesterol (mmol/l) 4.5 ± 0.8 4.4 ± 0.9 4.6 ± 1.1 0.63
LDL-C (mmol/l) 2.4 ± 0.7 2.4 ± 0.9 2.5 ± 0.9 0.90
HDL-C (mmol/l) 1.31 ± 0.35 1.37 ± 0.42 1.52 ± 0.52 0.12
Triglycerides (mmol/l) 1.85 ± 1.18 1.69 ± 1.11 1.47 ± 0.77 0.40
Apolipoprotein B (g/l) 0.87 ± 0.20 0.83 ± 0.21 0.84 ± 0.24 0.75
Apolipoprotein AI (g/l) 1.52 ± 0.28 1.59 ± 0.31 1.64 ± 0.35 0.26
1 Significantly different when compared to the corresponding 1st tertile (P < 0.05)
2 Significantly different when compared to the corresponding 2nd tertile (P < 0.05)
3 Significantly different when compared to the corresponding 3rd tertile (P < 0.05)
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Discussion
Our study confirmed the association of ery-apoB with clinical and subclinical athero-
sclerosis in an extended study population [14]. Ery-apoB was lower in subjects with 
increased CIMT and very low to undetectable values of ery-apoB were associated with 
an increased CVD risk. Recently, it was demonstrated in a mouse model that erythro-
cytes contribute to reverse cholesterol transport, particularly when the number of HDL 
particles is low [13]. Erythrocyte mediated reverse cholesterol transport by binding of 
atherogenic apo B containing lipoproteins could potentially explain the atheroprotec-
tive effect of ery-apoB suggested by the present data. In addition, we hypothesize a 
protective mechanism in which apo B containing lipoproteins bound to erythrocytes 
are less likely to interact with the endothelium [6,14]. The observation that anemia is 
associated with the development of CVD is also in line with our hypothesis [15].
Table 4: Characteristics of a select group of subjects with measurements of erythrocyte-bound 
apolipoprotein B (ery-apoB) and ABO blood group phenotype. Subjects were divided according to ABO 










Age (years) 61.7 ± 9.5 56.7 ± 16.7 67.6 ± 8.6 61.7 ± 9.3 0.23
Male gender (n, %) 24 (61.5) 3 (50.0) 5 (62.5) 31 (60.8) 0.96
History of T2DM (n, %) 9 (23.1) 0 (0.0) 3 (37.5) 10 (19.6) 0.38
History of CVD (n, %) 27 (69.2) 4 (66.7) 7 (87.5) 39 (76.5) 0.67
Use of statins (n, %) 27 (69.2) 5 (83.3) 8 (100.0) 41 (80.3) 0.30
BMI (kg/m2) 27.0 ± 5.2 28.3 ± 4.2 27.9 ± 3.8 27.1 ± 5.0 0.92
Hemoglobin (mmol/l) 8.8 ± 0.8 8.9 ± 0.6 8.5 ± 1.1 8.9 ± 0.8 0.72
Erythrocytes (*1012/l) 4.6 ± 0.4 4.7 ± 0.4 4.4 ± 0.6 4.6 ± 0.4 0.53
Leukocytes (*109/l) 7.1 ± 1.6 6.1 ± 1.2 6.8 ± 1.0 6.5 ± 1.6 0.22
Platelets (*109/l) 235 ± 56 237 ± 48 252 ± 63 226 ± 45 0.55
C-reactive protein (mg/l) 3.4 ± 3.9 1.8 ± 1.0 2.7 ± 2.5 2.2 ± 1.8 0.34
Ery-apoB (a.u.) 0.89 ± 1.15* 0.73 ± 1.12* 0.69 ± 0.69* 1.56 ± 0.94*** <0.001
Total cholesterol (mmol/l) 4.7 ± 1.0 4.4 ± 1.3 4.1 ± 0.8 4.4 ± 0.9 0.18
LDL-C (mmol/l) 2.7 ± 0.9* 1.9 ± 1.0 2.3 ± 0.6 2.2 ± 0.8** 0.04
HDL-C (mmol/l) 1.34 ± 0.37 1.63 ± 0.65 1.30 ± 0.41 1.42 ± 0.46 0.41
Triglycerides (mmol/l) 1.65 ± 0.85 1.88 ± 1.83 1.09 ± 0.60 1.76 ± 1.11 0.36
Apolipoprotein B (g/l) 0.91 ± 0.24 0.75 ± 0.24 0.80 ± 0.18 0.82 ± 0.19 0.12
Apolipoprotein AI (g/l) 1.57 ± 0.29 1.57 ± 0.27 1.52 ± 0.30 1.60 ± 0.35 0.90
*Significantly different when compared to blood group O (P < 0.05)
**Significantly different when compared to blood group A (P < 0.05)
***Significantly different when compared to blood group A, B or AB (all P < 0.05)
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We did not observe any changes in ery-apoB in the group of subjects who discon-
tinued their statin therapy, despite a marked increase in serum apo B. In our comparison 
between subjects with normal and increased CIMT we did not correct for the use of 
statins, although subjects with increased CIMT used statins more frequently. In the pres-
ent study we clearly demonstrated that statins do not influence ery-apoB since there 
was no change after discontinuation. In addition, there was no association between 
serum apo B and ery-apoB [14]. We have chosen to study the effects of statin withdrawal 
for a period of 6 weeks on ery-apoB, because serum concentrations of apo B and LDL-C 
return to baseline within 4 weeks. In addition, the lifespan of erythrocytes is approxi-
mately 12 weeks and half of all erythrocytes would have been renewed within 6 weeks, 
which potentially may have shown changes in the renewed erythrocyte population. 
We hypothesize that the adherence of apo B containing lipoproteins to erythrocytes is 
dynamic with a continuous process of adherence and release of lipoproteins. Therefore, 
we presume that a period of 6 weeks of statin withdrawal would have been sufficient to 
study the effects of statins and changes in serum apo B on ery-apoB. Furthermore, we 
do not think that it would be ethical for patients to refrain from a necessary treatment 
for a longer period of time.
The exact binding mechanism of apo B containing lipoproteins to erythrocytes has 
not yet been elucidated. The LDL receptor seems to be a logical candidate to bind apo B 
containing lipoproteins to erythrocytes but it is not expressed on erythrocytes [11,12]. 
Therefore, other binding mechanisms must be operational. The exchange of cholester-
olesters between LDL and erythrocyte membranes may be substantial and could not 
be explained by accidental collision [11,12]. Here we show for the first time that the 
ABO blood group system may influence the binding of apo B containing lipoproteins 
to erythrocytes. Interestingly, we found that ery-apoB levels were almost two-fold in-
creased in subjects with blood group O when compared to subjects with blood group 
A, B or AB. We have to admit that the ABO blood group was only available in 104 of the 
total 409 subjects and that the number of subjects with blood group B and AB was low. 
This could have resulted in a selection bias. However, the results were so striking, that we 
decided to include them in the current paper. Studies are underway in our laboratory to 
gain more insight in the relationship between blood groups and ery-apoB. It is tempting 
to speculate that different carbohydrate groups on the apo B molecule interact with 
fucose, galactose, N acetyl-galactosamine or N acetyle-glucosamine, which make up the 
A, B and H antigens [16].
The ABO blood group system has already been associated with plasma cholesterol 
concentrations more than 40 years ago [17,18]. Blood group O has been associated with 
slightly lower cholesterol levels [19], whereas others have found associations between 
blood group A and elevated plasma concentrations for total cholesterol [20,21], and 
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LDL-C [21]. We found similar results in our study with elevated plasma LDL-C levels in 
subjects with blood group A.
Besides with lipids, the ABO blood group system has been associated with CVD. 
Factors involved in this association are potentially Factor VIII, Von Willebrand Factor, en-
dothelial molecules and platelet proteins [22,23]. Recently, two large prospective cohort 
studies plus a meta-analysis demonstrated that the non-O blood group has a higher risk 
of CVD (RR 1.11; 95%CI 1.05 – 1.18) and that 6.27% of the CVD cases were attributable 
to inheriting the non-O blood group [24]. Our finding that ery-apoB is associated with 
both an atheroprotective effect similar to blood group O is in line with these observa-
tions. Prospective data regarding ery-apoB and incident CVD are still lacking and the 
clinical value of ery-apoB as a biomarker in cardiovascular risk prediction needs to be 
determined.
In conclusion, absence or very low ery-apoB is associated with the presence of 
clinical and subclinical atherosclerosis. The evaluation of ery-apoB as a clinical useful 
risk factor for CVD needs to be determined in a large prospective study. Blood group O 
was strongly associated with high ery-apoB and may provide a new explanation for the 
association between the ABO blood group system and CVD and plasma lipids. Statins 
and serum apo B do not affect ery-apoB.
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Chapter 8
Differential regulation of 
complement activation by native 
and acetylated LDL affects binding 
to complement receptor 1
Boudewijn Klop














Introduction: Lipoproteins can induce complement activation resulting in opsonization 
and binding of these complexes to complement receptors. We investigated the binding 
of opsonized native LDL and acetylated LDL (acLDL) to the complement receptor 1 (CR1). 
Methods: Binding of complement factors C3b, IgM, C1q, mannose-binding lectin (MBL) 
and properdin to LDL and acLDL were investigated by ELISA. Subsequent binding of 
opsonized LDL and acLDL to CR1 on CR1-transfected Chinese Hamster Ovarian cells 
(CHO-CR1) was tested by flow cytometry.
Results: Both native LDL and acLDL induced complement activation with subsequent 
C3b opsonization upon incubation with normal human serum. Opsonized LDL and 
acLDL bound to CR1. Binding to CHO-CR1 was reduced by EDTA, whereas MgEGTA only 
reduced the binding of opsonized LDL, but not of acLDL suggesting involvement of the 
alternative pathway in the binding of acLDL to CR1. In vitro incubations showed that LDL 
bound C1q, whereas acLDL bound to C1q, IgM and properdin. MBL did neither bind to 
LDL nor to acLDL. 
Conclusion: CR1 is able to bind opsonized native LDL and acLDL. Binding of LDL to CR1 
is mediated via the classical pathway, whereas binding of acLDL is mediated via both 
the classical and alternative pathways. Binding of lipoproteins to CR1 may be of clinical 
relevance due to the ubiquitous cellular distribution of CR1.
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Introduction
The complement system is part of the innate immune system, which provides protection 
against micro-organisms. Complement activation occurs via three different pathways: 
the classical pathway that depends on IgG and/or IgM antibodies and C-reactive protein 
(CRP), the alternative pathway initiated by factor B, factor D and properdin and the lectin 
pathway initiated by the recognition of neutral sugars like mannose and fructose via 
mannose-binding lectin (MBL) and ficolins [1-3]. All three pathways lead to the conver-
sion of complement component (C) 3, the most abundant complement component 
in serum, into C3a and C3b via surface-bound C3-convertases. The final step of the 
complement cascade is the formation of the membrane attack complex, resulting in 
removal of pathogens and immune complexes from the circulation [2,4,5]. 
The complement system and its activation are not only important in microbial de-
fence but also in the development of atherosclerosis, both by anti- and pro-atherogenic 
properties [6,7]. In addition, the complement system has been linked with lipoprotein 
metabolism, which is closely linked to atherosclerosis, e.g. by binding of complement 
factors to lipoproteins. C3 and C4 have been found on high density lipoproteins (HDL) [8] 
and MBL may be involved in postprandial lipid metabolism with effects on chylomicron 
and very low density lipoprotein (VLDL) handling [9]. Properdin has recently been linked 
to postprandial lipid metabolism as well [10]. Modified forms of low density lipoproteins 
(LDL), like acetylated LDL (acLDL), oxidized LDL (oxLDL) or enzymatically degraded LDL 
have been shown to induce complement activation [6,11], which was enhanced by the 
addition of CRP [6]. Finally, modified forms of LDL bind C3b and C1q [12]. 
Although binding of lipoproteins to specific lipoprotein receptors and heparan 
sulphate proteoglycans is well established [13,14], binding to complement receptors 
may also occur as suggested previously by our group [15]. In theory, C3b-opsonized 
lipoproteins may bind to the complement receptor 1 (CR1, also known as CD35 or C3b 
receptor), which is present on many types of cells such as erythrocytes, endothelial cells 
and inflammatory cells [16,17]. CR1 on erythrocytes is important for “immune adher-
ence”, which functions as a clearing mechanism for immune complexes [18,19] and 
microorganisms [20]. CR1 also facilitates phagocytosis of immune complexes by mono-
cytes, macrophages and neutrophils [17]. Therefore, CR1-mediated cellular binding of 
opsonized lipoproteins may also contribute to removal of lipoproteins from plasma [15].
The aim of this study was to investigate whether CR1 can bind native LDL and acLDL 
and which complement activation pathways may be involved. The clinical relevance of 
this question is based on the recent finding that circulating erythrocytes carry apoli-
poprotein B-containing lipoproteins on their surface [21]. Since erythrocytes express 
CR1 and not the classical lipoprotein receptors, CR1-mediated lipoprotein binding by 
erythrocytes may contribute to the clearance of these particles similarly to the earlier 
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mentioned process of immune adherence. For this purpose, a cell model with CR1 trans-




Transfected Chinese Hamster Ovary cells expressing the complement receptor 1 
(CHO-CR1) and negative controls (CHO) with CD46 cloned in reverse orientation were 
kindly provided by J.P. Atkinson and M.K. Liszewski (Washington University School of 
Medicine, St Louis, Needham, MA, USA) and by S. Rooijakkers (University Medical Center 
Utrecht, Utrecht, the Netherlands) [22,23]. The cells were cultured at 37°C in DMEM/F12 
+ GLUTAMAX (HAM) (1:1) medium (GIBCO, Invitrogen, Carlsbad, California, USA) with 1% 
penicillin-streptomycin, 0.5 µg/ml G-418 (Sigma-Aldrich, St. Louis, Missouri, USA) and 
10% heat-inactivated FCS. Trypsin was used to harvest the cells for experiments. A total 
of 200.000 cells per sample were used for each experiment. Expression and functionality 
of CR1 on CHO-CR1 was confirmed.
Binding of LDL and acLDL to Chinese Hamster Ovary cells
BODIPY® fluorochrome labeled LDL and acLDL were purchased (Invitrogen Molecular 
Probes, Eugene, Oregon, United States) and all experiments were conducted within two 
weeks after arrival of the labeled lipoproteins. All experiments regarding the binding of 
LDL and acLDL to CHO-CR1 and CHO were conducted with these labeled lipoproteins. 
CHO-CR1 and CHO were incubated with 10 µg/ml LDL or acLDL or with medium as con-
trol for 30 minutes on ice in the dark followed by flow cytometric analysis (FACSCalibur, 
Becton Dickinson, Franklin Lakes, New Jersey, USA). To investigate whether LDL binding 
to CHO could be reduced by blocking the LDL receptor, CHO cells were pre-incubated 
with an anti-human LDL receptor blocking antibody (catalog number AF2148, R&D 
Systems, Minneapolis, United States) for 30 minutes prior to LDL incubation. In addition, 
fluorescent LDL (10 µg/ml) was incubated with either normal human serum (NHS) or 
non-labeled LDL in different concentrations to test whether competition for binding 
to CHO cells occurred between fluorescent LDL, LDL present in NHS or with native LDL. 
Fluorescent LDL was incubated with NHS or with non-labeled LDL in culture medium for 
60 minutes on 37°C in the dark prior to incubation with CHO-CR1 and CHO. 
Binding of complement-opsonized LDL and acLDL to CR1
In experiments where it was necessary to impede complement activation heat inacti-
vated serum (HIS) (at 56°C for 30 minutes) was used. Labeled LDL and acLDL (10 µg/
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ml) were incubated with either 10% NHS or 10% HIS in culture medium for 60 minutes 
on 37°C in the dark. Next CHO and CHO-CR1 were incubated with either LDL in NHS, 
acLDL in NHS, LDL in HIS, acLDL in HIS or in culture medium as control for 30 minutes 
in the dark on ice. Binding of LDL or acLDL to CHO and CHO-CR1 was detected by flow 
cytometry (FACSCalibur, Becton Dickinson). 
Inactivation of different complement pathways
In order to inactivate the different complement pathways, the following experiments 
were carried out. Anti-C1q (20 µg/ml) was added to 10% NHS to inactivate the classical 
pathway. The lectin pathway was blocked by addition of D-mannose (200 mM) to 10% 
NHS. MgEGTA (20 mM) was used to block both the classical and lectin pathway. EDTA 
(20 mM) was used to block all three complement pathways. NHS with either anti-C1q, 
D-mannose, MgEGTA or EDTA was left on room temperature for ten minutes before 
incubation with labeled LDL (10 µg/ml) or acLDL (10 µg/ml). After the samples were 
incubated for 60 minutes on 37°C in the dark, CHO-CR1 were incubated with the differ-
ent samples for 30 minutes in the dark on ice and LDL and acLDL binding was assessed 
by flow cytometry.
Binding of complement factors to LDL and acLDL by ELISA
Human lipoproteins were isolated according to the technique described by Redgrave 
et al [24]. In short, PBS with 0.3 mM EDTA with densities of 1.0063 g/L, 1.019 g/L and 
1.063 g/L were prepared by using KBr. Serum was collected from non-fasting healthy 
volunteers, which was adjusted to 1.21 g/L by the addition of KBr. A gradient was pre-
pared and centrifuged with 40,000 rpm with slow acceleration and deceleration for 16 
hours at a temperature of 4°C. The LDL fraction was aspirated with a glass pipette and 
subsequently dialyzed overnight against PBS pH 7.4 using a dialysis cassette (Thermo 
Scientific, Pierce Protein Research Products, Rockford, Illinois, USA). The protein con-
centration was determined using the BCA protein assay kit (Thermo Scientific, Pierce 
Protein Research Products). In addition, a portion of LDL was acetylated according to 
the technique described by Van Berkel et al [25]. AcLDL was prepared by mixing LDL 
with saturated sodium acetate and acetic anhydride. After acetylation, the acLDL was 
dialyzed overnight against PBS buffer with pH 7.4.
Human properdin [26], human IgM [27], human C1q [28] and human MBL [27] were 
purified as described previously. Ninety-six well, flat bottom plates (NUNC, Thermo Fisher 
Scientific, Rochester, New York, USA) were coated with either LDL (50 µg/ml), acLDL (50 
µg/ml) or human serum albumin (HSA) (1 mg/ml) overnight at room temperature. The 
remaining sites were blocked with 1% HSA in PBS and incubated for 1 hour at 37°C. 
Wells were washed with PBS tween 0.05% including 2.5 mM CaCl2 and incubated with 
either NHS, human IgM, C1q, MBL or properdin diluted in Veronal buffer supplemented 
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with 1% HSA, 2.5 mM CaCl2, 2.5 mM MgCl2 and 0.05% tween for 1 hour at 37°C. The 
plate was washed again and incubated with either monoclonal antibodies against hu-
man C3 (RFK22, in-house, Leiden University Medical Center, Leiden, the Netherlands), 
monoclonal anti-human IgM (HB57, hybridoma obtained from the American Type 
Culture Collection, Manassas, VA, United States), monoclonal antibodies against human 
C1q (mAb 2214, kindly provided by Prof. C. E. Hack, Sanquin Blood Supply Foundation, 
Amsterdam, The Netherlands) monoclonal antibodies against human MBL (3E7, Hycult 
Biotech, Uden, the Netherlands) or rabbit anti-human properdin (in house, Leiden 
University Medical Center) followed by HRP-conjugated F(ab’)2 from goat IgG anti-dig 
(Boehringer Mannheim, Mannheim, Germany) or streptavidin-HRP conjugate (Zymed 
Laboratories, South San Francisco, California, USA) with ABTS/H2O2 (Sigma) to measure 
the deposition of C3b, IgM, C1q, MBL and properdin, respectively on LDL and acLDL. 
The optical density (OD) was measured at 415nm using a microtiter plate reader (Model 
680 Microtiter Reader, Bio-Rad Laboratories, California, United States). BSA instead of 
HSA was used as negative control for the determination of properdin binding. Mannan 
(Sigma-Aldrich) was used as a positive control for MBL deposition and IgM as a positive 
control for C1q binding. 
The contribution of the classical and lectin pathways to C3b opsonisation of LDL and 
acLDL were investigated. A similar kind of ELISA for the assessment of C3b deposition 
was done with some adjustments. Different concentrations of anti-C1q or D-mannose 
were added to a fixed concentration of 10% NHS and left on room temperature for ten 
minutes, which was used to incubate the LDL and acLDL coated plates. Human IgM (2.6 
µg/ml) and mannan (10 µg/ml) were used as controls for either inhibition of the classical 
or lectin pathway.
Statistics
Differences between groups were tested using the unpaired t-test when comparing 
two unrelated groups. One-way ANOVA with LSD as post-hoc analysis was used when 
multiple groups were compared. Graphpad 5.0 (Prism) and PASW 18.0 (SPSS, IBM) were 
used for the statistical analyses. A P-value of less than 0.05 (two-sided) was regarded as 
statistical significant.
Results
C3b-opsonization of LDL and acLDL
To determine whether both native LDL and acLDL were able to induce complement 
activation with subsequent C3b opsonization LDL and acLDL were incubated with NHS. 
This resulted in C3b opsonization of LDL and acLDL as established by ELISA (Figure 
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1A). C3b opsonization of acLDL occurred already at NHS concentrations as low as 0.3%, 
whereas concentrations of at least 2.5% were necessary to induce C3b-opsonization of 
LDL. Addition of EDTA to NHS prevented C3b opsonization of LDL and acLDL (Figure 1B).
Binding of opsonized LDL and acLDL to CR1 
The capability of CR1 to bind opsonized LDL and acLDL was tested. For this purpose a 
cell model with CHO-CR1 and control CHO cells was used. Binding of opsonized LDL 
to CHO-CR1 was significantly higher compared to CHO (11.6 ± 1.1 a.u. vs 5.5 ± 0.3 a.u., 
P<0.05). Similar results were found for opsonized acLDL (8.3 ± 1.4 a.u. vs 4.8 ± 0.8 a.u., 
P<0.05) (Figure 2A). This binding was dose-dependently reduced when LDL and acLDL 
were incubated with different ratios of HIS and NHS (Figures 2B and C). 
Binding of non-opsonized LDL and acLDL to CHO and CHO-CR1 was similar be-
tween CHO and CHO-CR1 (Figure 3A). Binding of LDL to CHO via the LDL receptor was 
demonstrated by a reduction in LDL binding to CHO by pre-incubation of CHO with an 
LDL receptor blocking antibody (Figure 3B). Similar reductions in LDL binding to CHO 
were achieved by inducing competition between fluorescent labeled LDL with increas-
ing concentrations of NHS or native LDL (Figures 3C and D).
Binding of human IgM, C1q, MBL and properdin to LDL and acLDL
The binding of several complement factors to LDL and acLDL was tested in order to 
explore which complement factors may be involved in CR1-bound LDL and acLDL. 


































































Figure 1: C3b opsonization of acLDL occurred already at very low concentrations of normal human serum 
(NHS), but concentrations of at least 2.5% were necessary to establish C3b opsonization of LDL (A). C3b 
opsonization occurred on both LDL and acLDL upon incubation with 10% NHS. Mannan served as a positive 
control, whereas human serum albumin (HSA) served as a negative control. The addition of EDTA to NHS 
prevented complement activation and C3b opsonization of LDL and acLDL completely (B). Every figure 

























































Figure 2: CHO-CR1 bound significantly more LDL (10 µg/ml) and acLDL (10 µg/ml) than CHO when LDL 
and acLDL were first incubated with normal human serum (NHS) (A). LDL and acLDL binding to CHO-CR1 
was diminished when heat inactivated serum (HIS) was used to pre-incubate LDL and acLDL instead of NHS 
(B and C). The dotted horizontal lines in the figures represent the autofluorescent background signal. *P < 
0.05, **P < 0.01
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Therefore, binding of purified forms of IgM, C1q, MBL and properdin to LDL and acLDL 
coated plates was established by ELISA. IgM bound to acLDL dose dependently, but not 
to LDL when the lipoproteins were incubated with IgM (Figure 4A and B). C1q bound 
to both LDL and acLDL, but binding to acLDL was more than two-fold higher when 
compared to LDL or to the positive control IgM (Figure 4C). Binding of C1q to acLDL 
was already observed at concentrations of 0.08 µg/ml, whereas C1q binding to LDL or 
natural IgM were observed at concentrations above 1 µg/ml (Figure 4D). MBL did not 
bind to either LDL or acLDL, whereas MBL effectively bound to mannan, which served as 
a positive control for MBL binding (Figure 4E and F). Properdin bound to acLDL, but not 
to LDL (Figure 4G and H). Altogether these results imply that opsonization of either LDL 













































































Figure 3: Non-opsonized LDL and acLDL binding to CHO cells was investigated by flow cytometry. CHO 
and CHO-CR1 bound LDL (10 µg/ml) in a similar proportion, but binding of acLDL (10 µg/ml) was less 
clear (A). Binding of LDL was reduced when CHO were pre-incubated with increasing concentrations anti-
human LDL receptor antibodies (B). Comparable reductions in LDL binding to CHO were observed when 
fluorescent LDL (10 µg/ml) was combined with increasing concentrations of native (non-labeled) LDL (C) 
























































































































































































































Figure 4: Binding of different complement factors to LDL and acLDL was investigated by ELISA. Isolated 
natural IgM (10 µg/ml) bound to acLDL, but not to LDL (A) and a clear dose response curve observed with 
natural IgM binding to acLDL (B). Isolated C1q (5 µg/ml) bound to LDL to a similar extent as the positive 
control natural IgM, whereas C1q was highly bound by acLDL (C) with a clear dose response curve (D). Isolated 
mannose binding lectin (MBL) (0.13 µg/ml) did not bind to either LDL or acLDL, in contrast to mannan, which 
served as a positive control (E), which was also observed with higher concentrations of MBL (F). Properdin (10 
µg/ml) highly bound acLDL, but not LDL (G). The binding of properdin to acLDL was already observed at very 
low concentrations (H). Every figure represents the mean ± SEM of at least three experiments.
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Involvement of different complement pathways in the binding of LDL and acLDL to CR1
The involvement of the classical and lectin pathways in C3b opsonization of LDL and 
acLDL were investigated. For this purpose C3b opsonization of LDL and acLDL was de-
tected using a C3b-ELISA on LDL or acLDL coated plates incubated with NHS substituted 
with different concentrations of either anti-C1q or D-mannose. C3b opsonization of LDL 
was almost completely diminished by anti-C1q at an anti-C1q concentration of 5 µg/
ml or higher. C3b opsonization of acLDL was only gradually reduced by anti-C1q with a 
maximum decrease in C3b opsonization of acLDL of 36% at an anti-C1q concentration of 
10 µg/ml (Figure 5A). D-mannose was able to block C3b opsonization of LDL at a maxi-















































































































































Figure 5: C3b opsonization of LDL was highly reduced by the addition of anti-C1q to 10% NHS, whereas 
C3b opsonization of acLDL was only modestly reduced by antiC1q (20 μg/ml). The dose response pattern 
of anti-C1q and its reduction on C3b deposition on LDL is almost comparable to its control IgM, whereas 
increasing concentrations of anti-C1q showed a more linear reduction in C3b opsonization of acLDL (A). 
The addition of D-mannose to 10% NHS reduced C3b deposition on LDL, but not on acLDL. The reduction 
in C3b opsonization of LDL by D-mannose was almost similar to its control mannan (B). Binding of LDL to 
CHO-CR1 was significantly reduced by the addition of D-mannose (100 mM), MgEGTA (20 mM) or EDTA 
(20mM) to normal human serum (NHS). Addition of anti-C1q (20 µg/ml) to NHS resulted in a non-significant 
reduction in LDL binding to CHO-CR1 (C). AcLDL binding to CHO-CR1 was only reduced by the addition of 
EDTA to NHS, but not by anti-C1q, D-mannose or MgEGTA (D). Every figure represents the relative mean ± 
SEM of at least three experiments. *P < 0.05, **P < 0.01
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mum concentration of 400 mM in a similar way as for mannan. In contrast, D-mannose 
did not affect C3b opsonization of acLDL (Figure 5B).
In addition, we conducted experiments to test, which complement pathways were 
involved in LDL and acLDL binding to CHO-CR1. For this purpose we incubated CHO-CR1 
with fluorescent labeled LDL and acLDL, which were incubated with NHS substituted 
with either anti-C1q, D-mannose, MgEGTA or EDTA. By blocking the classical pathway 
with anti-C1q LDL binding to CHO-CR1 was slightly decreased. When the lectin pathway 
was blocked with D-mannose LDL binding to CHO-CR1 was significantly decreased. 
LDL binding to CHO-CR1 could also be inhibited with MgEGTA, which blocks both the 
classical and lectin pathway but not the alternative pathway, and EDTA, which blocks 
all three complement pathways (Figure 5C). AcLDL binding to CHO-CR1 was signifi-
cantly decreased by the addition of EDTA and slightly affected by anti-C1q, but not by 
D-mannose or MgEGTA (Figure 5D). 
Discussion
The current experiments show for the first time that opsonized LDL and acLDL can bind 
to CR1. LDL and acLDL can activate the complement system through different pathways 
with subsequent C3b opsonization of these lipoproteins followed by binding to CR1. 
Recently, it was demonstrated in vitro that complement activation occurred when 
epithelial cells were incubated with oxLDL in NHS supplemented cell cultures. This 
resulted in increased C3b levels and the formation of membrane attack complexes and 
could be prevented by using HIS instead of NHS [11]. This study is in line with our results 
since we observed C3b opsonization and subsequent binding of LDL and acLDL to CR1 
only after incubation with NHS. Our experiments also demonstrated that besides acLDL, 
native LDL was able to induce complement activation.
Enzymatically modified LDL (E-LDL) activates the C1 complex via the classical path-
way [29]. Our data suggest that LDL binds to CR1 primarily via C3b formed by activation 
of the classical pathway, whereas acLDL binds to CR1 via both the classical and alter-
native pathways. We were able to demonstrate C1q binding to native LDL in a similar 
proportion as to IgM, but only with high concentrations of purified C1q. In contrast, a 
previous study showed that reconstitution of purified C1q to 10% C1q-depleted serum 
resulted only in C3b deposition on modified forms of LDL, but not on native LDL [11]. 
It is known that complement activity of serum decreases during C1q depletion and our 
results showed that acLDL was three times more potent in binding C1q when compared 
to native LDL or natural IgM [30]. This may explain the contrast with earlier results 
[11,30], since we observed that only sufficiently high enough NHS concentrations lead 
to C3b-opsonization of native LDL. 
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We also observed a reduction in CR1-bound LDL with decreased C3b opsonization 
with high concentrations of D-mannose. These results were unexpected since binding 
of MBL to LDL or acLDL could not be established in our hands, which is in line with 
published data [31]. A different study demonstrated binding of MBL to acLDL, but recon-
stitution of MBL deficient serum with purified MBL did not result in complement activa-
tion on acLDL [12]. Therefore, the exact contribution of MBL and the lectin pathway to 
the binding of LDL to CR1 needs to be explored further.
We studied the importance of the alternative pathway in these processes in addi-
tion to the classical and lectin pathways. Properdin was able to bind acLDL, but not 
native LDL. Moreover, MgEGTA, which blocks selectively the classical and lectin pathway 
but not the alternative pathway, did not affect acLDL binding to CHO-CR1, whereas it 
significantly reduced LDL binding to CHO-CR1. These results illustrate the importance 
of the alternative pathway in the binding of acLDL to CR1. It was already described that 
oxLDL is able to increase factor B in vitro, which is a stimulator of the alternative pathway 
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Figure 6: Schematic overview of the mechanism of CR1-bound LDL and acLDL. Binding of LDL to CR1 is 
mediated via the classical pathway. C1q binds first to LDL by C3b opsonization, which serves as the ligand 
for CR1. The role of Mannose-binding lectin (MBL) and the lectin pathway in CR1-bound LDL remains 
unclear since we were unable to show MBL binding to LDL despite an effect of alienating the lectin pathway. 
Binding of acLDL to CR1 is mediated via the classical and alternative pathway. AcLDL can be bound by 
both C1q and properdin (P), which are able to initiate the classical and alternative pathway, respectively. In 
addition, IgM, which is able to bind C1q, can also bind to acLDL. The LDL and modified LDL binding capacity 
of CR1 may provide an additional mechanism for cellular bound apolipoprotein B containing lipoproteins.
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have an increased postprandial triglyceride response [10]. It is tempting to speculate 
that properdin deficient mice have increased postprandial lipemia due to a lack of 
properdin-mediated alternative complement activation with reduced CR1 binding of 
lipoproteins, but definitive evidence is yet lacking. We have only investigated properdin 
and alternative complement activation with native LDL and acLDL, but not with triglyc-
eride-rich lipoproteins like VLDL and chylomicrons. Therefore, we cannot extrapolate 
our results to the metabolism of postprandial lipoproteins.
In Figure 6 a schematic model is provided, summarizing the complement pathways 
and its complement factors involved in LDL and acLDL binding to CR1. This model 
proposes that the classical pathway is involved in both LDL and acLDL binding to CR1, 
whereas the alternative pathway via properdin also regulates acLDL binding to CR1. The 
exact contribution of MBL and the lectin pathway in LDL binding to CR1 remains unclear.
Our data suggest an additional cellular binding mechanism for LDL and modified 
LDL via CR1, which is ubiquitously distributed throughout the human body. CR1 was 
first isolated from human erythrocytes where CR1 facilitates immune adherence of im-
mune complexes and microorganisms to erythrocytes [18-20,32]. CR1 is also present on 
various inflammatory cells. Monocytes, macrophages and neutrophils are able to inter-
nalize CR1 as a defense mechanism for phagocytosis of CR1-bound immune complexes 
in contrast to erythrocytes [17].
The expression of CR1 by inflammatory cells is highly variable within subjects, as 
reported previously showing that an increase in CR1 expression by monocytes and 
neutrophils occurs upon the ingestion of a fat meal [33]. On average, monocytes and 
neutrophils express 20000 to 140000 CR1 molecules per cell [34,35]. In theory, mono-
cytes, macrophages and neutrophils may internalize opsonized forms of LDL via CR1 
with subsequent clearance of LDL from the circulation, but with the risk of increased 
activation and initiation of an inflammatory reaction. Internalization of lipoproteins by 
neutrophils has been associated with increased neutrophil activation demonstrated 
by an increased expression of degranulation markers, which contributes to endothe-
lial dysfunction [36]. In addition, uptake of modified LDL by macrophages stimulates 
intracellular transcription of the C3 gene with subsequent increased secretion of C3 by 
macrophages [37]. In theory, this could lead to additional opsonization of circulating 
lipoproteins.
In contrast, erythrocyte-mediated lipoprotein clearance may have anti-atherogenic 
properties. Erythrocytes express only approximately 300-800 CR1 molecules per eryth-
rocyte, but most of the total CR1 in the circulation is present on erythrocytes since they 
form the majority of the cellular blood compartment [38]. The liver clears immune com-
plexes and microorganisms bound to erythrocytes at high rates [18]. Something similar 
may occur with CR1-mediated erythrocyte-bound LDL, which may be an atheroprotec-
tive mechanism [15,39]. Recently it was shown that erythrocytes contribute to reverse 
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cholesterol transport by an unknown mechanism [40]. We propose that this could be 
a CR1-mediated process in which opsonized LDL bind to CR1 present on erythrocytes. 
This may explain the presence of apolipoprotein B, the structural protein of LDL and of 
the triglyceride-rich lipoproteins, on circulating erythrocytes, as described by our group 
recently [21,39]. We have recently shown that the presence of apolipoprotein B on eryth-
rocytes is associated to lower intima media thickness values of the carotids in humanst 
[21,39]. Therefore, the capacity of erythrocytes to bind atherogenic lipoproteins via CR1 
may be atheroprotective.
It should be noted that all studies presented here have been done in vitro and it is 
still not clear whether LDL and modified forms of LDL are able to induce complement ac-
tivation in vivo. In our experiments C3b was not present on freshly isolated LDL or acLDL 
and addition of NHS was necessary to initiate C3b opsonization of LDL and acLDL. The 
absence of C3b on freshly isolated LDL may have been induced by the ultracentrifuga-
tion process or because C3b opsonized LDL are not present in serum due to avid binding 
to CR1 expressing cells like endothelial cells, leukocytes and erythrocytes [15,21,36,39]. 
Animal and clinical studies are necessary to further elucidate the importance of lipo-
protein mediated complement activation and the presence of CR1-mediated cellular 
lipoprotein transport in vivo. 
In conclusion, CR1 is able to bind opsonized native LDL and acLDL. Binding of LDL 
to CR1 is mediated via the classical pathway, whereas binding of acLDL is mediated via 
both the classical and alternative pathways. 
140 Chapter 8
References
1. Oksjoki R, Kovanen PT, Pentikainen MO. Role of complement activation in atherosclerosis. Curr 
Opin Lipidol 2003;14:477-482
2. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: A key system for immune surveil-
lance and homeostasis. Nat Immunol 2010;11:785-797
3. Kojima M, Presanis JS, Sim RB. The mannose-binding lectin (MBL) route for activation of comple-
ment. Adv Exp Med Biol 2003;535:229-250
4. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058-1066
5. Walport MJ. Complement. Second of two parts. N Engl J Med 2001;344:1140-1144
6. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: Binding of CRP 
to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 
1999;19:2348-2354
7. van Oostrom AJ, Alipour A, Plokker TW, Sniderman AD, Castro Cabezas M. The metabolic syn-
drome in relation to complement component 3 and postprandial lipemia in patients from an 
outpatient lipid clinic and healthy volunteers. Atherosclerosis 2007;190:167-173
8. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, et al. Shotgun proteomics 
implicates protease inhibition and complement activation in the antiinflammatory properties of 
HDL. J Clin Invest 2007;117:746-756
9. Alipour A, van Oostrom AJ, Van Wijk JP, Verseyden C, Plokker HW, Jukema JW, et al. Mannose bind-
ing lectin deficiency and triglyceride-rich lipoprotein metabolism in normolipidemic subjects. 
Atherosclerosis 2009;206:444-450
10. Gauvreau D, Roy C, Tom FQ, Lu H, Miegueu P, Richard D, et al. A new effector of lipid metabolism: 
Complement factor properdin. Mol Immunol 2012;51:73-81
11. Ebrahimi KB, Fijalkowski N, Cano M, Handa JT. Decreased membrane complement regulators 
in the retinal pigmented epithelium contributes to age-related macular degeneration. J Pathol 
2013;229:729-742
12. Fraser DA, Tenner AJ. Innate immune proteins C1q and mannan-binding lectin enhance clearance 
of atherogenic lipoproteins by human monocytes and macrophages. J Immunol 2010;185:3932-
3939
13. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 2009;29:431-438
14. Mitra S, Goyal T, Mehta JL. Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc Drugs Ther 
2011;25:419-429
15. Bovenberg SA, Alipour A, Elte JW, Rietveld AP, Janssen JW, van de Geijn GJ, et al. Cell-mediated 
lipoprotein transport: A novel anti-atherogenic concept. Atheroscler Suppl 2010;11:25-29
16. Langeggen H, Berge KE, Johnson E, Hetland G. Human umbilical vein endothelial cells express 
complement receptor 1 (CD35) and complement receptor 4 (CD11c/CD18) in vitro. Inflammation 
2002;26:103-110
17. Fearon DT, Wong WW. Complement ligand-receptor interactions that mediate biological re-
sponses. Annu Rev Immunol 1983;1:243-271
18. Cornacoff JB, Hebert LA, Smead WL, VanAman ME, Birmingham DJ, Waxman FJ. Primate erythro-
cyte-immune complex-clearing mechanism. J Clin Invest 1983;71:236-247
19. Waxman FJ, Hebert LA, Cornacoff JB, VanAman ME, Smead WL, Kraut EH, et al. Complement deple-
tion accelerates the clearance of immune complexes from the circulation of primates. J Clin Invest 
1984;74:1329-1340
20. Nelson Jr RA. The immune-adherence phenomenon. Science 1953;118:733-737
CR1-bound lipoproteins 141
21. Klop B, van de Geijn GJ, Bovenberg SA, van der Meulen N, Elte JW, Birnie E, et al. Erythrocyte-
bound apolipoprotein B in relation to atherosclerosis, serum lipids and ABO blood group. PLoS 
One 2013;8:e75573
22. Makrides SC, Scesney SM, Ford PJ, Evans KS, Carson GR, Marsh HC, Jr. Cell surface expression of the 
C3b/C4b receptor (CR1) protects Chinese hamster ovary cells from lysis by human complement. J 
Biol Chem 1992;267:24754-24761
23. Nickells M, Hauhart R, Krych M, Subramanian VB, Geoghegan-Barek K, Marsh HC, Jr., et al. Map-
ping epitopes for 20 monoclonal antibodies to CR1. Clin Exp Immunol 1998;112:27-33
24. Redgrave TG, Roberts DC, West CE. Separation of plasma lipoproteins by density-gradient ultra-
centrifugation. Anal Biochem 1975;65:42-49
25. Van Berkel TJ, Nagelkerke JF, Harkes L, Kruijt JK. Processing of acetylated human low-density lipo-
protein by parenchymal and non-parenchymal liver cells. Involvement of calmodulin? Biochem J 
1982;208:493-503
26. Gaarkeuken H, Siezenga MA, Zuidwijk K, van Kooten C, Rabelink TJ, Daha MR, et al. Comple-
ment activation by tubular cells is mediated by properdin binding. Am J Physiol Renal Physiol 
2008;295:F1397-1403
27. Roos A, Bouwman LH, Munoz J, Zuiverloon T, Faber-Krol MC, Fallaux-van den Houten FC, et al. 
Functional characterization of the lectin pathway of complement in human serum. Mol Immunol 
2003;39:655-668
28. Nauta AJ, Trouw LA, Daha MR, Tijsma O, Nieuwland R, Schwaeble WJ, et al. Direct binding of C1q 
to apoptotic cells and cell blebs induces complement activation. Eur J Immunol 2002;32:1726-
1736
29. Biro A, Thielens NM, Cervenak L, Prohaszka Z, Fust G, Arlaud GJ. Modified low density lipoproteins 
differentially bind and activate the C1 complex of complement. Mol Immunol 2007;44:1169-1177
30. van der Pol P, Roos A, Berger SP, Daha MR, van Kooten C. Natural IgM antibodies are involved 
in the activation of complement by hypoxic human tubular cells. Am J Physiol Renal Physiol 
2011;300:F932-940
31. Faro J, Chen Y, Jhaveri P, Oza P, Spear GT, Lint TF, et al. L-ficolin binding and lectin pathway activa-
tion by acetylated low-density lipoprotein. Clin Exp Immunol 2008;151:275-283
32. Fearon DT. Regulation of the amplification C3 convertase of human complement by an inhibitory 
protein isolated from human erythrocyte membrane. Proc Natl Acad Sci U S A 1979;76:5867-5871
33. Klop B, van de Geijn GJ, Njo TL, Janssen HW, Rietveld AP, van Miltenburg A, et al. Leukocyte cell 
population data (Volume Conductivity Scatter) in postprandial leukocyte activation. Int J Lab 
Hematol 2013;6:644-651
34. Quadri RA, Schifferli JA. Over-estimation of the number of complement receptor type 1 (CR1) on 
erythrocytes. Scand J Immunol 1992;36:125-130
35. Wilson JG, Wong WW, Schur PH, Fearon DT. Mode of inheritance of decreased C3b receptors on 
erythrocytes of patients with systemic lupus erythematosus. N Engl J Med 1982;307:981-986
36. Alipour A, van Oostrom AJ, Izraeljan A, Verseyden C, Collins JM, Frayn KN, et al. Leukocyte activa-
tion by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol 2008;28:792-797
37. Mogilenko DA, Kudriavtsev IV, Trulioff AS, Shavva VS, Dizhe EB, Missyul BV, et al. Modified low 
density lipoprotein stimulates complement C3 expression and secretion via liver X receptor and 
toll-like receptor 4 activation in human macrophages. J Biol Chem 2012;287:5954-5968
38. Hinderling PH. Red blood cells: A neglected compartment in pharmacokinetics and pharmacody-
namics. Pharmacol Rev 1997;49:279-295
142 Chapter 8
39. Bovenberg SA, Klop B, Alipour A, Martinez-Hervas S, Westzaan A, van de Geijn GJ, et al. Erythro-
cyte-associated apolipoprotein B and its relationship with clinical and subclinical atherosclerosis. 
Eur J Clin Invest 2012;42:365-370
40. Hung KT, Berisha SZ, Ritchey BM, Santore J, Smith JD. Red blood cells play a role in reverse choles-




General discussion and summary

Discussion and summary 147
Triglycerides: from measurement to treatment
The metabolism of cholesterol and triglycerides is a complex process and relates 
strongly to cardiovascular disease. All apolipoprotein (apo) B containing lipoproteins, 
which include chylomicrons, chylomicron remnants, VLDL, IDL and LDL are atherogenic 
[1-4]. Not surprisingly, non-HDL-C, LDL-C and apo B have all been associated with car-
diovascular disease [5,6]. Apo B48, which is the specific apolipoprotein for chylomicrons, 
was also found to correlate with the carotid intima media thickness [7]. In addition, tri-
glycerides have also been associated with cardiovascular disease since elevated triglyc-
erides reflect a surplus in circulating chylomicrons and VLDL [8-10]. Recently, multiple 
genetic studies confirmed this relation via strong associations between genes involved 
in primarily elevated triglycerides and cardiovascular disease [1,11]. Triglycerides are 
not only associated with cardiovascular disease, but high levels of triglycerides (> 10 
mmol/l) may also cause pancreatitis [12]. Therefore, treatment of elevated triglycerides 
is important, but the treatment strategy depends on the underlying disorder leading to 
hypertriglyceridemia. 
A physician oriented guideline for the treatment of hypertriglyceridemia based on 
the literature is provided in Chapter 2. Weight loss and improvement of dietary habits 
are the main treatment of hypertriglyceridemia and should be sufficient if hypertriglyc-
eridemia is caused by obesity without existing co-morbidity. However, pharmacological 
treatment is necessary in hypertriglyceridemic patients due to a primary lipid disorder 
like familial hypertriglyceridemia or familial combined hyperlipidemia [13]. The lipolysis 
of triglycerides is greatly disturbed in familial hypertriglyceridemia, which is best treated 
with fibrates since they stimulate lipolysis and fatty acid oxidation, and subsequently, the 
metabolism of chylomicrons into chylomicron remnants and VLDL into LDL. However, 
hypertriglyceridemia in patients with familial combined hyperlipidemia, cardiovascular 
disease or type 2 diabetes mellitus is most often a reflection of an elevated number 
of circulating triglyceride-rich lipoproteins with a surplus in remnant cholesterol. 
Recently, it was demonstrated that genetically elevated remnant cholesterol levels in 
hypertriglyceridemic subjects has a causal association with coronary artery disease [1]. 
Therefore, this condition is best treated with statin therapy to reduce specifically the 
number of circulating chylomicrons and VLDL, which may be combined with fibrates to 
further improve the clearance of these lipoproteins. 
Current guidelines advise to use apo B or non-HDL-C as a secondary treatment 
target next to LDL-C in patients with a combined hyperlipidemia [14]. Apo B represents 
the total number of atherogenic particles (chylomicrons, chylomicron remnants, VLDL, 
IDL and LDL), whereas non-HDL-C represents the amount of cholesterol in both the 
triglyceride-rich lipoproteins and LDL. Recently, a meta-analysis has shown that imple-
mentation of non-HDL-C or apo B as treatment target over LDL-C would prevent an 
additional 300,000 - 500,000 cardiovascular events in the US population over a 10-year 
period [15]. Apo B and non-HDL-C are also not affected by food intake in contrast to 
LDL-C, which can only be measured reliably in the fasting state. Current guidelines still 
recommend to measure lipid profiles in the fasting state [14,16], but emerging evidence 
consisting of large epidemiological studies show that measuring non-fasting lipids only 
affects the measured lipid parameters to a small extent [17,18]. 
In Chapter 3 we compared the intra-individual variability of triglycerides during 
the day. A problem with measuring triglycerides is the high intra-individual variability 
(approximately 25%) despite standardized fasting measurements. It is believed that the 
intra-individual variability of triglycerides is even higher in the non-fasting state, but 
this has never been investigated. We were able to demonstrate that the intra-individual 
variability of triglycerides does not differ between fasting and non-fasting states [19]. 
Only in men the intra-individual variability of triglycerides increased after dinner and at 
bedtime, but remained unchanged during daylight hours. With these data it would be 
possible to propose reference values for non-fasting triglycerides, which can contribute 
to the use of non-fasting triglycerides and other lipid parameters in clinical practise. The 
measurement of non-fasting over fasting lipid profiles is much more convenient for both 
patients and physicians. It helps patient adherance to follow-up programs and it may 
decrease the necessity to perform blood tests during the early morning, which reduces 
waiting times and further improves patient convenience [17,20].
A growing body of evidence concerning the use of non-fasting triglycerides for 
cardiovascular risk prediction in a clinical setting are emerging. Both fasting and non-
fasting triglycerides were predictive for cardiovascular disease in patients with systemic 
lupus erythematodes [21]. The results from the Women’s Health Study even suggest that 
non-fasting triglycerides are a stronger predictor for cardiovascular disease than fast-
ing triglycerides [9]. In addition, A large observational study showed little association 
between lipid subclass levels and fasting time illustrating the potential small effect on 
clinical practice by using non-fasting samples [17]. However, these large studies com-
pared lipid samples from different fasting intervals, but all samples were from different 
subjects. Little data is available related to the comparison of the clinical relevance of 
fasting versus non-fasting lipids within subjects. Therefore, a randomized-controlled 
trial is necessary where subjects are randomized between a group who measures a fast-
ing plus non-fasting sample versus a group who measures two times a fasting sample. 
This will provide the best data to compare the effects of fasting times on lipid changes 
and whether this would affect clinical decision making such as initiating or adjusting 
lipid lowering therapy.
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The measurement and modification of postprandial leukocyte 
activation
The development of atherosclerosis is not only initiated by mere cholesterol deposition 
in the arterial wall, but inflammation is an important contributor to atherosclerosis as 
well. It was recently demonstrated in a large population study with 60,608 participants 
that remnant cholesterol is causally associated with inflammation and cardiovascular 
disease [22]. Chylomicrons and VLDL can activate leukocytes directly ex vivo and in vivo, 
which is associated with endothelial dysfunction [23,24]. It is generally accepted that 
postprandial lipemia with accumulating chylomicrons and VLDL reflected by an increase 
in triglycerides induces an inflammatory response [25].
Normally, circulating leukocytes are present for host defence, but leukocytes recog-
nise VLDL and chylomicrons as pathogens just like bacteria and immune complexes. 
Activated leukocytes are able to enter the arterial wall due to upregulation of cellular 
adhesion molecules like CD11b, which contributes to the development of atherosclero-
sis. Upon activation, leukocytes increase in volume and degranulate and these param-
eters are normally used by hematology analysers for 5-part leukocyte differentiation. 
Our research described in Chapter 4 showed that standard a hematology analyser was 
able to detect activation of monocytes and neutrophils after a fat load with comparable 
changes in activation during infectious diseases, but to less extent [26]. Light scatter was 
decreased in monocytes and neutrophils together with an increase in size of monocytes 
postprandially. However, an oral fat load did not disturb the automatic differentiation of 
leukocytes to such extent that it would interfere with the potential use of leukocyte cell 
population data for infection detection in clinical practise. 
In general, the measurement of leukocyte activation using flow cytometry requires 
extensive labour, suitable equipment, highly trained technicians, time consuming 
blood handling and costly antibodies. This can be one of the reasons why little is known 
about postprandial leukocyte activation in specific conditions such as familial hyper-
triglyceridemia and familial combined hyperlipidemia. It is tempting to speculate that 
in conditions with postprandial hyperlipidemia, leukocyte activation is exaggerated 
postprandially. Therefore, leukocyte cell population data determined by standard hema-
tology analyzers can provide an easy, cheap and fast method to measure postprandial 
leukocyte activation in a wide array of conditions and study designs.
Little research has been done to search for interventions to reduce the atherogenic 
postprandial leukocyte activation. So far, only exercise shortly before a meal has been 
found to reduce postprandial leukocyte activation [27]. We investigated in Chapter 
5 whether vitamin D3 supplementation reduced postprandial leukocyte activation. 
Vitamin D3 is not only important for the metabolism of bone mineralisation. Vitamin 
D3 has also shown beneficial effects on arterial elasticity [28,29] and affects leukocyte 
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activation. In vitro studies had shown that 1.25-dihydroxyvitamin D3, which is the active 
metabolite of vitamin D3, reduced the activation state of leukocytes and formation of 
atherogenic foam cells [30,31].
We hypothesized that the reported beneficial effects of vitamin D3 on arterial 
elasticity may be related to a reduction in postprandial leukocyte activation. Our results 
showed indeed an improvement in arterial elasticity postprandially in men and women, 
but this was accompanied by a reduction in postprandial leukocyte activation mark-
ers only in women. Therefore, a direct relationship between the vitamin D3 associated 
improvement in arterial elasticity and reduction in postprandial leukocyte activation 
is questionable. A possible explanation for our observed gender difference may be 
related to sex steroids. It has been demonstrated that estradiol reduces the CD11b 
expression on monocytes in vitro [32], whereas testosterone potentiates neutrophil 
activation [33]. Others have also shown that women have fewer CYP24A1 transcripts 
encoding the 1,25-dihydroxyvitamin D3-inactivating enzyme when compared to men. 
Therefore, binding and cellular accumulation of 1,25-dihydroxyvitamin D3 is increased 
in women with subsequent increased anti-inflammatory effects [34]. Recently, it was 
also demonstrated in a large observational study that 25-hydroxyvitamin D3 serum 
concentrations is not consistently associated with the carotid intima media thickness, 
which demonstrates the complex relationship between vitamin D3 and cardiovascular 
disease [35]. Current studies in our laboratory are carried out to further investigate the 
relationship between vitamin D3, postprandial leukocyte activation and its interaction 
with sex steroids. Moreover, a large prospective randomized trial is currently carried 
out to investigate whether vitamin D3 supplementation will actually reduce incident 
cardiovascular disease.
Transport of atherogenic lipoproteins by erythrocytes
Our research group and others have demonstrated the uptake of lipoproteins by 
leukocytes [36,37] including the presence of apo B on the membrane of leukocytes 
using flow cytometry [24]. We were interested whether apo B was also detectable on 
erythrocytes and it was indeed possible to detect apo B on erythrocytes using similar 
techniques. A pilot study in 166 subjects described in Chapter 6 demonstrated that 
patients with cardiovascular disease express less erythrocyte-bound apo B (ery-apoB) 
compared to control subjects. There was also a negative correlation between the carotid 
intima media thickness, which is a marker of subclinical atherosclerosis, and ery-apoB 
[38]. Chapter 7 described the results of the extended study with a total of 409 subjects. 
Very low values to absence of ery-apoB in particular was associated with cardiovascular 
disease. Ery-apoB remained higher in subjects with a normal carotid intima media thick-
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ness when compared to subjects with an increased carotid intima media thickness [39]. 
Therefore, the capability of erythrocytes to bind apo B containing lipoproteins seems to 
be atheroprotective. So far, the exact molecular basis for this phenomenon remains un-
known. Erythrocyte mediated reverse cholesterol transport by binding of atherogenic 
apo B-containing lipoproteins may explain the atheroprotective effect of ery-apoB since 
it was recently demonstrated in a mouse model that erythrocytes can contribute to re-
verse cholesterol transport in a similar way as high density lipoproteins [40]. In addition, 
we hypothesized that apo B containing lipoproteins bound to erythrocytes less likely 
interact with the endothelium when compared to unbound lipoproteins [41].
We continued our research investigating potential determinants of ery-apoB since 
the the expression of apo B on erythrocytes was highly variable among study subjects. 
Since elevated serum concentrations of apo B are associated with cardiovascular disease 
it would be logical to hypothesize that more ery-apoB just reflects low serum concentra-
tions of apo B. However, we did not observe any association between serum apo B and 
ery-apoB, nor was ery-apoB affected by temporary discontinuation of statin therapy 
despite an increase in serum apo B as described in Chapter 7. Therefore, ery-apoB is 
independent from the standard lipid parameters and may provide additional informa-
tion as a clinical biomarker for cardiovascular risk prediction. However, its predictive and 
clinical value still needs validation in future studies.
Ery-apoB was measured using a polyclonal antibody against apo B, which is present 
on all different atherogenic lipoproteins including modified forms of LDL. This antibody 
should be able to bind different epitopes of apo B. Nevertheless, we presume that the 


















Figure 1: A postprandial change in erythrocyte-bound apolipoprotein B (ery-apoB) could not be detected. 
Ery-apoB was measured up to eight hours after the ingestion of a standardized oral fat loading test (n = 12). 
Data represent mean ± SEM. MFI = mean fluorescent intensity.
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performed oral fat loading tests in 12 healthy subjects, which did not affect ery-apoB 
up to eight hours postprandially, which suggests that the triglyceride-rich lipoproteins 
are not involved (Figure 1). In addition, we were unable to detect a positive signal on 
erythrocytes with flow cytometry by using an antibody specifically targeted against apo 
B48.
Interestingly, we found that the ABO blood group was strongly associated with ery-
apoB, which was measured in a relatively small subgroup (n = 104) [39]. In Chapter 7 it 
was shown that the expression of ery-apoB was almost twice as high in subjects with 
blood group O when compared to subjects with blood group A, B or AB. The prevalence 
of blood group O was lowest in the lowest ery-apoB tertile and highest in the highest 
ery-apoB tertile, whereas the prevalence of blood group A was exactly the opposite. It 
should be noted that the number of study subjects with blood group B and AB was very 
low. Therefore, our group is currently further exploring the relationship between blood 
groups and ery-apoB. Nevertheless, these results may indicate a direction for future 
research to investigate possible mechanisms for apo B to bind erythrocytes. 
The complement receptor 1 may contribute to cellular transport of 
lipoproteins
Since apo B can be detected on both erythrocytes and different types of leukocytes 
we explored possible binding mechanisms. Multiple receptors such as the scavenger 
receptor CD36, LDL receptor, LOX-1 and apo B48 receptor have already been identified, 
which are involved in binding and uptake of lipoproteins by leukocytes [37,42,43]. Be-
sides these classical lipoprotein receptors, complement receptors may also be involved, 
especially because the complement system has been linked to lipoprotein metabolism 
and the complement receptor 1 (CR1) is present on both leukocytes and erythrocytes 
[41,44]. The in vitro experiments described in Chapter 8 demonstrate that CR1 is indeed 
capable of binding LDL and modified LDL, but only once the lipoproteins were first 
opsonized with C3b by complement activation. The classical pathway contributed to 
C3b opsonisation of both LDL and modified LDL, whereas the alternative pathway only 
contributed to C3b opsonisation of modified LDL. Whether the lectin pathway was im-
portant in C3b opsonisation of LDL or modified LDL remained unclear, but it was clearly 
demonstrated that mannose binding lectin (MBL) did not bind LDL nor modified LDL.
The capability of CR1 to bind C3b opsonized forms of LDL may explain the presence 
of apo B on erythrocytes and in part on leukocytes. In contrast to leukocytes, eryth-
rocytes do not express any established receptors capable of binding LDL or modified 
forms of LDL. CR1 on erythrocytes functions as an immune complex clearing mechanism 
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and a similar mechanism may contribute to apo B-containing lipoproteins bound to 
erythrocytes, explaining the atheroprotective mechanism of ery-apoB [45,46]. 
It must be noted that all described results were obtained from in vitro experiments 
and that C3b was not originally present on the isolated lipoproteins. The absence of 
C3b on freshly isolated LDL may have been induced by the ultracentrifugation process 
or because C3b opsonized LDL are not present in serum anymore due to avid binding 
to CR1 expressing cells. Therefore, we have started experiments to investigate the rela-
tionship between CR1 and ery-apoB in vivo. Others have shown a positive relationship 
between the number of CR1 per erythrocyte and the capacity of erythrocytes to bind 
immune complexes [47]. We measured the expression of CR1 by erythrocytes in subjects 
with absence or very low levels of ery-apoB and in subjects with very high levels of ery-
apoB. Ery-apoB was significantly different between the groups, but we did not observe a 
significant difference in CR1 expression by erythrocytes. In addition, no correlation was 
found between ery-apoB and the CR1 expression by erythrocytes (Figure 2). Other fac-
tors than just the amount of CR1 per erythrocyte must be responsible to initiate binding 
of apo B to erythrocytes (Figure 3). Future studies need to address whether specific CR1 
polymorphisms like the A3650G and C5507G polymorphisms [48], CR1 gene methyla-
tion, modified LDL serum concentrations and different states of complement activation 





















































Figure 2: Erythrocyte-bound apolipoprotein B (ery-apoB) was unrelated to the expression of complement 
receptor 1 (CR1 or CD35) by erythrocytes. Subjects with low (n = 25) and high (n = 28) ery-apoB (≤ 0.20 a.u. 
and ≥ 2.00 a.u., respectively) were asked to have their ery-apoB measured again on a separate occasion, 
which was combined with measuring their erythrocyte CR1 expression simultaneously. Ery-apoB remained 
significantly higher in subjects with high ery-apoB on their first occasion when compared to subjects with 
low ery-apoB on their initial visit (A). CD35 or CR1 expression was similar between subjects with low or 
high ery-apoB (B). No correlation between CD35 expression by erythrocytes and ery-apoB was found as 
shown in the scatter dotplot (n = 53) (C). Data in A and B represent the mean ± SEM. MFI = mean fluorescent 
intensity. *P < 0.001
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Final remarks
The studies performed in this thesis illustrate the complex pathophysiology of athero-
sclerosis: from postprandial lipemia with continuous diurnal accumulation of triglyc-
erides to complex cross-talk between circulating lipoproteins and blood cells. From a 
clinical point of view, the relatively simple implementation of non-fasting lipid profiles 
in clinical practice can already provide an improvement in patient convenience. Future 
studies are necessary to prove the effectiveness of vitamin D3 in reducing cardiovascu-
lar disease and whether binding of apo B containing lipoproteins to erythrocytes can 




Potential determinants of ery-apoB: 
-CR1 polymorphisms 
-Methylation of CR1 genes 
-C3b deposition on LDL and modified LDL 
-Serum oxidized LDL concentrations 






Figure 3: Potential determinants of erythrocyte-bound apolipoprotein B (ery-apoB), which should be 
further explored in future studies.
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“De Interactie tussen Lipoproteїnen, het 
Complement Systeem en Bloedcellen 




Cholesterol en triglyceriden zijn vetten en kunnen daarom niet oplossen in water of 
bloed. Daarom worden cholesterol en triglyceriden “verpakt” samen met specifieke 
eiwitten tot een lipoproteїne (“cholesterolpartikel”), zodat het cholesterol en de triglyc-
eriden vervoerd kunnen worden door het bloed. De stofwisseling van cholesterol en 
triglyceriden (vetzuren) is complex en gaat verder dan “goed” en “slecht” cholesterol. In 
beide gevallen gaat het om dezelfde stof (cholesterol), maar de verpakking waarin het 
door het bloed vervoerd wordt, bepaalt of het cholesterol in de vaatwand afgezet wordt 
(het slechte cholesterol, het zogenaamde LDL-cholesterol) of juist uit de vaatwand kan 
worden teruggehaald (het goede cholesterol, het HDL-cholesterol). 
De beschreven studies in dit proefschrift zijn voornamelijk gericht op de stofwis-
seling en transport van de “slechte” lipoproteїnen met het apolipoproteїne (apo) B als 
kenmerkende eiwit. Hierbij is altijd precies één apo B per “slechte” lipoproteїne aan-
wezig. Na een maaltijd worden cholesterol en triglyceriden opgenomen in de dunne 
darm en verpakt met apo B48 om vervolgens in de bloedbaan terecht te komen. De 
lipoproteїnen na een maaltijd (chylomicronen en VLDL) bevatten vooral triglyceriden 
uit de maaltijd en een relatief kleine hoeveelheid cholesterol. In de bloedbaan worden 
vervolgens de triglyceriden uit deze lipoproteïnen vrijgemaakt voor energiegebruik of 
voor opslag van energie in vetcellen. Uiteindelijk blijven kleine, compacte lipoproteïnen 
over waar voornamelijk nog cholesterol in aanwezig is, de zogenaamde low-density 
lipoproteïnen (LDL). Alle “slechte” lipoproteïnen met het apo B: de chylomicronen, 
VLDL en LDL kunnen zorgen voor cholesterolafzetting in de vaatwand (atherosclerose, 
oftewel aderverkalking).
De behandeling van verhoogde triglyceriden
Het cholesterol in zowel LDL als in VLDL en chylomicronen draagt bij aan de ontwik-
keling van atherosclerose wat uiteindelijk leidt tot hart- en vaatziekten (bijvoorbeeld 
een hartinfarct of beroerte). Daarnaast zijn verhoogde triglyceriden ook gerelateerd aan 
hart- en vaatziekten, onder andere omdat zij een goede maat vormen voor een toe-
name in VLDL en chylomicronen die niet gemeten worden wanneer het LDL-cholesterol 
bepaald wordt in het bloed. Daarom is naast het LDL-cholesterol, ook de behandeling 
van verhoogde triglyceriden belangrijk, waarbij de behandeling wordt bepaald door 
de onderliggende aandoening. Zo kunnen overgewicht, diabetes mellitus (suikerziekte), 
alcoholgebruik en specifieke erfelijke aandoeningen leiden tot verhoogde triglyceriden 
met elk hun eigen behandeling. In Hoofdstuk 2 worden de diagnostiek en behandeling 
van patiënten met verhoogde triglyceriden besproken onderbouwd door de huidige 
wetenschappelijke literatuur. Gewichtsverlies en een vetarm dieet zijn het belangrijkste 
in de behandeling van verhoogde triglyceriden, wat meestal afdoende is bij patiënten 
met alleen overgewicht. Echter medicamenteuze behandeling is meestal noodzakelijk 
bij patiënten met een erfelijke stoornis waarbij de triglyceriden niet uit de chylomicronen 
en VLDL gehaald kunnen. Fibraten hebben dan de voorkeur, omdat zij het vrijmaken van 
triglyceriden uit de lipoproteïnen stimuleren, evenals het metabolisme van de vetzuren 
afkomstig uit die triglyceriden. Bij patiënten met hart- en vaatziekten en/of diabetes 
mellitus worden in eerste instantie statines, de klassieke cholesterolverlagers, geadvi-
seerd, eventueel aangevuld met een fibraat. De doseringen van de statines dienen op-
gehoogd te worden bij deze patienten die ook een hypertriglyceridemie hebben totdat 
de streefwaarden van apo B (< 0.8 g/l) danwel non-HDL-C (< 3.3 mmol/l) behaald is.
De variabiliteit van triglyceriden gedurende de dag
Een probleem bij het meten van triglyceriden in het bloed is dat de waarde afhankelijk 
is van het feit of de patiënt wel of niet gegeten heeft. In nuchtere toestand zijn de tri-
glyceriden het laagst en stijgen door het eten gedurende de dag. Daarom wordt in de 
regel geadviseerd om triglyceriden en cholesterol (waarbij het LDL-cholesterol geschat 
wordt met behulp van de triglyceridenwaarde) te meten in nuchtere toestand. Ondanks 
een nuchtere toestand zijn triglyceriden reeds zeer variabel. Wij hebben de variabiliteit 
van triglyceriden in nuchtere toestand en niet-nuchtere toestand onderzocht en met 
elkaar vergeleken in Hoofdstuk 3. Het bleek dat de variabiliteit van triglyceriden bin-
nen een individu hoog is, namelijk ongeveer 25%, maar dat deze redelijk hetzelfde 
blijft gedurende de dag. De absolute variabiliteit van triglyceriden in nuchtere toestand 
bedroeg 0.28 – 0.35 mmol/l en steeg tot maximaal 0.28 – 0.69 mmol/l voor het slapen 
gaan. Dit was ondanks de geleidelijke triglyceriden stijging in het bloed van 0.45 mmol/l 
bij vrouwen en 1.05 mmol/l bij mannen gedurende de dag. Derhalve zal het gebruik 
van niet-nuchtere triglyceridewaarden in plaats van nuchtere de nauwkeurigheid van 
het voorspellen van het risico op hart- en vaatziekten weinig beïnvloeden. Deze kennis 
kan bijdragen aan de implementatie van het meten van triglyceriden en cholesterol in 
niet-nuchtere toestand wat in de klinische praktijk wat prettiger is voor patiënten.
Activatie van witte bloedcellen na de maaltijd
De ontwikkeling van atherosclerose komt niet alleen door afzetting van cholesterol in 
de vaatwand, maar het afweersysteem levert ook een belangrijke bijdrage. Daarnaast 
beїnvloeden lipoproteïnen die rijk zijn aan triglyceriden, die met name na de maaltijd 
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vrijkomen, de circulerende witte bloedcellen. De witte bloedcellen zijn bedoeld voor 
de afweer tegen bacteriën en virussen, maar zij reageren ook op chylomicronen en 
VLDL alsof zij indringers van buitenaf zijn. Na een maaltijd is dan ook een activatie van 
witte bloedcellen in het bloed te meten. De witte bloedcellen scheiden cytokinen (ac-
tiverende stoffen) uit, nemen toe in grootte en krijgen een verhoogd aantal ankers om 
te kunnen plakken aan de vaatwand met schadelijke gevolgen. De mate van activatie 
van witte bloedcellen is te meten, maar vereist veel werk in het laboratorium. Recent 
is ontdekt dat geautomatiseerde meetapparatuur in het klinische laboratorium op een 
eenvoudige manier patiënten met een infectie kan onderscheiden van patiënten zonder 
infectie door middel van een drietal parameters: de mate waarin de witte bloedcel licht 
verstrooit, de grootte van de witte bloedcel en de elektrische geleiding door een witte 
bloedcel. Wij waren geïnteresseerd of dezelfde geautomatiseerde meetapparatuur 
ook dergelijke veranderingen in witte bloedcellen na vetinname kon meten. Uit ons 
onderzoek beschreven in Hoofdstuk 4 blijkt dat dit inderdaad het geval is, waarbij de 
lichtverstrooiing van witte bloedcellen 1.4 – 1.7% afneemt na de maaltijd, terwijl de 
grootte van de witte bloedcellen licht toeneemt wat inderdaad duidt op activatie van 
de witte bloedcellen. Deze resultaten kunnen nieuw onderzoek naar activatie van witte 
bloedcellen na de maaltijd vereenvoudigen in de toekomst.
Vitamine D en activatie van witte bloedcellen na de maaltijd
De activatie van witte bloedcellen na een maaltijd is schadelijk voor de vaatwand, doordat 
de cellen die de vaatwand bekleden zich anders gaan gedragen door de schadelijke stof-
fen die witte bloedcellen uitscheiden na een maaltijd. Daarnaast kunnen geactiveerde 
witte bloedcellen die cholesterol hebben opgenomen ook de vaatwand binnendringen 
wat kan leiden tot atherosclerose. Tot nu toe zijn er weinig behandelingen bekend om 
de maaltijd geїnduceerde activatie van witte bloedcellen te verminderen. Wij hebben 
onderzocht in Hoofdstuk 5 of de toediening van vitamine D mogelijk de schadelijke 
activatie van witte bloedcellen kon tegengaan. Vitamine D heeft namelijk niet alleen 
effect op de botstofwisseling, maar ook op witte bloedcellen en hart- en vaatziekten. 
Gezonde proefpersonen ondergingen tweemaal een slagroomproef, een controle proef 
zonder vitamine D en een tweede slagroomproef na vitamine D suppletie. Gedurende 
de slagroomproef werd zowel bij de mannelijke als de vrouwelijke proefpersonen na 
vitamine D suppletie een verbetering van de elasticiteit van de slagaders waargenomen. 
Daarnaast was er na vitamine D de activatie van witte bloedcellen na de maaltijd vermin-
derd, maar alleen bij vrouwen. De expressie van CD11b en CD35, celstructuren die toen-
emen op het celoppervlak van witte bloedcellen tijdens activatie, daalden 10.5 – 17.0% 
bij vrouwen na vitamine D suppletie vergeleken met de controle slagroomproef. Een 
164 Chapter 10
dergelijke vermindering in activatie in witte bloedcellen werd echter niet waargenomen 
bij mannen. Waarom er een verschil tussen de mannelijke en vrouwelijke proefpersonen 
in de activatie van witte bloedcellen werd waargenomen is nog niet duidelijk, maar we 
vermoeden een samenwerking tussen vitamine D en oestrogenen die een gunstig effect 
op de witte bloedcellen bewerkstelligt. De resultaten van dit onderzoek tonen wederom 
aan dat vitamine D een positief effect heeft op de slagaders, maar onduidelijk is of dit di-
rect gerelateerd is aan een verminderde activatie van witte bloedcellen na een maaltijd.
Transport van lipoproteїnen door rode bloedcellen
Aangezien de interactie tussen lipoproteїnen met witte bloedcellen gerelateerd is aan 
de ontwikkeling van atherosclerose, waren we geїnteresseerd of binding van lipopro-
teïnen aan rode bloedcellen ook een relatie heeft met atherosclerose. Ongeveer 99% 
van alle cellen in het bloed zijn namelijk rode bloedcellen die voornamelijk belangrijk 
zijn voor het transport van zuurstof. Theoretisch zou het beschermend zijn als de rode 
bloedcellen de slechte lipoproteïnen (met het eiwit apo B) door binding zouden we-
gvangen en zo het contact tussen de lipoproteїnen en de vaatwand kunnen voorkomen. 
In Hoofdstuk 6 wordt beschreven dat patiënten met hart- en vaatziekten minder apo B 
op hun rode bloedcellen hebben dan gezonde controlepersonen (0.62 ± 0.09 a.u. versus 
1.18 ± 0.10 a.u.). Tevens bleek dat hoe lager de hoeveelheid apo B gebonden aan de rode 
bloedcellen was, hoe dikker de vaatwand van de halsslagader (correlatiecoëfficiënt van 
-0.214). Deze resultaten zijn suggestief voor een beschermend effect op de ontwikkel-
ing van atherosclerose, wanneer rode bloedcellen veel slechte lipoproteïnen met apo B 
aan zich binden.
De resultaten werden nog eens bevestigd in een uitgebreidere studie beschreven in 
Hoofdstuk 7, waarbij proefpersonen met een verdikte halsslagader 23.2% minder apo B 
aan hun rode bloedcellen gebonden hadden in vergelijking tot proefpersonen met een 
normale dikte van hun halsslagader. Tevens werd aangetoond dat de hoeveelheid apo 
B op rode bloedcellen niet werd beïnvloed door het tijdelijk staken van cholesterolver-
lagende statines (-0.04 ± 0.39 a.u.) of door de hoeveelheid vrije lipoproteïnen met apo B 
in het bloed. De correlatiecoëfficiënt tussen het vrije apo B en het apo B gebonden aan 
rode bloedcellen bedroeg namelijk slechts -0.025 tot 0.038. 
Met deze twee studies hebben we aangetoond dat apo B gebonden aan rode bloedcel-
len geassocieerd is met hart- en vaatziekten onafhankelijk van het gebruikelijke lipid-
enspectrum dat dagelijks gemeten wordt in de klinische praktijk. Opvallend was dat 
mensen met bloedgroep O gemiddeld twee keer zoveel apo B op hun rode bloedcellen 
hadden als mensen met bloedgroep A, B of AB. Een duidelijke verklaring hiervoor is nog 
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niet gevonden. Echter dit effect van de ABO bloedgroep kan een aanwijzing zijn voor 
het potentiële bindingsmechanisme van lipoproteïnen aan rode bloedcellen. 
De complement receptor 1 als mechanisme voor celgebonden 
lipoproteїnen
Het is bijzonder dat lipoproteïnen aan rode bloedcellen kunnen binden, omdat deze 
cellen geen bekende receptoren of ankers hebben om lipoproteïnen te kunnen binden. 
Naast zuurstoftransport kunnen rode bloedcellen ook bacteriën en antilichaamcom-
plexen binden en vervoeren om hen vervolgens af te geven aan witte bloedcellen of 
aan de lever of milt voor een effectieve afweerreactie. Dit mechanisme op rode bloe-
dcellen functioneert via de specifieke complement receptor 1 die op de rode en witte 
bloedcellen aanwezig is. De complement receptor 1 maakt deel uit van het complement 
systeem, wat deel uitmaakt van het niet-specifieke afweersysteem. De activatie van het 
complement systeem kan via drie verschillende routes lopen: de klassieke route, de 
lectine route en de alternatieve route. Uiteindelijk leidt activatie van van één van deze 
routes tot complement activatie, opsoniseren van celoppervlakten met complementfac-
toren en eventueel verval van cellen/bacterieën. Wij hebben onderzocht of de binding 
van LDL en speciaal gemodificeerd LDL (die beiden ook het eiwit apo B bevatten) kan 
binden aan de complement receptor 1. 
Hoofdstuk 8 beschrijft de resultaten van dit onderzoek. Met behulp van laborato-
riumproeven en gemuteerde kweekcellen bleek het normale en gemodificeerde LDL 
inderdaad aan de complement receptor 1 te kunnen binden. Het LDL en gemodificeerd 
LDL konden echter niet op een directe manier aan de complement receptor 1 binden, 
maar alleen na vorming van complement component C3b door activatie van het 
complementsysteem. Tevens vonden we dat de activatie van het complement systeem 
door LDL en gemodificeerd LDL licht verschilde, waarbij de klassieke route voor beide 
belangrijk was, maar dat ook de alternatieve route geactiveerd werd door gemodificeerd 
LDL.
Deze resultaten kunnen een verklaring geven hoe apo B-bevattende lipoproteïnen 
aan rode, maar ook witte bloedcellen kunnen binden aangezien de complement recep-
tor 1 ook in grote aantallen op witte bloedcellen aanwezig is. Onderzocht zal moeten 
worden of dit daadwerkelijk ook het geval is in het menselijk lichaam aangezien de 
experimenten beschreven in Hoofdstuk 8 allemaal in een kunstmatige proefopstelling 
(“in vitro”) waren verricht. 
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Concluderend
Er is toenemend bewijs dat het niet noodzakelijk is om cholesterol en triglyceriden in 
nuchtere toestand te meten, maar dat een niet-nuchtere meting in de meeste gevallen 
ook kan volstaan. De ontwikkeling van atherosclerose is complex en gaat veel verder 
dan alleen het cholesterolgehalte in het bloed. Atherosclerose, vet- en cholesterol-
stofwisseling en het immuunsysteem inclusief rode bloedcellen zijn nauw met elkaar 
verbonden. Hierbij lijkt het immuunsysteem zowel schadelijk als beschermend tegen de 
ontwikkeling van atherosclerose te kunnen werken. Vitamine D kan deels de schadelijke 
activatie van witte bloedcellen na vetinname voorkomen en heeft een gunstig effect op 
de elasticiteit van van de slagaders. Rode bloedcellen kunnen juist een beschermend 
effect uitoefenen op de vaatwand door middel van transport van apo B-bevattende 
lipoproteїnen. Dit transportmechanisme kan mogelijk plaatsvinden door middel van 
het complement systeem met de complement receptor 1 danwel de ABO bloedgroep of 
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